---
document_datetime: 2025-10-15 14:18:31
document_pages: 136
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/lynparza-h-c-3726-ii-0051-g-epar-assessment-report-variation_en.pdf
document_name: lynparza-h-c-3726-ii-0051-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 204.7385505
conversion_datetime: 2025-12-21 13:05:27.501377
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
23 June 2022 EMA/CHMP/566771/2022

Committee for Medicinal Products for Human Use (CHMP) Corr.1 1

## Assessment report

## Lynparza

International non-proprietary name: olaparib

Procedure No. EMEA/H/C/003726/II/0051/G

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

1  25 September 2025 to delete an incorrect statement in section 2.8 Clinical safety.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                  | 8                                                                                                      |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| 1.1. Type II group of variations ..................................................................................       | 8                                                                                                      |
| 1.2. Steps taken for the assessment of the product.......................................................                 | 9                                                                                                      |
| 2. Scientific discussion..............................................................................                    | 10                                                                                                     |
| 2.1. Introduction.....................................................................................................10  |                                                                                                        |
| 2.1.1. Problem statement.........................................................................................10       |                                                                                                        |
| 2.1.2. About the product                                                                                                  | ..........................................................................................12           |
| 2.2. Quality aspects.................................................................................................13   |                                                                                                        |
| 2.3. Discussion on quality aspects..............................................................................13        |                                                                                                        |
| 2.4. Conclusion on quality aspects                                                                                        | .............................................................................14                        |
| 2.5. Non-clinical aspects...........................................................................................16    |                                                                                                        |
| 2.5.1. Introduction                                                                                                       | ..................................................................................................16   |
| 2.5.2. Ecotoxicity/environmental risk assessment                                                                          | ........................................................16                                             |
| 2.5.3. Discussion on non-clinical aspects                                                                                 | ....................................................................18                                 |
| 2.5.4. Conclusion on the non-clinical aspects...............................................................19            |                                                                                                        |
| 2.6. Clinical aspects.................................................................................................20  |                                                                                                        |
| 2.6.1. Introduction                                                                                                       | ..................................................................................................20   |
| 2.6.2. Pharmacokinetics                                                                                                   | ...........................................................................................20          |
| 2.6.3. Discussion on clinical pharmacology..................................................................24            |                                                                                                        |
| 2.6.4. Conclusions on clinical pharmacology................................................................24             |                                                                                                        |
| 2.7. Clinical efficacy.................................................................................................25 |                                                                                                        |
| 2.7.1. Main study                                                                                                         | ....................................................................................................25 |
| 2.7.2. Discussion on clinical efficacy...........................................................................80       |                                                                                                        |
| 2.7.3. Conclusions on the clinical efficacy....................................................................84         |                                                                                                        |
| 2.8. Clinical safety...................................................................................................84 |                                                                                                        |
| 2.8.1. Discussion on clinical safety...........................................................................124        |                                                                                                        |
| 2.8.2. Conclusions on clinical safety                                                                                     | .........................................................................127                           |
| 2.8.3. PSUR cycle..................................................................................................128    |                                                                                                        |
| 2.9. Risk management plan                                                                                                 | ....................................................................................128                |
| 2.10. Update of the Product information                                                                                   | ...................................................................129                                 |
| 2.10.1. User consultation........................................................................................130      |                                                                                                        |
| 3. Benefit-Risk Balance ...........................................................................                       | 130                                                                                                    |
| 3.1. Therapeutic Context........................................................................................130       |                                                                                                        |
| 3.1.1. Disease or condition                                                                                               | .....................................................................................130               |
| 3.1.2. Available therapies and unmet medical need....................................................130                  |                                                                                                        |
| 3.1.3. Main clinical studies......................................................................................131     |                                                                                                        |
| 3.2. Favourable effects...........................................................................................131     |                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects                                                               | ..........................................132                                                          |
| 3.4. Unfavourable effects                                                                                                 | .......................................................................................132             |
| 3.5. Uncertainties and limitations about unfavourable effects.......................................132                   |                                                                                                        |
| 3.6. Effects Table                                                                                                        | ..................................................................................................133  |
| 3.7. Benefit-risk assessment and discussion..............................................................134              |                                                                                                        |

<div style=\"page-break-after: always\"></div>

| 3.7.1. Importance of favourable and unfavourable effects ...........................................134                 |
|-------------------------------------------------------------------------------------------------------------------------|
| 3.7.2. Balance of benefits and risks..........................................................................135       |
| 3.7.3. Additional considerations on the benefit-risk balance.........................................135                |
| 3.8. Conclusions....................................................................................................135 |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| ADR     | adverse drug reaction                                                                                                                       |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------|
| AE      | adverse event                                                                                                                               |
| AESI    | adverse event of special interest                                                                                                           |
| AML     | acute myeloid leukaemia                                                                                                                     |
| AUC     | area under plasma concentration-time curve from zero to infinity                                                                            |
| AUC ss  | area under plasma concentration-time curve from zero to infinity at steady state                                                            |
| bd      | twice daily                                                                                                                                 |
| BICR    | blinded independent central review                                                                                                          |
| BIG     | Breast International Group                                                                                                                  |
| BRCA    | breast cancer susceptibility gene                                                                                                           |
| CI      | confidence interval                                                                                                                         |
| CLIA    | Clinical Laboratory Improvement Amendments                                                                                                  |
| Cmax    | maximum plasma concentration                                                                                                                |
| Cmax ss | maximum plasma concentration at steady state                                                                                                |
| CNS     | central nervous system                                                                                                                      |
| CPS&EG  | clinical stage (CS), oestrogen receptor status (E), nuclear grade (G), and post- treatment pathologic stage (PS) - a disease scoring system |
| CRF     | case report form                                                                                                                            |
| CSP     | Clinical Study Protocol                                                                                                                     |
| CSR     | Clinical Study Report                                                                                                                       |
| CT      | computed tomography                                                                                                                         |
| CTCAE   | Common Terminology Criteria for Adverse Events                                                                                              |
| CYP     | cytochrome P450                                                                                                                             |
| DBL     | database lock                                                                                                                               |
| DCO     | data cut-off                                                                                                                                |
| DDFS    | distant disease free survival                                                                                                               |
| DDI     | drug-drug interaction                                                                                                                       |
| DDR     | DNA damage response                                                                                                                         |
| DFS     | disease free survival                                                                                                                       |
| DNA     | deoxyribonucleic acid                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| DSB   | double strand break                                        |
|-------|------------------------------------------------------------|
| ECOG  | Eastern Cooperative Oncology Group                         |
| eCRF  | electronic case report form                                |
| EFS   | event free survival                                        |
| EMA   | European Medicines Agency                                  |
| EORTC | European Organisation for Research and Treatment of Cancer |
| ER    | oestrogen receptor                                         |
| ESMO  | European Society for Medical Oncology                      |
| EU    | European Union                                             |
| FAS   | full analysis set                                          |
| FACIT | Functional Assessment of Chronic Illness Therapy           |
| FFPE  | formalin fixed paraffin embedded                           |
| FIGO  | International Federation of Gynecology and Obstetrics      |
| FISH  | fluorescence in-situ hybridisation                         |
| GCP   | Good Clinical Practice                                     |
| GI    | gastrointestinal                                           |
| GLS   | Geometric least squares                                    |
| HER2  | human epidermal growth factor receptor 2                   |
| HR    | hazard ratio                                               |
| HRD   | homologous recombination deficiencies                      |
| HRQoL | health-related quality of life                             |
| HRR   | homologous recombination repair                            |
| HRRm  | homologous recombination repair mutation                   |
| ICH   | International Council for Harmonisation                    |
| IDFS  | invasive disease free survival                             |
| IDMC  | Independent Data Monitoring Committee                      |
| IHC   | immunohistochemistry                                       |
| ITT   | intention-to-treat                                         |
| LS    | least squares                                              |
| MAH   | Marketing authorisation holder                             |
| MDS   | myelodysplastic syndrome                                   |
| MRI   | magnetic resonance imaging                                 |

<div style=\"page-break-after: always\"></div>

| n          | number of patients                                        |
|------------|-----------------------------------------------------------|
| N          | total number of patients                                  |
| NCCN       | National Comprehensive Cancer Network                     |
| NCI        | National Cancer Institute                                 |
| NRG        | NCI supported National Clinical Trials Network Group      |
| od         | once daily                                                |
| ORR        | objective response rate                                   |
| OS         | overall survival                                          |
| PARP       | polyadenosine 5'diphosphoribose polymerase                |
| PBRER      | Periodic Benefit-risk Evaluation Report                   |
| pCR        | pathological complete response                            |
| PD-1       | programmed cell death protein-1                           |
| PD-L1      | programmed death-ligand 1                                 |
| PFS        | progression free survival                                 |
| PFS2       | time to second progression                                |
| PgR        | progesterone receptor                                     |
| PK         | pharmacokinetic(s)                                        |
| PRO        | patient reported outcome                                  |
| PSR        | platinum-sensitive relapsed                               |
| PT         | preferred term                                            |
| QLC-C30    | quality of questionnaire core 30 item module              |
| QoL        | quality of life                                           |
| RECIST 1.1 | response evaluation criteria in solid tumours version 1.1 |
| RMP        | risk management plan                                      |
| RMST       | restricted mean survival time                             |
| ROW        | rest of world                                             |
| rPFS       | radiological progression-free survival                    |
| RSI        | Reference Safety Information                              |
| SAE        | serious adverse event                                     |
| SAP        | statistical analysis plan                                 |
| SAS        | Safety analysis set                                       |
| SD         | standard deviation                                        |

<div style=\"page-break-after: always\"></div>

| SSB   | single strand break                         |
|-------|---------------------------------------------|
| STEEP | standardised terms for efficacy endpoints   |
| TNBC  | triple negative breast cancer               |
| VUS   | genetic mutation of uncertain significance. |
| vs    | versus                                      |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II group of variations

Pursuant to Article 7.2 of Commission Regulation (EC) No 1234/2008, AstraZeneca AB submitted to the European Medicines Agency on 11 October 2021 an application for a group of variations.

The following variations were requested in the group:

| Variations requested   | Variations requested                                        | Type    | Annexes affected   |
|------------------------|-------------------------------------------------------------|---------|--------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition | Type II | I and IIIB         |
| B.I.z                  | B.I.z - Quality change - Active substance - Other variation | Type IB | None               |

C.I.6.a - Extension of indication to include adjuvant treatment of breast cancer for Lynparza (for tablets); as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. In addition, sections 4.8 of the SmPC for Lynparza hard capsules are revised based on the updated safety data analysis. The Package Leaflet is updated in accordance. Version 23 of the RMP has also been submitted.

B.I.z - to reassess the control strategy for potentially mutagenic impurities in the active substance in view of the proposed extension of indication to an earlier line of cancer treatment.

The group of variations requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0250/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0250/2020 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

Karin Janssen van Doorn

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 11 October 2021  |
| Start of procedure:                                  | 30 October 2021  |
| CHMP Rapporteur Assessment Report                    | 22 December 2021 |
| PRAC Rapporteur Assessment Report                    | 3 January 2022   |
| CHMP Co-Rapporteur Critique                          | 5 January 2022   |
| PRAC Outcome                                         | 13 January 2022  |
| CHMP members comments                                | 17 January 2022  |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 21 January 2022  |
| Request for supplementary information (RSI)          | 27 January 2022  |
| CHMP Rapporteur Assessment Report                    | 22 March 2022    |
| PRAC Rapporteur Assessment Report                    | 25 March 2022    |
| PRAC members comments                                | 30 March 2022    |
| PRAC Outcome                                         | 7 April 2022     |
| CHMP members comments                                | 11 April 2022    |
| Updated CHMP Rapporteur Assessment Report            | 20 April 2022    |
| Request for supplementary information (RSI)          | 22 April 2022    |
| CHMP Rapporteur Assessment Report                    | 10 June 2022     |
| CHMP members comments                                | 13 June 2022     |
| Updated CHMP Rapporteur Assessment Report            | 23 June 2022     |
| Opinion                                              | 23 June 2022     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Breast cancer is the most common cancer in the world, with an estimated 2.2 million new cases in 2020 globally (11.7% of all new cancers). Breast cancer is also the fifth most common cause of death from cancer, with an estimated 684,000 deaths in 2020. In the European Community in 2020, the number of cases of breast cancer in women and men was 355,457 and the number of deaths was 91,826 (ECIS 2020). Over 90% of patients with breast cancer are diagnosed at an early stage (Cardoso et al. 2018b).

Nearly 30% of women with cancer confined to the breast and 75% of women with nodal involvement will ultimately  relapse  (Rosen  et  al  1989).  Metastatic  breast  cancer  remains  an  incurable  disease  with  an estimated 5-year OS of 25% (Cardoso et al 2009).

Breast cancer is a heterogeneous disease and optimal treatment depends on pathological and molecular characterization of the tumour. Early-stage Breast cancer (Stages I to III) is defined as disease confined to the breast with or without regional lymph node involvement and in the absence of metastatic disease. Treatment for Stages I to III breast cancer usually includes surgery and radiation therapy, with the addition of chemotherapy for patients with high risk of recurrence, either before (neoadjuvant) or after (adjuvant) surgery. Other drug therapies including endocrine and anti-HER2 therapy are additionally given depending on ER and/or PgR and HER2 status.

The  presence  of  micrometastases  or  clinically  occult  tumour  present  after  surgery  with  a  potential  to metastasize confer both morbidity and mortality. Pretreatment clinical stage (CS), estrogen receptor status (E),  histological  grade  (G),  and  post-treatment  pathologic  stage  (PS)  can  be  used  to  estimate  relapse probability  with  higher  risk  conferred  by  higher  CPS,  ER  negativity  and  Grade  3  (Jeruss  et  al  2008, Mittendorf et al 2011).

## Claimed therapeutic indication

The MAH applied for the following indication:

Olaparib is indicated as monotherapy for the adjuvant treatment of adult patients with BRCA mutated, HER2-negative,  high  risk  early  breast  cancer  who  have  previously  been  treated  with  neoadjuvant  or adjuvant chemotherapy.

The recommended indication is as follows:

Lynparza is indicated as:

- monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see SmPC sections 4.1, 4.2 and 5.1).

<div style=\"page-break-after: always\"></div>

Before  Lynparza  treatment  is  initiated  for  adjuvant  treatment  of  HER2  negative  high  risk  early  breast cancer, patients must have confirmation of deleterious or suspected deleterious gBRCA1/2 mutation using a validated test (see SmPC sections 4.2 and 5.1).

## Biologic features - BRCA Mutations in Breast Cancer

In the general population, germline BRCA mutation carriers have an increased relative risk of breast cancer (Kuchenbaecker et al 2017, Antoniou et al 2003). Onset of gBRCAm associated breast cancer is early (Mavaddat et al 2012), as also evidenced by the OlympiA and the OlympiAD trial populations where the median  age  of  study  participants  at  the  time  of  randomisation  following  completion  of  neo/adjuvant treatment  in  OlympiA  was  42  years  (Tutt  et  al  2021)  and  at  the  time  of  randomisation  with advanced/metastatic disease in OlympiAD was 45 years (Robson et al 2017).

BRCAm breast cancer is most frequently HER2 negative (IHC 0, 1+ or 2+/FISH non-amplified) breast cancer, which can be either ER and/or PgR positive (ER and/or PgR IHC nuclear staining ≥ 1%) or TNBC (ER and/or PgR IHC nuclear staining &lt;1%). The development of HER2 positive BRCAm breast cancer, whilst it does occur, is rare (Mavaddat et al 2012, Evans et al 2016, Winter et al 2016).

Approximately 3% to 5% of patients with breast cancer carry BRCA1/2 mutations (Dorling et al 2021; Malone et al 2006). Approximately 70% of BRCA1 mutation carriers who develop breast cancers present with TNBC; in contrast, breast cancer patients carrying mutations in the BRCA2 gene are more likely to be positive for expression of the ER and/or PgR (Mavaddat et al 2012, Song et al 2020).

BRCAm breast cancer is associated with high-risk features with a poor prognosis for patients. BRCA1/2 breast cancer hallmarks include high histological grade, continuous pushing margins, TP-53 mutations, loss of RAD51 focus information, extreme genomic instability and sensitivity to DNA crosslinking agents, with BRCA1 tumours additionally more frequently basal-like and ER-negative (Turner et al 2004). TNBC, which is  more frequently associated with BRCA1m, generally has a poor prognosis despite high sensitivity to chemotherapy  (Metzger-Filho  et  al  2012)  with  early  recurrence  between  the  first  and  third  year  after diagnosis, frequently in association with visceral and/or brain metastases and a shorter period between time of recurrence and death (Dent et al 2007). Germline BRCA-associated hormone receptor-positive breast cancer is also associated with intrinsically less favourable biology with more high- and intermediaterisk disease and less low-risk disease compared to controls (Shah et al 2016). Within BRCAm tumours, the proportions with high-risk features are very similar for each gene, regardless of the mutation being germline or somatic (Winter et al 2016). When compared to BRCA wildtype primary breast carcinomas, tumours harbouring a BRCA1/2 mutation (gBRCA1 n=10, gBRCA2 n=10, sBRCA1 n=4, sBRCA2 n=5), showed a higher proportion of patients with higher risk features including N1-N3, grade 3 tumours, ER/PR negative disease and basal subtype (Winter et al 2016).

The development of metastatic disease in BRCAm breast cancer is also associated with a poor prognosis. Song  et  al  2020  reported  that  breast  cancer  patients  with  a  BRCA1  mutation  frequently  experience metastasis to lung and distant lymph nodes, and BRCA2 mutation carriers most often to bone and liver; the  data  also  indicate  that  at  least  one-half  of  patients  with  BRCA1-associated  or  BRCA2-associated metastatic breast cancer will develop CNS metastases. Involvement of CNS and other non-CNS distant sites (relative to locoregional recurrence or contralateral disease) as first recurrence events were associated with increased mortality risk.

<div style=\"page-break-after: always\"></div>

## Management

The decision  to  treat  patients  with  early  breast  cancer  with  neoadjuvant  or  adjuvant  chemotherapy  in addition to surgery/radiotherapy is driven by the consideration of clinical characteristics, tumour stage and pathology. Randomised clinical trials have found no significant differences in long-term outcomes when systemic chemotherapy is given before or after surgery (Mauri et al 2005, Rastogi et al 2008).

For TNBC, neoadjuvant/adjuvant chemotherapy has been the main systemic treatment option for patients. Chemotherapy treatment of patients with early stage ER and/or PgR positive HER2 negative breast cancer depend on the individual risk of recurrence and presumed responsiveness to endocrine therapy (ESMO 2019, NCCN Guidelines). For hormone receptor positive patients with ≥ 4 positive nodes at definitive surgery, NCCN guidelines recommend that all patients should receive adjuvant chemotherapy followed by endocrine therapy  (NCCN  Guidelines);  additional  chemotherapy  is  also  recommended  to  patients  with  hormone receptor positive cancers that have high risk characteristics, such as high-grade tumour, large tumour size ( ≥ 2 cm), pathologically involved lymph nodes, and/or high recurrence score (OncotypeDX 21-gene or other multigene assay). Adjuvant endocrine therapy is recommended following neo/adjuvant chemotherapy for all ER and/or PgR positive HER2 negative patients (NCCN Guidelines; ESMO 2019).

Standard neo/adjuvant chemotherapy for HER2 negative early disease is an anthracycline alkylator, and taxane-containing regimen. The ESMO  Guidelines (ESMO 2019) recommend that a sequential anthracycline/taxane-based  regimen  be  standard  for  the  majority  of  patients.  The  NCCN  and  ESMO guidelines consider there is insufficient evidence for the routine use of platinum in neoadjuvant regimens for TNBC patients. Whilst platinum compounds are not routinely recommended, the addition of a platinum compound may be considered in high risk TNBC patients with deleterious BRCA1/2 mutations (ESMO 2019) and in selected patients where better local control is desirable (NCCN Guidelines). In high risk TNBC patients not  achieving  pCR  after  standard  neoadjuvant  chemotherapy,  the  addition  of  adjuvant  capecitabine postoperatively may be considered (NCCN Guidelines, ESMO 2019).

## 2.1.2. About the product

Olaparib, is a potent oral human polyadenosine 5'diphosphoribose polymerase (PARP) inhibitor that exploits deficiencies  in  DNA  repair  pathways  to  preferentially  target  cancer  cells  carrying  such  deficiencies. Dysfunctional homologous recombination repair (HRR) in tumour cells results in reliance on error prone repair pathways, leading to an accumulation of DNA damage and cell death in tumour cells. Lynparza is approved in EU for the treatment of ovarian cancer, breast cancer, adenocarcinoma of the pancreas and prostate cancer (see section 4.1 of the SmPC).

The antitumour effects of the PARP inhibitor olaparib is dependent on an underlying defect in a cancer cell's DNA damage response (DDR) mechanisms, rather than a direct interaction with a mutated gene or protein. These defects in DDR mechanisms arise from cells with homologous recombination deficiencies (HRD), of which BRCA mutations are one subtype. Olaparib traps PARP at the sites of single-strand DNA damage and prevents their repair (Murai et al 2012). During replication, the single strand breaks (SSBs) trapped with PARP are converted to double strand break (DSBs). These DSBs are normally repaired by a high-fidelity process known as HRR. BRCA mutated tumours with HRD cannot accurately repair the DNA damage, which may become lethal to cells as it accumulates.

Breast  cancers  harbouring  mutations  in  BRCA1  or  BRCA2  result  in  tumour  cells  lacking  BRCA  protein functionality  that  are  deficient  in  homologous  recombination,  making  BRCA  mutated  breast  cancer appropriate for treatment with PARP inhibitors whereby the process of synthetic lethality can be exploited.

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

This Type II variation is being grouped with a consequential quality Type IB variation (category B.I.z) reassessing the control strategy for potentially mutagenic impurities.

In view of the proposed extension of the patient population to an earlier line of cancer treatment (i.e., adjuvant setting), the Applicant has reassessed the control strategy for potentially mutagenic impurities to consider a non ICH S9 patient population, in line with ICH M7 guidance. Consequently, the Applicant has submitted an updated Quality Overall Summary in Module 2.3 and updates in Module 3, S.3.2 Impurities and S.4.5 Justification of Specification for Drug Substance.

## 2.3. Discussion on quality aspects

The Applicant stated that nothing has changed in the quality of the olaparib active substance or Lynparza Tablets, and the way they are manufactured has not changed. The Applicant considers that there is no change to the drug substance specification required as the existing control strategy is appropriate for a non ICH S9 population.

The recommended dose of olaparib tablets is 300 mg (two 150 mg tablets) taken twice daily, equivalent to a total daily dose of 600 mg per day. It is recommended that treatment in the early breast cancer setting be continued for a maximum of 12 months. The threshold of toxicological concern (TTC) limit of 10 μg/day has been proposed based on ICH M7, applying a less than lifetime (LTL) exposure where the expected duration of the use of the product is less than 10 years. Based on this, the permitted limit for mutagenic impurity in olaparib drug substance would equate to 16.7 ppm using a staged TTC of 10 µg/d and a MDD of 600 mg.

As a reminder, olaparib showed no mutagenic potential in the Ames bacterial mutation tests but was clastogenic in an in vitro chromosome aberration test.

Following review of the initially submitted data, the control of potentially mutagenic impurities was not considered acceptable for the proposed additional indication. In addition, the applicant was asked to revise the nitrosamine risk-assessment. The applicant submitted satisfactory responses to the questions raised.

At the time of the CHMP opinion, a post-approval measure (PAM) was agreed with the MAH and is put forward as recommendation: to provide the results of a GLP Ames test for one impurity.

## Active substance

A  Risk  Assessment  of  Potentially  Mutagenic  Impurities  (PMI)  has  been  provided  in  the  revised  section 3.2.S.3.2.

Mutagenic  impurities  have  been  evaluated  using  a  (Q)SAR  analysis  employing  two  complementary methodologies (DEREK), a rule based expert system (SAR), and Leadscope modeller, a statistical QSAR model, Expert evaluation of SAR predictions, in vivo/in vitro mutagenicity testing. This evaluation takes into  account  all  the  starting  materials,  intermediates,  reagents,  as  well  as  potential  impurities  and degradation products of both the active substance and finished product. For each compound, it includes its chemical structure, origin, mutagenicity risk assessment results, Ames assessment when applicable, and ICH M7 classification (class 1 to 5).

Eight compounds were predicted to be mutagenic by (Q)SAR analysis. Of those, the mutagenicity of five compounds was confirmed. Impurities which are reported as known animal carcinogens were not assessed using the QSAR modeller but have been treated as Class 1 in accordance with ICH M7.

<div style=\"page-break-after: always\"></div>

The  classification  of  certain  impurities  as  class  5  compounds  was  not  acceptable  based  on  Amberg's publication  only.  In  absence  of  relevant  additional  data,  the  Applicant  was  asked  to  categorize  these impurities as Class 3 compounds.

The risk of one impurity being present either in the intermediate or in the final active substance can be considered as unlikely since the conditions required to form this impurity are not employed.

Two of the remaining structures were ruled out based on negative results in mutagenicity tests or based on structural analogy to a compound which was non-mutagenic in an Ames test.

One impurity gives a positive prediction in Derek Nexus and it is categorized as Class 5 compound based on a negative result in Ames test. However, some issues have been raised on this test and a GLP Ames test is requested in order to confirm the negative results. Currently, the impurity is not specifically named on the olaparib specification but is controlled as 'Any individual unspecified impurity'. The current control strategy for the impurity is acceptable provided that the negative results are confirmed (see conclusion).

All the other impurities were classified as Class 5 compounds based on two negative predictions which is sufficient to conclude that these impurities are of no mutagenic concern according to ICH M7. Based on this, no further action is required for these impurities that include all the specified impurities of the drug substance and the potential degradation impurity of the drug product

Omission of test for potentially mutagenic impurities has been justified in the revised section 3.2.S.4.5.

One class 1 impurity is controlled via option 4, as described in ICH M7. The removal of this impurity through the downstream processes was demonstrated by purging studies. No further action is required given the effective purge.

A further class 1 impurity is controlled via option 3, as described in ICH M7. Levels of this impurity have been reported as well below the specification limit, no further action is required.

One class 3 impurity is controlled via option 4, as described in ICH M7, in order to ensure that olaparib meets the established toxicological limit. The predicted purge factor of this class 3 impurity through the whole process has been determined.  Given a purge ratio well above 1000, no specification is required for this mutagenic impurity as per ICH M7 guidance.

Further class 3 impurities are also controlled via option 4, as described in ICH M7.

One  impurity  is  currently  controlled  under  'Unspecified  Impurity'.  The  predicted  purge  factor  of  this impurity  through  the  whole  process  has  been  determined.  Given  a  purge  ratio  well  above  1000,  no specification is required as per ICH M7 guidance.

One impurity is currently specified with a limit, while two related impurities are controlled as any other impurity. Based on this, and considering their purge through the whole process, these impurities can be controlled via option 4, as described in ICH M7.

## Finished product

Given the proposed extension of the patient population to an earlier line of cancer treatment (i.e. adjuvant setting),  the  control  strategy  for  potential  nitrosamines  in  the  drug  product  has  been  reassessed.  No significant risk of presence of nitrosamine impurities in the finished product has been identified.

## 2.4. Conclusion on quality aspects

Based on the review of the data on quality, the CHMP considers that the control strategy for potential mutagenic impurities is acceptable for the proposed (adjuvant) indication. The data provided sufficiently

<div style=\"page-break-after: always\"></div>

support the proposed changes. Relevant sections of Module 3 have been updated accordingly. The MAH is recommended to provide the results of a GLP Ames test for one impurity (see also non-clinical aspects).

<div style=\"page-break-after: always\"></div>

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

The  Applicant  has  submitted  an  updated  Nonclinical  Overview.  The  nonclinical  package  of  studies  was reviewed in accordance with the ICH M3(R2) guidance and an abbreviated package was proposed in view of the high-risk nature of the intended patient population i.e. BRCAm HER2-negative high risk early breast cancer. No additional nonclinical studies to further investigate carcinogenicity, reproductive toxicity or the safety of metabolites were submitted (see discussion on non-clinical aspects).

## 2.5.2. Ecotoxicity/environmental risk assessment

An updated Environmental Risk Assessment (ERA) was submitted.

Table 1: Summary of Environmental risk assessment

| Substance (INN/Invented Name): olaparib CAS-number (if available): 763113-22-0   | Substance (INN/Invented Name): olaparib CAS-number (if available): 763113-22-0   | Substance (INN/Invented Name): olaparib CAS-number (if available): 763113-22-0                                                                                                        | Substance (INN/Invented Name): olaparib CAS-number (if available): 763113-22-0   |
|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| PBT screening                                                                    |                                                                                  | Result                                                                                                                                                                                | Conclusion                                                                       |
| Bioaccumulation potential- log K ow                                              | OECD107 (study 06-0182/C)                                                        | 1.55                                                                                                                                                                                  | < 4.5 : not PBT or vPvB                                                          |
| PBT-assessment                                                                   |                                                                                  |                                                                                                                                                                                       |                                                                                  |
| Parameter                                                                        | Result relevant for conclusion                                                   |                                                                                                                                                                                       | Conclusion                                                                       |
| Bioaccumulation                                                                  | log P ow BCF                                                                     | 1.55 NA                                                                                                                                                                               | Conclusion                                                                       |
| Persistence                                                                      | DT 50 or ready biodegradability                                                  | DT50, total system, 20°C = 260 (S1) & 251 (S2) DT50, total system, 12°C = 551 (S1) & 534 (S2)                                                                                         | Not PBT nor vPvB                                                                 |
| Toxicity                                                                         | NOEC                                                                             | 0.32 mg/L                                                                                                                                                                             | Conclusion                                                                       |
| PBT-statement:                                                                   | The compound is not considered as PBT nor vPvB.                                  | The compound is not considered as PBT nor vPvB.                                                                                                                                       | The compound is not considered as PBT nor vPvB.                                  |
| Phase I                                                                          |                                                                                  |                                                                                                                                                                                       |                                                                                  |
| Calculation                                                                      | Value                                                                            | Unit                                                                                                                                                                                  | Conclusion                                                                       |
| PEC surfacewater , default or refined (e.g. prevalence, literature)              | 0.40                                                                             | µ g/L                                                                                                                                                                                 | > 0.01µg/L                                                                       |
| Phase II Physical-chemical properties and fate                                   | Phase II Physical-chemical properties and fate                                   |                                                                                                                                                                                       |                                                                                  |
| Study type                                                                       | Test protocol                                                                    | Results                                                                                                                                                                               | Remarks                                                                          |
| Hydrolysis                                                                       | OECD 111                                                                         | <10 %(120 hours) at pH 5, 7 and 9                                                                                                                                                     | Hydrolytically stable.                                                           |
| Ready Biodegradability Test                                                      | OECD 301F                                                                        | Negligible biodegradation (Day 28: <6%)                                                                                                                                               | Not readily biodegradable                                                        |
| Aerobic Transformation in Aquatic Sediment systems                               | OECD 308 ( 08- 0028/C)                                                           | DT50 values at 20°C LOM DT50water = 7.06 days HOM DT50water = 4.22 days LOM DT50total system = 251 days HOM DT50total system = 260 days DT50 values at 12°C LOM DT50water = 15.0 days | Sediment toxicity study triggered.                                               |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | HOM DT50water = 8.96 days LOM DT50total system = 534 days HOM DT50total system = 551 days No metabolites >10% were                                                                                                                                                                                                                                                                                                                                                            | HOM DT50water = 8.96 days LOM DT50total system = 534 days HOM DT50total system = 551 days No metabolites >10% were                                                                                                                                                                                                                                                                                                                                                            | HOM DT50water = 8.96 days LOM DT50total system = 534 days HOM DT50total system = 551 days No metabolites >10% were                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Adsorption-Desorption                                                                                                                                                                                                                                                                                                                                                                                                                                                         | OECD 106(study 12-0285/A)                                                                                                                                                                                                                                                                                                                                                                                                                                                     | observed. High Organic Carbon (HOC) sediment mean K d =111 K oc = 1986 Low Organic Carbon (LOC) sediment mean K d = 3.8 K oc = 27487                                                                                                                                                                                                                                                                                                                                          | observed. High Organic Carbon (HOC) sediment mean K d =111 K oc = 1986 Low Organic Carbon (LOC) sediment mean K d = 3.8 K oc = 27487                                                                                                                                                                                                                                                                                                                                          | observed. High Organic Carbon (HOC) sediment mean K d =111 K oc = 1986 Low Organic Carbon (LOC) sediment mean K d = 3.8 K oc = 27487                                                                                                                                                                                                                                                                                                                                          | KFoc values indicated that [ 14 C]Olaparib was of low mobility in the HOC sediment (KFoc 500-2000), and immobile in the LOC sediment (KFoc >5000)                                                                                                                                                                                                                                                                                                                             |
| Adsorption /desorption tosludge                                                                                                                                                                                                                                                                                                                                                                                                                                               | OPPTS 835.1110 (study 08-0028/B)                                                                                                                                                                                                                                                                                                                                                                                                                                              | Kd sludge(ads) = 25                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Kd sludge(ads) = 25                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Kd sludge(ads) = 25                                                                                                                                                                                                                                                                                                                                                                                                                                                           | [ 14 C]AZD2281 did not show significant adsorption to sewage sludge and therefore, is not predicted to adsorb to bio-solids during wastewater treatment. A Kd value of 25 was calculated assuming a linear adsorption isotherm                                                                                                                                                                                                                                                |
| Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Phase IIa Effect studies                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Study type                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Test protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | value                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Unit                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Remarks                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Algae, Growth Inhibition Test/ Species                                                                                                                                                                                                                                                                                                                                                                                                                                        | OECD 201 (study 06-0182/F)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 83                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | mg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | EC 50 = > 83 mg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Daphnia sp . Reproduction Test                                                                                                                                                                                                                                                                                                                                                                                                                                                | OECD 211 (study 06-0182/H)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.32                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | µg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 21 day LOEC = 1.0 mg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Fish, Early Life Stage Toxicity Test/ Species                                                                                                                                                                                                                                                                                                                                                                                                                                 | OECD 210 (study 06-0182/I)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 0.32                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | µg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 32 day LOEC 1.0 mg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Activated Sludge, Respiration Inhibition Test                                                                                                                                                                                                                                                                                                                                                                                                                                 | OECD 209 (study 06-0182/E)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NOEC                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 100                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | µg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 3 hour EC 50 > 100 mg/L                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| PNEC microorganism = 10 000 μg/L PNEC surfacewater = 32 µg/L PEC groundwater = 0.1 µg/L PNEC groundwater = 32 µg/L PEC surfacewater/ PNEC microorganism = 4.0 x 10-5: Olaparib is unlikely to present a risk to microorganisms PEC surfacewater /PNEC surfacewater = 1.25 x 10-2: Olaparib is unlikely to present a risk to organisms in surface water PEC groundwater /PNEC groundwater = 3.13 x 10-3: Olaparib is unlikely to present a risk to the groundwater environment | PNEC microorganism = 10 000 μg/L PNEC surfacewater = 32 µg/L PEC groundwater = 0.1 µg/L PNEC groundwater = 32 µg/L PEC surfacewater/ PNEC microorganism = 4.0 x 10-5: Olaparib is unlikely to present a risk to microorganisms PEC surfacewater /PNEC surfacewater = 1.25 x 10-2: Olaparib is unlikely to present a risk to organisms in surface water PEC groundwater /PNEC groundwater = 3.13 x 10-3: Olaparib is unlikely to present a risk to the groundwater environment | PNEC microorganism = 10 000 μg/L PNEC surfacewater = 32 µg/L PEC groundwater = 0.1 µg/L PNEC groundwater = 32 µg/L PEC surfacewater/ PNEC microorganism = 4.0 x 10-5: Olaparib is unlikely to present a risk to microorganisms PEC surfacewater /PNEC surfacewater = 1.25 x 10-2: Olaparib is unlikely to present a risk to organisms in surface water PEC groundwater /PNEC groundwater = 3.13 x 10-3: Olaparib is unlikely to present a risk to the groundwater environment | PNEC microorganism = 10 000 μg/L PNEC surfacewater = 32 µg/L PEC groundwater = 0.1 µg/L PNEC groundwater = 32 µg/L PEC surfacewater/ PNEC microorganism = 4.0 x 10-5: Olaparib is unlikely to present a risk to microorganisms PEC surfacewater /PNEC surfacewater = 1.25 x 10-2: Olaparib is unlikely to present a risk to organisms in surface water PEC groundwater /PNEC groundwater = 3.13 x 10-3: Olaparib is unlikely to present a risk to the groundwater environment | PNEC microorganism = 10 000 μg/L PNEC surfacewater = 32 µg/L PEC groundwater = 0.1 µg/L PNEC groundwater = 32 µg/L PEC surfacewater/ PNEC microorganism = 4.0 x 10-5: Olaparib is unlikely to present a risk to microorganisms PEC surfacewater /PNEC surfacewater = 1.25 x 10-2: Olaparib is unlikely to present a risk to organisms in surface water PEC groundwater /PNEC groundwater = 3.13 x 10-3: Olaparib is unlikely to present a risk to the groundwater environment | PNEC microorganism = 10 000 μg/L PNEC surfacewater = 32 µg/L PEC groundwater = 0.1 µg/L PNEC groundwater = 32 µg/L PEC surfacewater/ PNEC microorganism = 4.0 x 10-5: Olaparib is unlikely to present a risk to microorganisms PEC surfacewater /PNEC surfacewater = 1.25 x 10-2: Olaparib is unlikely to present a risk to organisms in surface water PEC groundwater /PNEC groundwater = 3.13 x 10-3: Olaparib is unlikely to present a risk to the groundwater environment |
| Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Phase IIb Studies                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Toxicity to Chironomus riparius                                                                                                                                                                                                                                                                                                                                                                                                                                               | OECD 218 (study 08-0028/D)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28 d NOEC = 0.6 mg/kg dry sediment and; NOEC normalised to 10% o.c. = 2.61 mg/Kg 28 d LOEC = 1.25 mg/kg dry sediment, based on                                                                                                                                                                                                                                                                                                                                                | 28 d NOEC = 0.6 mg/kg dry sediment and; NOEC normalised to 10% o.c. = 2.61 mg/Kg 28 d LOEC = 1.25 mg/kg dry sediment, based on                                                                                                                                                                                                                                                                                                                                                | 28 d NOEC = 0.6 mg/kg dry sediment and; NOEC normalised to 10% o.c. = 2.61 mg/Kg 28 d LOEC = 1.25 mg/kg dry sediment, based on                                                                                                                                                                                                                                                                                                                                                | 28 d NOEC = 0.6 mg/kg dry sediment and; NOEC normalised to 10% o.c. = 2.61 mg/Kg 28 d LOEC = 1.25 mg/kg dry sediment, based on                                                                                                                                                                                                                                                                                                                                                |
| Toxicity to Lumbriculus variegatus                                                                                                                                                                                                                                                                                                                                                                                                                                            | OECD 225 (study 123A-124)                                                                                                                                                                                                                                                                                                                                                                                                                                                     | development rate 28 day NOEC = 86 mg/kg dry weight                                                                                                                                                                                                                                                                                                                                                                                                                            | development rate 28 day NOEC = 86 mg/kg dry weight                                                                                                                                                                                                                                                                                                                                                                                                                            | development rate 28 day NOEC = 86 mg/kg dry weight                                                                                                                                                                                                                                                                                                                                                                                                                            | development rate 28 day NOEC = 86 mg/kg dry weight                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Toxicity to Hyalella azteca                                                                                                                                                                                                                                                                                                                                                                                                                                                   | U.S. EPA 600/R-99/064 (study 123A-125)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 28 day NOEC = 89.6 mg/kg dry weight                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28 day NOEC = 89.6 mg/kg dry weight                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28 day NOEC = 89.6 mg/kg dry weight                                                                                                                                                                                                                                                                                                                                                                                                                                           | 28 day NOEC = 89.6 mg/kg dry weight                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

PECsediment = 48.6 µg/kg (dry weight) PNECsediment = 260 μg/kg (NOEC from the chironomus test (normalised to 10% o.c.) / 10) PEC/PNECsediment = 0.19: Olaparib is unlikely to present a risk to sediment dwelling organisms

## 2.5.3. Discussion on non-clinical aspects

With this application, Lynparza is proposed to be indicated in early breast cancer that falls under ICH M3(R2) for non-advanced cancers.

No additional non-clinical studies were submitted in support of this application. The non-clinical and clinical risks are considered to be well characterised and the adverse effects in animals are sufficiently known.

Olaparib is not mutagenic but causes clastogenicity consistent with the mechanism of action. The potential for genotoxicity in humans is mentioned in section 5.3 of the SmPC and a subsection on myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) is included in sections 4.4 and 4.8 of the SmPC. New primary malignancies (NPM) and MDS/AML are also described as important potential risk and important identified risk,  respectively,  in  the  olaparib  risk  management  plan  (RMP).  Since  2014,  these  risks  have  been proactively  monitored during clinical development, which included solicited reporting of adverse events (AEs) during the overall survival follow-up phase in the majority of MAH-sponsored clinical trials.

Olaparib has shown embryo-foetal toxicity and teratogenicity. The product information includes adequate warnings in relation to pregnancy and contraception. The duration of contraception use following the end of treatment for women of childbearing potential was revised in line with the document 'Response from SWP  to  CMDh  questions  regarding  genotoxicity  and  contraception'  (EMA/CHMP/SWP/74077/2020). Lynparza should not be used during pregnancy and in women of childbearing potential not using reliable contraception during therapy and for 6 months after receiving the last dose of Lynparza (see sections 4.4 and 4.6). Breastfeeding during treatment and for 1 month after the last dose is a contraindication due to the pharmacological properties of the product (see SmPC section 4.3).

M18 (a product of phase 1 metabolic pathways) was identified as the only major circulating metabolite in humans (15.8% of total drug-related exposure). This metabolite was also found in humans. Because M18 was less potent than olaparib in primary pharmacology and structurally similar to olaparib, additional risks are considered unlikely.

A complete and acceptable environmental risk assessment was submitted for Lynparza. Olaparib was found to be very persistent in the environment (DT50 &gt; 180 days). Olaparib did not demonstrate any other environmental risks. The conclusions of this updated ERA are consistent with that of the previously submitted ERA. The patient use of Lynparza is not predicted to present a risk to the environment.

An Ames study provided for one of the impurities (see quality aspects) did not show any mutagenic potential of the impurity up to a concentration of 500 µg/well without S9 and up to 1600 µg/well with S9. However, the study provided was not GLP compliant and the MAH is recommended to provide the results of a GLP Ames test for the impurity. It is recommended that the maximum doses with and without S9 are selected as  the  highest  doses  where  a  precipitate  is  observed  without  interfering  with  scoring.  Triple  plating  is recommended at each dose level and the use of the preincubation method is encouraged.

<div style=\"page-break-after: always\"></div>

## 2.5.4. Conclusion on the non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP. The risks associated with olaparib have been characterised based on available non-clinical and clinical data and are adequately described in the Lynparza EU SmPC and addressed in the EU Risk Management Plan (RMP).

The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of olaparib. Considering the above data, olaparib is not expected to pose a risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical aspects

## 2.6.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 2: Tabular overview of clinical studies

| Type of study        | Study identifier, status                                                                                                | Objective(s) of the study                                              | Study design/type of control                                      | Test product, dosage regimen, routeof administration   | No of patients randomised /treated   | Patientpopulation                                                                                                                                                    | Location of study report    |
|----------------------|-------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| Efficacy, safety, PK | D081CC00006 (OlympiA [BIG 6-13, NSABP B 55]) Ongoing; interim (primary) superiority analysis (IDFS, DDFS, OS) completed | Determine the efficacy (asscssed byIDFS)of olaparibcompared to placcbo | Phase III, randomised, double-blind, placcbo-control, multicentre | Olaparib 300 mg bd tablet (oral) Matching placcbo      | 1836/1815                            | Patients with germline BRCA1/2mutationsand HER2negativehigh-risk carlybrcast cancerwhohave completed definitivelocal treatmcntandncoadjuvant oradjuvant chemotherapy | OlympiA CSR, Module 5.3.5.1 |

bd= twice daily;BRCA =breast cancer susceptibility gene; BRCAm =BRCA mutated; DDFS=distant disease free survival;HER2 =human epidermal growth factor receptor 2; IDFS =invasive disease free survival; OS = overall survival; PK =pharmacokinetics.

Source:OlympiA CSR,Module5.3.5.1.Data cut-off27March 2020.

## 2.6.2. Pharmacokinetics

## PK in breast cancer patients

No additional formal PK investigations were submitted in the context of the variation under review. However, the population-PK model was updated (Olaparib-MS-09) using data from patients with breast cancer investigated in OlympiA study.

<div style=\"page-break-after: always\"></div>

Figure 1 : Overlap between OlympiA PK observations and model predictions from Olaparib-MS09

<!-- image -->

The shaded area and dotted line represent the PK model predictions at 300mg bd from Olaparib-MS-09 (n=497) (2.5 th , 50 th  and 97.5 th  percentiles). The black dots are the observed olaparib PK data in OlympiA after the 300 mg bd dose (n=69). Source: Olaparib-MS-09

## Effect of intrinsic Factors on the PK of Olaparib

The updated pop-PK analysis (Olaparib-MS-09) did not identify gender, race, tumour location, age or body weight as significant covariates. Additionally, BRCA1/2 status was not identified as a significant covariate.

## Effect of Extrinsic Factors on the PK of Olaparib

Considering that the claimed indication implies co-administration of olaparib and anti-hormonal drugs such as tamoxifen, and letrozole and anastrozole, the potential for DDI interaction of olaparib and antihormonal drugs was investigated. Study D081CC00001 was conducted to evaluate the DDI between olaparib and anti-hormonal agents at steady state, such as anastrozole (1 mg od), letrozole (2.5 mg od) and tamoxifen (20 mg od). It was an open label, non-randomised, parallel group, multicentre, Phase I study to assess the safety and the effect of olaparib at steady state on the PK of the anti-hormonal agents anastrozole, letrozole and  tamoxifen  at  steady  state,  and  the  effect  of  the  anti-hormonal  agents  on  olaparib,  following administration in patients with advanced solid cancer. Part A of the study (mandatory) assessed the effect of olaparib on the PK parameters of anastrozole, letrozole and tamoxifen and vice versa; Part B allowed patients (if eligible) continued access to olaparib after the PK phase and provided additional safety data.

The main findings of Study D081CC00001are summarised below.

<div style=\"page-break-after: always\"></div>

Table 3: Effect of tamoxifen on olaparib

| Olaparib PK parameter   | Olaparib +tamoxifen   | Olaparib +tamoxifen   | Olaparib   | Olaparib   | Point estimate of GLSmean ratio tamoxifen + olaparib   | 90%CI of GLSmean ratio tamoxifen + olaparib   |
|-------------------------|-----------------------|-----------------------|------------|------------|--------------------------------------------------------|-----------------------------------------------|
| Olaparib PK parameter   | N                     | GLSmean               | N          | GLSmean    | Point estimate of GLSmean ratio tamoxifen + olaparib   | 90%CI of GLSmean ratio tamoxifen + olaparib   |
| (μg/mL)                 | 19                    | 7.553                 | 26         | 9.444      | 0.80                                                   | 0.71, 0.90                                    |
| AUCs. (μg.h/mL)         | 18                    | 44.81                 | 25         | 61.58      | 0.73                                                   | 0.63, 0.84                                    |

AUC, Area under the plasma concentration time curve over the dosing interval at steady state, Cmxs Maximum plasma concentration at steady state; CI Confidence interval; GLS Geometric least squares;

PK Pharmacokinetic.

Data Source: Table 14 from CSR D081CC00001 in Module 5.3.3.2.

When olaparib (300 mg tablet) was co-administered with tamoxifen (20 mg od), there was a decrease in olaparib Geometric least squares (GLS) mean AUCss of 27% (mean ratio: 0.73; 90% CI: 0.63, 0.84), and a decrease in steady state GLS mean Cmaxby 20% (mean ratio: 0.80; 90% CI: 0.71, 0.90).

Table 4: Effect of olaparib on tamoxifen

<!-- image -->

| Tamoxifen PK parameter   | Olaparib +tamoxifen   | Olaparib +tamoxifen   | Tamoxifen   | Tamoxifen   | Point estimate of GLSmean ratio tamoxifen + olaparib   | 90% CI of GLSmean ratio tamoxifen + olaparib   |
|--------------------------|-----------------------|-----------------------|-------------|-------------|--------------------------------------------------------|------------------------------------------------|
|                          | N                     | GLSmean               | N           | GLSmean     |                                                        |                                                |
| Cmax ss (μg/mL)          | 18                    | 147.9                 | 24          | 130.3       | 1.13                                                   | 1.06, 1.22                                     |
| AUCs. (μg.h/mL)          | 18                    | 2583                  | 24          | 2233        | 1.16                                                   | 1.11, 1.21                                     |

AUCss Area under the plasma concentration time curve over the dosing interval at steady state; Cmax,ss Maximum plasma concentration at steady state; CI Confidence interval; GLS Geometric least squares; PK

Pharmacokinetic.

## Effects of Other anti-hormonal Drugs (anastrozole and letrozole) on the PK of Olaparib

The anti-hormonal drugs, anastrozole (1 mg od) and letrozole (2.5 mg od) had no relevant impact on the steady state exposure to olaparib (300 mg bd) when given in combination. The mean ratio (90%CI) for olaparib  AUCss  and  Cmax,ss  were  0.89,  (0.76-1.05)  and  0.94(0.84-1.04)  when  co-administered  with anastrozole; and the GLS mean ratio for olaparib AUCssand Cmax,sswere 1.15 (1.07-1.25) and 1.09 (0.991.21) for Cmax,ss when co-administered with letrozole.

## Effects of Olaparib on the PK of Other anti-hormonal Drugs (anastrozole and letrozole)

Olaparib had no marked effect on the exposure to anastrozole or letrozole at steady state. The GLS mean ratio (90%CI) on anastrozole AUCss and Cmax,ss were 0.86, (0.80-0.93) and 0.90 (0.84-0.97) respectively; and the mean ratio on letrozole AUCss and Cmax,ss were 0.95 (0.91-0.99) and 0.94 (0.914-0.98) for Cmax,ss respectively.

<div style=\"page-break-after: always\"></div>

## PK/PD modelling /Exposure-Response relationshipExposure-Efficacy Relationship

In OlympiA, Kaplan-Meier curves for IDFS stratified by the tertile exposure for any of the exposure metrics showed no apparent exposure-response trend. In addition, Cox proportional hazard analysis based on AUCss values spanning over the range of 13.2 μg.h/mL to 101 μg.h/mL could not detect a statistically significant correlation between this exposure metric and IDFS. In patients with PK data who received concomitant tamoxifen and were demonstrated to have lower exposure of olaparib, the Kaplan-Meier curve was similar to that of patients with PK data who did not receive concomitant tamoxifen ( Figure 2 ).

Figure 2: Kaplan Meier Curves for patients with PK data on concomittant tamoxifen  (n =8) and for patients with PK data not on concomittant (n=61) in OlympiA

<!-- image -->

Similarly, graphical analyses in OlympiAD did not reveal any apparent relationship in breast cancer patients between olaparib exposure metrics and PFS, OS, or PFS2.

## Exposure-Safety Relationship

The most recent exposure-safety analysis based on pooled data from monotherapy studies with the tablet formulation (Olaparib-MS-09) suggested daily Cmax and daily AUC behaved similarly as the best predictor for  safety  endpoints.  Similar  to  the  previous  analyses,  it  identified  relatively  weak  exposure -response relationships between at least one of the exposure metrics of olaparib and anaemia, decreased appetite, fatigue,  nausea,  vomiting,  and  diarrhoea.  Anaemia  had  a  statistically  significant  relationship  with  all exposure metrics while there was no increased dysgeusia, headache and neutropenia event rate detected for any for the exposure metrics.

<div style=\"page-break-after: always\"></div>

## 2.6.3. Discussion on clinical pharmacology

The tablet formulation was used in study OlympiA. The proposed recommended total dose of olaparib in the indication under review is 600 mg per day. The drug is recommended to be administered as two 150 mg tablets (300 mg) taken twice daily. The 100 mg strength could be used for dose reduction when needed.

No complementary formal PK investigations were provided in the context of the variation under review. However, the already assessed pop-PK model was updated by the inclusion of data from study OlympiA. The PKs of olaparib in the target patients was assessed and compared to the PK profile characterised in other cancer patients. Also, based on the updated model, the exposure-response (Efficacy and safety) relationship in target patients was investigated.

Exposure to olaparib in the OlympiA study, collected from breast cancer patients, was shown to be similar to that observed in previous studies with the olaparib 300mg bd tablet.

The potential for DDI for olaparib as a victim or perpetrator has been previously investigated and characterized. The results of study D081CC00001 (effect of anti-hormonal agents on olaparib) were previously submitted in procedure EMEA/H/C/003726/X/0016/G supporting the use of the tablet formulation. Based on this study, it was concluded that no significant interaction was observed with anastrozole or letrozole whereas tamoxifen decreased exposure to olaparib by 27%. However, results from PK/PD modelling suggested that the exposure response for efficacy in breast cancer was flat at the 300 mg bd dose level. Therefore, the reduction in olaparib exposure due to co-administration of tamoxifen is not considered clinically relevant. Section 4.5 of the SmPC has been updated accordingly.

The potential for DDI of olaparib with exemestane and goserelin has not been investigated. Nevertheless, the potential for relevant PK-based DDI between olaparib and exemestane or goserelin is unlikely given the different metabolic pathways, the clinical data available and the PBPK predictions.

The Exposure-Response (efficacy-safety) relationship was investigated in the proposed target population included in study OlympiA. The outcome of this analysis is consistent with that described for patients in other indications.

## 2.6.4. Conclusions on clinical pharmacology

No significant difference in PKs characteristics was observed in breast cancer patients from the OlympiA study compared to the PK profile of olaparib tablet formulation observed in previous studies in approved indications.

<div style=\"page-break-after: always\"></div>

## 2.7. Clinical efficacy

## 2.7.1. Main study

## Study D081CC00006 (OlympiA)

## Methods

OlympiA was a randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and HER2 negative high-risk early breast cancer who had completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

The study flow chart for the OlympiA study is provided in Figure 3 .

<div style=\"page-break-after: always\"></div>

<!-- image -->

bd = twice daily; BRCA = breast cancer susceptibility gene; BRCAm = BRCA mutated; CPS&amp;EG = clinical stage (CS), oestrogen receptor status (E), nuclear grade (G), and post treatment pathologic stage (PS)- a disease scoring system; CR = complete response ER = 0estrogen feceptor; gBRCA = germline BRCA; HER2 = human epidermal growth factor receptor 2; ICF = informed consent form; IDFS = invasive disease free survival; MRI = magnetic resonance imaging: OS = overall survival; PgR = progesterone receptor; PK = pharmacokinetics TNBC = triple negative breast cancer.

Figure 3: Study Design - OlympiA

## Study participants

## Main inclusion criteria

For inclusion in the study patients should fulfil the following criteria:

<div style=\"page-break-after: always\"></div>

1. Provision of informed consent prior to any study specific procedures
2. Female or male patients must be ≥ 18 years of age

3A. For patients who underwent initial surgery and received adjuvant chemotherapy

- -TNBC patients must have been axillary node-positive ( ≥ pN1, any tumour size) or axillary nodenegative (pN0) with invasive primary tumour pathological size &gt; 2 cm ( ≥ pT2)
- -ER and/or PgR positive/HER 2 negative patients must have had ≥ 4 pathologically confirmed positive lymph nodes
- 3B. For patients who underwent neoadjuvant chemotherapy followed by surgery
1. TNBC patients must have residual invasive breast cancer in the breast and/or resected lymph nodes (non pCR)
2. ER and/or PgR positive/HER 2 negative patients must have residual invasive cancer in the breast and/or the resected lymph nodes (non pCR) AND a CPS&amp;EG score ≥ 3.

4. Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast that is one of the two following phenotypes:

- a) TNBC defined as:
2. -ER and PgR negative defined as IHC nuclear staining &lt;1%.

## AND

- -HER2 negative (not eligible for anti-HER2 therapy) defined as:
- o IHC 0, 1+ without ISH OR
- o IHC 2+ and ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number &lt; 4 signals/cells OR
- o ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number &lt; 4 signals/cells (without IHC)
- b) ER and/or PgR positive, HER2 negative breast cancer defined as:
- -ER and/or PgR positive defined as IHC nuclear staining ≥1%.

## AND

- -HER2 negative (not eligible for anti-HER2 therapy) defined as:
- o IHC 0, 1+ without ISH OR
- o IHC 2+ and ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number &lt; 4 signals/cells OR
- o ISH non-amplified with ratio less than 2.0 and if reported, average HER2 copy number &lt; 4 signals/cells (without IHC)

Patients with multifocal or multicentric invasive disease are eligible as long as all the lesions for which HER2 characterization is available are HER2 negative.

Patients with synchronous bilateral invasive disease are eligible as long as all the lesions assessed for HER2 on both sides are negative.

<div style=\"page-break-after: always\"></div>

In both the above cases the lesion considered at highest risk for recurrence based on the investigator's discretion will be used for eligibility determination.

5. Documented germline mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function). Local gBRCA testing results, if available, will be used for establishing eligibility. If local gBRCA testing results are not available, central testing will be provided for those patients who otherwise appear to be eligible.

6A. Completed adequate breast surgery defined as:

- -The inked margins of breast conservation surgery or mastectomy must be histologically free of invasive breast cancer and ductal carcinoma in situ with the exception of the posterior margin if this margin is the pectoralis major fascia or the anterior margin if this is the dermis. Patients with resection margins positive for lobular carcinoma in situ are eligible.
- -Patients with breast conservation must have adjuvant radiotherapy. Patients having mastectomy may have adjuvant radiotherapy according to local policy and/or international guidelines.

## 6B. Completed adequate axilla surgery defined as:

## Adjuvant Chemotherapy Patients:

- -Sentinel lymph node biopsy alone if negative or if lymph node(s) only contain micrometastases ( ≤ 2.0 mm) OR
- -Positive sentinel lymph node biopsy followed by axillary nodal dissection or radiotherapy as per local guidelines OR
- -Axillary dissection

## Neoadjuvant Chemotherapy Patients:

- -Sentinel lymph node biopsy performed before neoadjuvant chemotherapy:
- o If negative or if lymph node(s) only contain micrometastases ( ≤ 2.0 mm) additional axillary surgery is not required
- o If positive, axillary node dissection or axillary nodal radiotherapy should follow completion of neoadjuvant chemotherapy
- -Sentinel lymph node biopsy performed after neoadjuvant chemotherapy:
- o If negative, additional axillary surgery not mandated
- o If  positive  (micrometastases  are  regarded  as  positive),  additional  axillary  surgery  is required unless the patient is enrolled in a Phase III multicenter clinical trial proposing radiotherapy as alternative treatment of the axilla. The trial must be pre-approved by the OlympiA Executive Committee
- -Axillary dissection

7. Completed at least 6 cycles of neoadjuvant or adjuvant chemotherapy containing anthracyclines, taxanes or the combination of both. Prior platinum as potentially curative treatment for prior cancer (e.g. ovarian) or  as  adjuvant  or  neoadjuvant  treatment  for  breast  cancer  is  allowed.  (For  neoadjuvant  patients  all chemotherapy should be delivered prior to surgery. No further cycles of chemotherapy post-surgery are allowed.)

<div style=\"page-break-after: always\"></div>

8.  Patients  must  have  adequate  organ  and  bone  marrow  function  measured  within  28  days  prior  to randomisation with no blood transfusions (packed red blood cells and/or platelet transfusions) in the past 28 days prior to testing for organ and bone marrow function as defined below:

- -Haemoglobin ≥ 10.0 g/dL
- -Absolute neutrophil count (ANC) ≥ 1.5 x 10 9 /L
- -Platelet count ≥ 100 x 10 9 /L
- -Total Bilirubin ≤ ULN (institutional upper limit of normal) except elevated total bilirubin &lt;1.5 x ULN due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin
- -AST (SGOT)/ALT (SGPT) ≤ 2.5 x ULN
- -ALP ≤ 2.5 x ULN

To rule out metastatic breast cancer, patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, CT or MRI at any time point between diagnosis of current breast cancer and randomisation. Screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit. (Note: PET CT scan may be used as an alternative imaging technique).

## 9. Serum or plasma creatinine ≤ 1.5 x ULN

## 10. ECOG performance status 0-1

11A. Women who are not postmenopausal or have not undergone hysterectomy must have documented negative pregnancy test within 28 days prior to randomisation:

Postmenopausal is defined as:

- -Age ≥ 60 years
- -Age  &lt;60  years  and  amenorrheic  for  1  year  or  more  in  the  absence  of  chemotherapy  and/or hormonal treatment
- -Follicle stimulating hormone (FSH) and plasma estradiol levels in the postmenopausal range for women under 60 years
- -Radiation-induced oophorectomy with last menses &gt;1 year ago
- -Bilateral oophorectomy

11B. Women of childbearing potential and their partners, who are sexually active, must agree to the use of two highly effective forms of contraception in combination.

12. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations

13. Formalin fixed, paraffin embedded (FFPE) tumour sample from the primary tumour, mandatory*.

*NOTE: For adjuvant patients, this refers to the surgical specimen; for neoadjuvant patients, both the pretreatment  core  biopsy  and  the  surgical  specimen  with  residual  disease  are  requested  but  only  one  is mandatory.

14. Patient should be randomised in the trial ideally within a maximum of 8 weeks of completion of their last treatment (surgery, chemotherapy or radiotherapy), but in no case longer than 12 weeks.

<div style=\"page-break-after: always\"></div>

## Main exclusion criteria:

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

1. Involvement in the planning and/or conduct of the study.

2. Patients who do not have deleterious or suspected deleterious gBRCA1 and/or 2 mutations but only have BRCA1 and/or BRCA2 mutations that are considered to be non-detrimental (e.g., 'Variants of uncertain clinical  significance'  or  'Variant  of  unknown significance' or 'Variant, favour polymorphism' or 'benign polymorphism' etc.).

3. Previous randomisation in the present study.

4. Evidence of metastatic breast cancer. Patient considered at high risk of having disseminated disease (i.e. those  with  locally  advanced  disease,  clinical  N2-3  or  pathological  N1-3  with  the  exception  of  pN1a  in adjuvant patients) should have a CT/MRI scan of the Thorax/Abdomen/Pelvis or any other area as clinically indicated and a bone scan at any point between diagnosis of the current breast cancer and randomisation to rule out metastatic breast cancer. (Note PET/ CT scan may be used as an alternative imaging technique and precludes the need for bone scan). Patients with screening ALT/AST or ALP above institutional upper limit of normal should have liver ultrasound, CT or MRI at any time point between diagnosis of current breast cancer and randomisation. Screening bone scan is required if ALP and/or corrected calcium level are above the institutional upper limit. (Note PET/ CT scan may be used as an alternative imaging technique).

5. Exposure to an investigational product within 30 days or five half-lives (whichever is the longer) prior to randomisation.

6. Any previous treatment with a PARP inhibitor, including olaparib and/or known hypersensitivity to any of the excipients of study treatment.

7. Patients with second primary malignancy. Exceptions are:

- -adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, Ductal Carcinoma in situ (DCIS) of the breast, stage 1 grade 1 endometrial carcinoma.
- -other solid tumours and lymphomas (without bone marrow involvement) diagnosed ≥ 5 years prior to randomisation and treated with no evidence of disease recurrence and for whom no more than one line of chemotherapy was applied.

8. Resting ECG with QTc &gt;470 msec detected on 2 or more time points within a 24-hour period or family history of long QT syndrome. If ECG demonstrates QTc &gt;470 msec, patient will be eligible only if repeat ECG demonstrates QTc ≤ 470 msec.

9. Patients receiving systemic chemotherapy within 3 weeks prior to randomisation.

10. Patients receiving adjuvant radiotherapy within 2 weeks prior to randomisation.

11. Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease  inhibitors  boosted  with  ritonavir  or  cobicistat,  indinavir,  saquinavir,  nelfinavir,  boceprevir, telaprevir)  or  moderate  CYP3A  inhibitors  (e.g.,  ciprofloxacin,  erythromycin,  diltiazem,  fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks. Concomitant use of known strong (e.g., phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.

<div style=\"page-break-after: always\"></div>

12. Persistent toxicities ( ≥ CTCAE grade 2) caused by previous cancer therapy, excluding alopecia and CTCAE grade 2 peripheral neuropathy.
13.  Patients  with  current  or  past  history  of  haematologic  malignancies  and  any  clonal  non-malignant haematological disorder which predisposes the patient to develop a haematological malignancy. Exception: lymphoma (refer to Exclusion Criterion 7).
14. Major surgery within 2 weeks prior to randomisation: patients must have recovered from any effects of any major surgery.

## CPS&amp;ES score

In the OlympiA study, non-pCR combined with CPS&amp;EG score ≥ 3 was implemented within the eligibility criteria to select ' high risk ' ER and/or PgR positive, HER2 negative gBRCAm patients following neoadjuvant chemotherapy whose risk of recurrence would be expected to be comparable to that of a TNBC non-pCR population.

In clinical practice, there is no universal system/tool on how to define a 'high-risk' patient for subgroups of early breast cancer, and definition of high-risk breast cancer may be based on local/regional clinical guidelines (Cardoso et al 2019, NCCN Guidelines 2021). However, non-pCR post neoadjuvant chemotherapy, high tumour burden, nodal involvement, aggressive biology and young age are among the common 'high-risk' factors (Cardoso et al 2019, NCCN Guidelines 2021). To illustrate the correlation between the CPS&amp;EG scoring system and the conventional high-risk criteria, Table 5 shows how AJCC (TNM) staging, oestrogen receptor status and tumour nuclear grade were utilized to assign points to the CPS&amp;EG scoring system. With higher pre-treatment clinical staging (per AJCC criteria) and post-treatment pathological staging (per AJCC criteria), more points were assigned. In addition, points were given to well-recognized high-risk factors, such as ER negativity and tumour nuclear grade 3 based on the CPS&amp;EG scoring system.

Table 5: CPS&amp;EG score a

| Stage/feature                     | Stage/feature   | AJCC staging                     |   Points |
|-----------------------------------|-----------------|----------------------------------|----------|
| Clinical Stage (pre-treatment)    | 1               | T1NO; T0N1mi; T1N1mi             |        0 |
|                                   | IIA             | TON1; T1N1; T2NO                 |        0 |
|                                   | IIB             | T2N1; T3N0                       |        1 |
|                                   | IIIA            | T0-3 N2; T3N1                    |        1 |
|                                   | IIIB            | T4 N0-2                          |        2 |
|                                   | IIC             | ANY TN3                          |        2 |
| Pathologic Stage (post-treatment) | 0               | ypT0/is ypNO                     |        0 |
| Pathologic Stage (post-treatment) | I               | ypT1ypNO; ypTOypN1mi; ypT1ypN1mi |        0 |
| Pathologic Stage (post-treatment) | IIA             | ypTOypN1; ypT1ypN1; ypT2ypNO     |        1 |
| Pathologic Stage (post-treatment) | IIB             | ypT2ypN1; ypT3ypNO               |        1 |
| Pathologic Stage (post-treatment) | IIIA            | ypT0-2 ypN2; ypT3ypN1            |        1 |
| Pathologic Stage (post-treatment) | IIIB            | ypT4 ypN0-2                      |        1 |
| Pathologic Stage (post-treatment) | IIC             | Any ypT ypN3                     |        2 |
| Receptor status                   | ER negative °   |                                  |        1 |
| Nuclear graded                    | Nuclear grade 3 |                                  |        1 |

to derive a sum (CPS&amp;EG score) between O and 6.

- ER: Estrogen receptor, definitions for ER negativity see eligibility criteria Section 4.1.4.a.
- AJCC: American Joint Committee on Cancer (https://cancerstaging.org/Pages/default.aspx).

In the unlikely situationnuclear gradecannot be determined, regular histologic grade should be used; if only Nottingham overall grade is reported, theNottingham overall grade must be 9 to be scored as 1 point in the CPS&amp;EG score (http://pathology.jhuedu/breast/grade.php).

<div style=\"page-break-after: always\"></div>

## BRCA Testing Methodologies

Data on gBRCA mutation status for OlympiA was to be obtained from a combination of locally generated BRCA mutation status obtained from medical records and reported in the CRFs, and/or assessment at a central laboratory, Myriad Genetic Laboratories Inc. BRCA testing of all patients in China was to be conducted locally by BGI Laboratory.

Germline BRCA testing conducted for OlympiA by Myriad was performed either using their CLIA-based assay, BRACAnalysis, or BRACAnalysis CDx.

Local testing laboratories could use a variety of methods to detect BRCA variants. Locally identified BRCA mutations were to be taken from medical records and reported within the CRF, however details of the specific methods used to detect the variants were not required to be provided. Confirmatory testing of locally reported mutations was to be subsequently performed by central testing at Myriad.

## Treatments

Patients were randomised in a 1:1 ratio to receive either olaparib tablets 300 mg bd or the matching placebo tablets orally bd for up to a maximum of 12 months.

The 100 mg olaparib tablets were used to manage dose reductions.

Patients were allowed to have concurrent treatment with endocrine therapy as per local guidelines .

## Objectives

## Primary objective

The primary objective was to assess the effect of adjuvant treatment with olaparib on Invasive Disease Free Survival (IDFS).

## Safety objective

To assess the safety and tolerability of adjuvant treatment with Olaparib.

## Secondary objectives

- -To assess the effect of adjuvant treatment with olaparib on overall survival (OS)
- -To assess the effect of adjuvant treatment with olaparib on Distant Disease Free Survival (DDFS)
- -To  assess  the  effect  of  adjuvant  treatment  with  olaparib  on  the  incidence  of  new  primary contralateral invasive breast cancer, primary contralateral non-invasive breast cancer, new primary ovarian cancer, new primary fallopian tube cancer and new primary peritoneal cancer
- -To assess the effect of olaparib on patient reported outcomes using the FACIT-Fatigue and EORTC QLQ-C30 questionnaires
- -To  assess  the  efficacy  of  olaparib  in  patients  identified  as  having  a  deleterious  or  suspected deleterious variant in either of the BRCA genes using variants identified with current and future germline BRCA mutation assays (gene sequencing and large rearrangement analysis)
6. To determine the exposure to olaparib (in plasma) in patients receiving olaparib as adjuvant therapy

<div style=\"page-break-after: always\"></div>

## Exploratory objectives

- -To assess the consistency of treatment effects on efficacy endpoints across potential or expected prognostic factors, including the baseline stratification factors with special emphasis on hormone receptor status
- -To explore methods for estimating overall survival (OS) adjusting for the impact of confounding by subsequent therapies, specifically the control arm receiving subsequent Polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerisation (PARP) inhibitors or platinum salts
- -To explore whether resistance mechanisms to olaparib can be identified through analysis of tumour and blood sample derivatives (cells, plasma and protein and nucleic acid derivatives) - archival tumour  samples  (mandatory),  tumour  sample  at  recurrence  (optional)  and  blood  samples  at baseline, 30 days post study treatment and on disease recurrence (mandatory)

For adjuvant patients, this refers to the surgical specimen; for neoadjuvant patients, both the pretreatment core biopsy and the surgical specimen with residual disease are requested but only one is mandatory.

- -To determine the frequency of and describe the nature of BRCA mutation/s in tumour samples and to compare this with germline BRCA mutation status
- -To  conduct  future  exploratory  research  into  factors  that  may  influence  development  of  cancer and/or response to treatment (where response is defined broadly to include efficacy, tolerability or safety). This may be performed on the collected and stored tumour and blood samples
- -To  collect  and  store  DNA  according  to  each  country's  local  and  ethical  procedures  for  future exploratory research into genes/genetic variation that may influence response (i.e. distribution, safety, tolerability and efficacy) to study treatments and/or susceptibility to disease (optional)

## Outcomes/endpoints

## Primary endpoint

Invasive Disease Free Survival (IDFS) defined as the time from randomisation to date of first recurrence, where recurrence is defined according to the standardised terms for efficacy endpoints (STEEP) system definition as one of the following:

- -Ipsilateral invasive breast tumour recurrence: Invasive breast cancer involving the same breast parenchyma as the original primary.
- -Regional invasive breast cancer recurrence: Invasive breast cancer in the axilla, regional lymph nodes, chest wall, and skin of the ipsilateral breast.
- -Distant  recurrence:  Metastatic  disease-breast  cancer  that  has  either  been  biopsy  confirmed  or radiologically diagnosed as recurrent invasive breast cancer.
- -Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause.
- -Contralateral invasive breast cancer.
- -New primary non-breast invasive cancers (i.e., excluding new in situ carcinomas of any site). New primary non-breast invasive cancers include haematologic cancers and MDS. Squamous or basal cell skin cancers will not be counted as primary endpoint events.

<div style=\"page-break-after: always\"></div>

Secondary endpoints

- -Overall survival (OS) defined as the time from the date of randomisation until death due to any cause.
- -Distant disease free survival (DDFS) defined as the time from randomisation until documented evidence  of  first  distant  recurrence  of  breast  cancer.  Distant  recurrence  included  the  following events:
- o Distant recurrence: Metastatic disease-breast cancer that had either been biopsy confirmed or radiologically diagnosed as recurrent invasive breast cancer.
- o Death attributable to any cause, including breast cancer, non-breast cancer, or unknown cause.
- o New primary non-breast invasive cancer.
- -New primary contralateral breast cancers (invasive and non-invasive), new primary ovarian cancer, new primary fallopian tube cancer and new primary peritoneal cancers in patients at risk for these events
- -HRQoL/PROs:  FACIT-Fatigue  symptom  scale  score  and  EORTC-QLQ-C30  global  health  status, functional, and symptoms scales/items scores
- -IDFS, DDFS and OS based on patients with gBRCA mutations confirmed by the central test (only required if population differs from the ITT (intention to treat) population)
- -Pharmacokinetic analysis

Safety endpoints: Adverse Events (AE), physical examination, vital signs including blood pressure (BP), pulse, and laboratory findings including clinical chemistry and haematology

Exploratory endpoints:

- -Potential retrospective biomarker (mandatory) &amp; pharmacogenetic research (optional)
- -Adjusted overall survival estimates (if applicable)

## Sample size

A total of 1800 patients were to be randomised into the study to achieve 330 IDFS events. If the true HR for the comparison of olaparib versus placebo in terms of IDFS was 0.7 then with 330 events, the analysis of IDFS will have 90% power to demonstrate a statistically significant difference in IDFS, assuming a 2sided 5% significance level. The critical HR value at the primary analysis at 330 events was 0.805.

During the study, the Steering Committee was to monitor the recruited patient population and actual event rate whilst remaining blinded to treatment. If the data suggested that the original sample size assumptions were incorrect such that achieving the required number of events with the current number of patients did not seem feasible, then in consultation with the IDMC a decision could be made to increase the number of patients recruited into the study to achieve the required 330 events.

## Sample Size Consideration for PRO Endpoints

It was assumed that half of triple negative patients and a quarter of hormone receptor positive patients would have received neoadjuvant chemotherapy and it was anticipated that 95% of patients enrolled in the study would complete the HRQoL instrument. In addition, adjusting downward to allow for 20% of missing

<div style=\"page-break-after: always\"></div>

data at the 12 months assessment point, it was expected that data from 633 neoadjuvant and 735 adjuvant patients would be available (assuming that 15% of the total 1800 enrolled patients were ER and/or PgR positive,  HER2  negative).  These  would  be  sufficient  to  provide  statistical  power  of  93%  and  96% correspondingly to detect a difference of 3 points on the FACIT-Fatigue scale score between treatment arms assuming a SD of 10.9 (Cella et al 2002b; estimated SD of mean baseline score) and controlling α -level at 0.05. No multiple comparisons adjustment was employed since these outcomes evaluated the toxicity of the study treatment. A collection of PROs and QoL from all patients enrolled in the main study was expected to provide sufficient statistical power to detect important differences between the 2 treatment arms.

## Randomisation

Patients were randomised in a 1:1 ratio to either olaparib or placebo for up to a maximum of 12 months.

Randomisation used permuted blocks and was stratified by:

- -hormone receptor status (ER and/or PgR positive/HER2 negative vs TNBC),
- -prior neoadjuvant vs adjuvant chemotherapy,
- -prior platinum use for breast cancer (yes vs no).

## Blinding (masking)

OlympiA was a double-blind study.

## Statistical methods

A superiority interim analysis of IDFS was protocolled to occur when half of the events required for the primary IDFS analysis (165 events) had been observed from the first 50% of patients recruited (i.e., from the first 900 patients). The IDFS interim analysis was to be performed on all 1836 recruited patients, whilst additionally providing a cohort of 900 patients with a similar level of maturity to that planned for the primary IDFS analysis.

## Statistical methods

IDFS (Time from randomisation to invasive disease recurrence or death due to any cause):

- -Primary analysis stratified log-rank test and Cox regression
- -Key supportive analysis: stratified Cox regression in randomised patients confirmed as gBRCAm positive by central Myriad test (if different from FAS [ITT])

DDFS (Time from randomisation to distant recurrence or death due to any cause):

- -Stratified log-rank test and Cox regression
- -Key supportive analysis: stratified Cox regression in randomised patients confirmed as gBRCAm positive by central Myriad test (if different from FAS [ITT])

OS (Time from randomisation to death due to any cause):

- -Stratified log-rank test and Cox regression
- -Key supportive analysis: stratified Cox regression in randomised patients confirmed as gBRCAm positive by central Myriad test (if different from FAS [ITT])

<div style=\"page-break-after: always\"></div>

- -Incidence of contralateral invasive breast cancer, contralateral non-invasive breast cancer, new primary ovarian cancer, new primary fallopian tube cancer, and new primary peritoneal cancer: Fine and Gray models

## FACIT-Fatigue:

- -Primary analysis MMRM at 6 and 12 months
- -Sensitivity analysis MMRM

EORTC QLQ-C30 GI symptoms and EORTC QLQ-C30 HRQoL: mixed model for repeated measures (MMRM)

For the primary analysis, invasive disease free survival, p-values were calculated using a log-rank test stratified  by  the  stratification  factors  determined  by  the  pooling  strategy.  The  hazard  ratio  (HR)  was estimated using a Cox proportional hazards model with the same stratification factors as the log-rank test. The 2-sided 95% CIs were calculated using the profile likelihood approach. IDFS times were summarised using  Kaplan-Meier  (KM)  survival  curves  and  the  percentages  of  surviving  subjects  who  were  invasive disease free at 1 year, 2 years, and 3 years from the time of randomisation were estimated from the KM curves.  Approximate  95%  confidence  limits  were  calculated,  based  on  Greenwood's  formula  for  the standard error of the KM estimate.

Four IDFS sensitivity analyses were performed to assess the robustness of the primary analysis: including only  patients  with  central  pathology  review  data  for  hormone  receptor  status  (ER  and  PgR),  using unadjusted analysis, using interval censoring, and using the restricted mean survival time (RMST) method.

Exploratory  subgroup  analyses  of  IDFS  in  the  full  analysis  set  (FAS)  were  conducted  to  assess  the consistency  of  treatment  effect  across  potential  or  expected  prognostic  factors,  including  the  baseline stratification factors.

A multiple testing procedure was employed across the IDFS, DDFS, and OS endpoints to strongly control the overall type I error at 5% 2-sided, accounting for any interim analyses on IDFS, DDFS and OS and also planned further analyses post the primary IDFS Data Cut Off (DCO).

A hierarchical testing strategy was employed where IDFS was tested first using the full test mass (i.e., full 5%, 2-sided alpha), then DDFS and OS were tested if IDFS was significant based on a weighted proportion of the test mass (4% for DDFS and 1% for OS, 2-sided) which was recycled to secondary endpoints not yet rejected. Testing stopped when the entire test mass was allocated to non-rejected endpoints (Figure 4).

<!-- image -->

DDFS=distant disease free survival;IDFS=invasive disease free survival;OS=overall survival.

Figure 4  OlympiA: Multiple testing procedure

Invasive disease free survival was planned to be analysed at the interim (165 IDFS events in the first 900 patients) and the primary (330 IDFS events) IDFS analysis. If IDFS was statistically significant at the interim based on the ITT population then secondary endpoints were formally tested at the interim based on the

<div style=\"page-break-after: always\"></div>

MTP outlined above. To account for multiple analyses on each endpoint a separate alpha spending function was applied to each endpoint (Glimm et al 2010). It was anticipated that further analyses of DDFS and OS with  more  mature  follow-up  may  have  been  required  for  which  some  alpha  would  be  reserved  for significance testing.

## Study populations

- -Full analysis set (FAS)
- o Intention-to-treat (ITT): This included all randomised patients and compared the treatment arms on the basis of randomised treatment, regardless of the treatment actually received. Note: it was anticipated that all patients would be randomised by the time of the interim analysis.
- o Mature cohort ITT population: This included the first 900 randomised patients only and compared the treatment arms on the basis of randomised treatment, regardless of the treatment  actually  received.  This  analysis  was  to  be  regarded  as  supportive,  to  aid interpretation  of  the  result  in  the  ITT  population  based  on  interim  data.  Statistical significance was not required for the mature cohort population.

The  primary  analysis  population  was  all  patients  randomised  (ITT).  A  subgroup  analysis (supportive) based on prior chemotherapy (adjuvant or neoadjuvant), prior platinum therapy (yes or no) and hormone receptor status (ER and/or PgR positive, HER2 negative versus TNBC) was conducted to check for consistency in the treatment effect.

- -Safety  Analysis  Set  (SAS):  All  patients  who  received  at  least  one  dose  of  randomised  study treatment, olaparib or placebo, were to be included in the SAS. If a patient received at least one dose of olaparib he/she was included in the olaparib arm for safety summaries (ie, olaparib arm included patients randomised to olaparib who received at least one dose of olaparib or placebo patients who received at least one dose of olaparib in error at any time). If a patient randomised to olaparib received only placebo treatment, then he/she was summarised as part of the placebo arm.
- -PK Analysis Set: Approximately 150 patients randomised to olaparib/placebo will have provided PK samples at those sites that had confirmed that they were able to collect the PK assessment samples. Placebo samples were not analysed unless specified. Pharmacokinetic sampling was performed in a subset of patients who had signed the optional PK informed consent. Pharmacokinetic data were analysed according to treatment received. This population comprised those that were randomised to olaparib who received at least one dose of study treatment, had at least one PK sample collected, and did not violate  or  deviate  from  the  Clinical  Study  Protocol  (CSP)  in  ways  that  would  have significantly affected the PK analyses.
- -PRO Analysis Set: This population comprised patients who consented to participate in the PRO assessment  portion  of  the  study,  who  started  treatment  and  who  provided  evaluable  baseline FACIT-Fatigue or EORTC QLQ-C30 data, where evaluable means that at least one sub-scale baseline score was determined. Baseline was defined as the last result on or before the first day of study drug. For patients who were randomised but not treated, baseline was not derived and they were to  be  excluded  from  the  PRO  analysis  set.  Since  the  PRO  analysis  set  included  those  with  an evaluable baseline score for either the FACIT-Fatigue or the EORTC QLQ-C30, the analyses for each questionnaire were based on a subset of the PRO analysis set with an evaluable baseline for that questionnaire. The PRO analysis was to be summarised by planned treatment arm.

<div style=\"page-break-after: always\"></div>

## Patient reported outcomes

## Hypotheses

The hypotheses and measurement strategy focused on the fact that patients in the study would be starting with significant decrements in HRQoL and high rates of symptoms at study entry (baseline) due to previous chemotherapy and local treatments (surgery with or without radiation therapy). Therefore, the following hypotheses were proposed based on the expected toxicities of olaparib.

## Primary PRO Hypothesis

Patients receiving olaparib may experience greater fatigue severity during treatment than those receiving placebo as measured by the FACIT-Fatigue scale at 6 and 12 months after randomisation.

No multiple comparisons adjustments were to be employed since these outcomes evaluate the toxicity of the study treatment.

## Secondary PRO Hypotheses

- Patients receiving olaparib may experience greater GI symptoms (nausea/vomiting, diarrhoea, and pain) severity during treatment than those receiving placebo as measured at 6 and 12 months after randomisation but no difference expected by 24 months after randomisation.
- There will be no difference in fatigue post-discontinuation of study treatment as measured at 18 and 24 months.
- There will be no difference in QoL between the two treatment arms as measured by the global health status/QoL score and other functional sub-scales from the EORTC QLQ-C30 at 6, 12, 18, and 24 months after randomisation and patients will demonstrate improvements in functioning over time.

All secondary analyses were considered exploratory and therefore no adjustments for multiplicity were to be made.

The FACIT-Fatigue and EORTC QLQ-C30 questionnaires were completed at baseline (prior to randomisation) and every 6 months for a period of 2 years.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

## Germline BRCA testing results in OlympiA and routes to randomisation

In total, 14387 patients were screened for entry into OlympiA. This includes 203 patients with unknown gBRCA status (due to no sample available for testing and no pre-existing local gBRCA result), resulting in 14184 patients with pre-existing available local gBRCA result or a blood sample available for testing. Of these patients, 1114 patients had a pre-existing gBRCA result from local testing, 2515 patients were screened prospectively in China using the BGI test, 10554 patients were screened prospectively using the Myriad CLIA or CDx gBRCA test and 1 patient was prospectively tested at Myriad under the SOLO3 study. Within patients meeting the OlympiA study eligibility criteria, 1114 patients were randomised based on an existing local gBRCA result, 474 based on a Myriad gBRCA CLIA or CDx result, 247 based on a gBRCA result from BGI testing in China and the remaining patient was prospectively tested at Myriad under the SOLO3 study (no result was reported under OlympiA study ID). In total, 1836 patients were randomised onto the OlympiA study.

## Participant flow

A total of 1836 patients with breast cancer and gBRCA1/2 mutations were randomised to receive either olaparib 300 mg bd (n=921) or placebo (n=915). At the DCO date (27 March 2020), 1353 patients (73.7%) had completed study treatment per CSP and 39 patients (2.1%) were still receiving study treatment.

Of 1836 patients randomized, 21 patients did not receive their planned study medication (10 patients in the olaparib arm, 11 patients in the placebo arm).

A higher proportion of olaparib-treated patients than placebo-treated patients discontinued study treatment due to AEs (97 patients [10.5%] versus 41 patients [4.5%]) and patient decision to stop study drug (60 patients [6.5%] versus 32 patients [3.5%]). A lower proportion of olaparib-treated patients than placebotreated patients discontinued study treatment due to recurrence of disease (40 patients [4.3%] versus 80 patients [8.7%]).

The majority of patients (73.7%) completed 12 months of treatment per protocol, with a similar proportion of patients in each treatment arm: 19 patients and 20 patients are still ongoing study treatment at data cut-off in olaparib and placebo arm respectively.

<div style=\"page-break-after: always\"></div>

<!-- image -->

- Does not include patients who did not receive treatment.

n = number of patients in the category or analysis;PtD =patient decision

Source:Table 14.1.1.1 andTable 14.1.1.2.

Figure 5: Patient disposition in OlympiA

## Recruitment

A total of 1836 patients with breast cancer and gBRCA1/2 mutations were randomised from 546 centres in 23 countries worldwide: Austria, Argentina, Australia, Belgium, Canada, China, France, Germany, Israel, Japan,  United  Kingdom  and  Northern  Ireland,  Hungary,  Iceland,  Italy,  Netherlands,  Poland,  Portugal, Province of China, Republic of Korea, Spain, Sweden, Switzerland, Taiwan, USA.

First patient enrolled: 22 April 2014

Last subject enrolled: 17 April 2019

Data cut-off date: 27 March 2020

## Conduct of the study

## Premature unblinding

A total of 133 participants were prematurely unblinded as follows (DCO):

- -olaparib arm: n=45 patients [4.9%]. One patient was unblinded prior to the investigator-assessed IDFS event and 36 patients were unblinded on or after an IDFS event. Eight patients did not have an IDFS event; all of which were unblinded after discontinuation of randomised study treatment.
- -placebo arm: n=88 patients [9.6%]. Two patients were unblinded prior to investigator-assessed IDFS event and 82 patients were unblinded on or after an IDFS event. Four patients did not have an IDFS event; all of which were unblinded after discontinuation of randomised study treatment.

## Protocol deviations

The number of patients with important protocol deviations and important GCP violations in each treatment arm and overall is summarised in Table 6 .

<div style=\"page-break-after: always\"></div>

Table 6. Patients with Important Protocol Deviations (FAS)

<!-- image -->

|                                                                                                                                       | Number () of patients      | Number () of patients   | Number () of patients   |
|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-------------------------|-------------------------|
|                                                                                                                                       | Olaparib 300 mg bd (N=921) | Placebo (N=915)         | Total (N=1836)          |
| Number of patients with at least one important protocol deviation ercl. important GCP violations                                      | 130 (14.1)                 | 122 (13.3)              | 252 (13.7)              |
| invasiveadenocarcinoma of thebreast                                                                                                   | 3 (0.3)                    | 0                       | 3 (0.2)                 |
| No documented germline mutation in BRCAl or BRCA?                                                                                     | 3 (0.3)                    | 3 (0.3)                 | 6 (0.3)                 |
| Randomised but did not receive any study treatment                                                                                    | 10 (1.1)                   | (tD11                   | 21 (1.1)                |
| Not fiulfilling criteria for high risk disease                                                                                        | 25 (2.7)                   | 12 (1.3)                | 37 (2.0)                |
| Inadequate breast sugery and/or radiotherapy                                                                                          | 7 (0.8)                    | 8 (0.9)                 | 15 (0.8)                |
| Inadequate axilla swgery                                                                                                              | 5 (0.5)                    | 1 (0.1)                 | 6 (0.3)                 |
| Completed less than 6 cycles of neoadjuvant or adjuvant chemotherapy containing anthracyclines. taxanes or the combination of both    | 7 (0.8)                    | 15 (1.6)                | 22 (1.2)                |
| Peri-operative chemotherapy (patients who had both neondjuvant and adjuvant therapy: unquantifiable risk of disease relapse')         | 4 (0.4)                    | 6 (0.7)                 | 10 (0.5)                |
| Evidence of metastatic disease (to include only those patients who had suspicion or confimmation of recurence prior to randomisation) | 2 (0.2)                    | 4 (0.4)                 | 6 (0.3)                 |
| No staging or insufficient staging                                                                                                    | 67 (7.3)                   | 66 (7.2)                | 133 (7.2)               |
| Prior PARP inhibitor use                                                                                                              | 0                          | 0                       | 0                       |
| Prior cancer <5 years ago including MDS/t-AML                                                                                         | 0                          | 2 (0.2)                 | 2 (0.1)                 |
| of more than 7 days due to errors in dispensing of medication                                                                         | 5 (0.5)                    | 4 (0.4)                 | 9 (0.5)                 |
| Received an altemativeshudy treatment to thatwhich they were randomised                                                               | 0                          | 0                       | 0                       |
| Received prohibited concomitant medication                                                                                            | 5 (0.5)                    | 4 (0.4)                 | 9 (0.5)                 |
| Lack of confirmatory exams for events that count towards the analysis endpoints, efficacy and safety                                  | 0                          | 1 (0.1)                 | 1 (0.1)                 |
| Received additional anti-cancer therapy prior to DFS event                                                                            | 0                          | 0                       | 0                       |
| Received other investigational agent prior to DFS event                                                                               | 0                          | 0                       | 0                       |

<!-- image -->

|                                                              | Number (h) of patients     | Number (h) of patients   | Number (h) of patients   |
|--------------------------------------------------------------|----------------------------|--------------------------|--------------------------|
|                                                              | Olaparib 300 mg bd (N=921) | Placebo (N=915)          | Total (N=1836)           |
| Number of patients with at least one important GCP violation | 41 (4.5)                   | 39 (4.3)                 | 80 (4.4)                 |
| GCP violation relating to informed consent                   | 26 (2.8)                   | 22 (2.4)                 | 48 (2.6)                 |
| GCP violation relating to serious adverse events             | 2 (0.2)                    | 10 (1.1)                 | 12 (0.7)                 |
| GCP violation: Other                                         | 13 (1.4)                   | 7 (0.8)                  | 20 (1.1)                 |

Important protocol deviations were those that could have had a strong influence on the interpretation of the efficacy or safety results. Excluding GCP violations.

Other than hormone therapy permitted in the protocol.

The same patient may have had more than one important protocol deviation

There was a data privacy breach with a patient's details sent by email, but all comespondence was deleted without a patient D recorded so this important protocol deviation could not be included in the table.

bd = twice daily: BRCA = breast cancer susceptibility gene: FAS = full analysis set; GCP = Good Clinical Practice; DFS = invasive disease free survival; MDS = myelodysplastic syndrome; N = total number of patients; PARP = polyadenosine 5'diphosphoribose polymerase, t-AML therapy-related acute myeloid leukaemia.

Souce: [able 14.1.2

<div style=\"page-break-after: always\"></div>

## Protocol amendment

Important amendments to the original CSP (ROW CSP: Version 1.0, dated 25 October 2013), including when those amendments came into effect with respect to the recruitment of patients, and other significant changes to study conduct are shown in Table 7.

Table 7 : Protocol Amendments Related to Changes in Study Conduct

<!-- image -->

| RoW CSP Version/US CSP amendment (Date)                   | Key details of amendment                                                                                                                                                                                                                                                    | Main reason(s) for amendment                                                                                                                   |
|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendmentsmade after the start of patient recruitment     | Amendmentsmade after the start of patient recruitment                                                                                                                                                                                                                       | Amendmentsmade after the start of patient recruitment                                                                                          |
| ROW CSP: 3.0 (210ct2015) US CSP Amendment 2.0 (190ct2015) | Target patient population for the study updated to include ER and/or PgR positive high-risk HER2 negative patient population.                                                                                                                                               | Extrapolations from the metastatic setting supported the expectations that these patients would also benefit from adjuvant olaparib treatment. |
| ROW CSP: 3.0 (210ct2015) US CSP Amendment 2.0 (190ct2015) | New secondary PK objective and endpoint included: To determine the exposure to olaparib (in plasma) in patients receiving olaparib as adjuvant therapy.                                                                                                                     | Implemented PK analysis in a subset of patients who signed an optional PK Informed consent.                                                    |
| ROW CSP: 3.0 (210ct2015) US CSP Amendment 2.0 (190ct2015) | Addition of hormone receptor status (ER and/or PgR positive, HER2 negative versus TNBC) to the stratification factors.                                                                                                                                                      | Addition of ER and/or PgR positive high-risk HER2 negative patient population.                                                                 |
| ROW CSP: 3.0 (210ct2015) US CSP Amendment 2.0 (190ct2015) | New exploratory study objective included: To assess the consistency of treatment effects on efficacy endpoints across potential or expected prognostic factors, including the baseline stratification factors with special emphasis on hormone receptor status.             | Stratification factors updated.                                                                                                                |
| ROW CSP: 3.0 (210ct2015) US CSP Amendment 2.0 (190ct2015) | Randomisation window wording changed to say patients were to be randomised in the study ideally within a maximum of 8 weeks of completing their last treatment modality (chemotherapy and definitive local or locoregional treatment), but in no case longer than 12 weeks. | Randomisation window extended.                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| RoW CSP Version/US CSP amendment (Date)   | Key details of amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Main reason(s) for amendment              |
|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
|                                           | Following changes made to inclusion criteria: 3 and 4: updated to include specific requirements and definitions for ER and/or PgR positive, HER 2 negative patients. 5: clarified that local gBRCA testing results, if available. could be used for establishing eligibility and that if local gBRCA testing results were not available, central testing would be provided for those patients who otherwise appeared to be eligible. 6: definitions for completed adequate breast surgery and completed adequate axilla surgery clarified. 7: clarified that for neoadjuvant patients all chemotherapy should be delivered prior to surgery and that no further cycles of chemotherapy post surgery are allowed 8: removal of *no blood transfusions in the past 28 days and clarification that CT/MRI was to be performed at any time point between diagnosis of current breast cancer and randomisation. 9: addition of 'plasma* creatinine 11: updated to clarify definition of female patients of childbearing potential and the requirements for birth control. 13: updated to clarify requirements for mandatory tumour sample collection from adjuvant and neoadjuvant patients. 14: added to state that patients should be randomised in the study ideally within a maximum of 8 weeks of completion of their last treatment, but in no case longer than 12 weeks. Following changes made to exclusion criteria: 4: clarification that liver ultrasound/CT/MRI was to be performed at any time point between diagnosis of current breast cancer and randomisation. 9 and 10: timing of systemic radiotherapy and adjuvant radiotherapy, respectively, changed to within 3 weeks prior to randomisation and within 2 weeks prior to randomisation not start of study treatment. 13: clarification that AML did not have to be treatment related, and patients with features suggestive of MDS/AML were also excluded. 14: timing of major surgery changed to within 2 weeks prior to randomisation, not start of study treatment. | Inclusion and exclusion criteria updated. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| RoW CSP Version/US CSP amendment (Date)                   | Key details of amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Main reason(s) for amendment                                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                           | Number of study centres increased from approximately 300 to 500 in the US and ROW countries and number of patients randomised increased from 1320 to 1500 patients. Approximately 150 randomised patients were to be analysed for PK at sites that were able to collect the PK assessment samples.                                                                                                                                                                                | Implemented PK analysis in a subset of patients who signed an optional PK Informed consent.                                                                                                                                                                                                                 |
|                                                           | PK analysis included in the study schedule and PK methods added: The plasma concentration-time data were to be analysed by non-linear mixed effects modelling in order to evaluate the PK characteristics of olaparib, quantify variability in the PK, identify demographic or pathophysiological covariates, which may explain the observed variability and explore exposure-response relationships. PK sample timings/collection/handling and sample analysis details included. | Implemented PK analysis in a subset of patients who signed an optional PK Informed consent.                                                                                                                                                                                                                 |
|                                                           | Family history of cancer added to the study schedule for collection at screening.                                                                                                                                                                                                                                                                                                                                                                                                 | Collection of the family cancer history.                                                                                                                                                                                                                                                                    |
| ROW CSP: 4.0 (23Mar2017) US CSP Amendment 4.0 (25Ju12017) | Inclusion criterion 4 wording changed to remove \"All ER and PgR assessments that are locally available must be negative” from the TNBC definition and \"Any tumour that has been locally assessed as ER and/or PgR positive in either the core biopsy or the surgical specimen is considered to be ER and/or PgR positive\" removed from the ER and/or PgR positive, HER2 negative breast cancer definition.                                                                        | Wording was overly restrictive for patients with tumours classified as TNBC based on the receptor status analysis from the core needle biopsy, but who had low levels of peroxidase staining for ER and PgR in their post-neoadjuvant surgical specimen.                                                    |
| ROW CSP: 5.0 (18May2018) US CSP Amendment 6.0 (27Ju12018) | Number of study centres increased from approximately 500 to 700 in the US and ROW countries and number of patients randomised increased from 1500 to 1800 patients.                                                                                                                                                                                                                                                                                                               | The simulations that were run support the addition of the ER positive cohort to the study were too pessimistic with respect to event rates for the triple negative adjuvant population. Based on extracted study data new predictions were nn which indicated the need to increase the sample size to 1800. |
| ROW CSP: 5.0 (18May2018) US CSP Amendment 6.0 (27Ju12018) | The estimation for study recruitment was increased to 5 years.                                                                                                                                                                                                                                                                                                                                                                                                                    | To account for the 300 extra patients.                                                                                                                                                                                                                                                                      |
| ROW CSP: 5.0 (18May2018) US CSP Amendment 6.0 (27Ju12018) | Removal of the minimum 24-month follow-up from the DCO for the primary analysis.                                                                                                                                                                                                                                                                                                                                                                                                  | The expected high event rate in the first 2 years had not been seenl.                                                                                                                                                                                                                                       |
| ROW CSP: 5.0 (18May2018) US CSP Amendment 6.0 (27Ju12018) | Confirmed that the interim analysis would be triggered by events in the first 900 patients (previously 750 patients)                                                                                                                                                                                                                                                                                                                                                              | To account for the continued randomisation of patients                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

## Baseline data

The demographic and key baseline characteristics of FAS and Myriad gBRCAm patients are summarised in Table 8.

The Myriad gBRCAm patient population excluded patients with only a local or Breast International Group (BIG)  result.  Out  of  1836  patients  enrolled  into  OlympiA,  1623 were  confirmed  as  g BRCA m by central testing, either prospectively (n=474) or retrospectively (n=1149, based on local or BIG result).

Table 8: Patient Demographics (FAS: Overall and Myriad gBRCAm Patients DCO 27 March 2020)

|                                         | Number (%) of patients                  | Number (%) of patients                  | Number (%) of patients                  | Number (%) of patients                  | Number (%) of patients                  | Number (%) of patients                  |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                         | Full analysis set                       | Full analysis set                       | Full analysis set                       | Myriad gBRCAm patients                  | Myriad gBRCAm patients                  | Myriad gBRCAm patients                  |
|                                         | Olaparib 300 mg bd (N=921)              | Placebo (N=915)                         | Total (N=183 6)                         | Olaparib 300 mg bd (N=816)              | Placebo (N=807)                         | Total (N=162 3)                         |
| Sponsor                                 |                                         |                                         |                                         |                                         |                                         |                                         |
| AstraZeneca                             | 810 (87.9)                              | 806 (88.1)                              | 1616 (88.0)                             | 712 (87.3%)                             | 704 (87.2%)                             | 1416 (87.2%)                            |
| NRG                                     | 111 (12.1)                              | 109 (11.9)                              | 220 (12.0)                              | 104 (12.7%)                             | 103 (12.8%)                             | 207 (12.8%)                             |
| Geographic region                       |                                         |                                         |                                         |                                         |                                         |                                         |
| North America                           | 122 (13.2)                              | 132 (14.4)                              | 254 (13.8)                              | 114 (14.0%)                             | 126 (15.6%)                             | 240 (14.8%)                             |
| South America                           | 16 (1.7)                                | 12 (1.3)                                | 28 (1.5)                                | 14 (1.7%)                               | 12 (1.5%)                               | 26 (1.6%)                               |
| Europe                                  | 481 (52.2)                              | 452 (49.4)                              | 933 (50.8)                              | 466 (57.1%)                             | 437 (54.2%)                             | 903 (55.6%)                             |
| Asia Pacific and South Africa a         | 302 (32.8)                              | 319 (34.9)                              | 621 (33.8)                              | 222 (27.2%)                             | 232 (28.7%)                             | 454 (28.0%)                             |
| Age (years) b                           |                                         |                                         |                                         |                                         |                                         |                                         |
| Mean (SD)                               | 43.0 (9.82)                             | 43.6 (10.12)                            | 43.3 (9.97)                             | 42.9 (9.89)                             | 43.8 (10.13)                            | 43.4 (10.02)                            |
| Median (range)                          | 42.0 (22-77)                            | 43.0 (24-78)                            | 42.0 (22-78)                            | 42.0 (22-77)                            | 43.0 (24-78)                            | 42.0 (22-78)                            |
| Age groups                              |                                         |                                         |                                         |                                         |                                         |                                         |
| <30 years                               | 51 (5.5)                                | 59 (6.4)                                | 110 (6.0)                               | 46 (5.6%)                               | 47 (5.8%)                               | 93 (5.7%)                               |
| 30-39 years                             | 333 (36.2)                              | 306 (33.4)                              | 639 (34.8)                              | 296 (36.3%)                             | 267 (33.1%)                             | 563 (34.7%)                             |
| 40-49 years                             | 315 (34.2)                              | 308 (33.7)                              | 623 (33.9)                              | 275 (33.7%)                             | 278 (34.4%)                             | 553 (34.1%)                             |
| 50-59 years                             | 166 (18.0)                              | 172 (18.8)                              | 338 (18.4)                              | 150 (18.4%)                             | 150 (18.6%)                             | 300 (18.5%)                             |
| 60-69 years                             | 48 (5.2)                                | 66 (7.2)                                | 114 (6.2)                               | 41 (5.0%)                               | 61 (7.6%)                               | 102 (6.3%)                              |
| ≥70 years                               | 8 (0.9)                                 | 4 (0.4)                                 | 12 (0.7)                                | 8 (1.0%)                                | 4 (0.5%)                                | 12 (0.7%)                               |
| Age groups (alternative categorisation) | Age groups (alternative categorisation) | Age groups (alternative categorisation) | Age groups (alternative categorisation) | Age groups (alternative categorisation) | Age groups (alternative categorisation) | Age groups (alternative categorisation) |

<div style=\"page-break-after: always\"></div>

|                                           | Number (%) of patients     | Number (%) of patients   | Number (%) of patients   | Number (%) of patients     | Number (%) of patients   | Number (%) of patients   |
|-------------------------------------------|----------------------------|--------------------------|--------------------------|----------------------------|--------------------------|--------------------------|
|                                           | Full analysis set          | Full analysis set        | Full analysis set        | Myriad gBRCAm patients     | Myriad gBRCAm patients   | Myriad gBRCAm patients   |
|                                           | Olaparib 300 mg bd (N=921) | Placebo (N=915)          | Total (N=183 6)          | Olaparib 300 mg bd (N=816) | Placebo (N=807)          | Total (N=162 3)          |
| <65 years                                 | 892 (96.9)                 | 883 (96.5)               | 1775 (96.7)              | 790 (96.8%)                | 775 (96.0%)              | 1565 (96.4%)             |
| 65-84                                     | 29 (3.1)                   | 32 (3.5)                 | 61 (3.3)                 | 26 (3.2%)                  | 32 (4.0%)                | 58 (3.6%)                |
| ≥85                                       | 0                          | 0                        | 0                        | 0                          | 0                        | 0                        |
| Sex                                       |                            |                          |                          |                            |                          |                          |
| Female                                    | 919 (99.8)                 | 911 (99.6)               | 1830 (99.7)              | 814 (99.8%)                | 803 (99.5%)              | 1617 (99.6%)             |
| Male                                      | 2 (0.2)                    | 4 (0.4)                  | 6 (0.3)                  | 2 (0.2%)                   | 4 (0.5%)                 | 6 (0.4%)                 |
| Race                                      |                            |                          |                          |                            |                          |                          |
| White                                     | 626 (68.0)                 | 599 (65.5)               | 1225 (66.7)              | 602 (73.8%)                | 580 (71.9%)              | 1182 (72.8%)             |
| Asian                                     | 259 (28.1)                 | 272 (29.7)               | 531 (28.9)               | 180 (22.1%)                | 186 (23.0%)              | 366 (22.6%)              |
| Black or African American                 | 19 (2.1)                   | 29 (3.2)                 | 48 (2.6)                 | 19 (2.3%)                  | 27 (3.3%)                | 46 (2.8%)                |
| Native Hawaiian or other Pacific Islander | 1 (0.1)                    | 0                        | 1 (0.1)                  | 1 (0.1%)                   | 0 (0.0%)                 | 1 (0.1%)                 |
| American Indian or Alaska native          | 3 (0.3)                    | 1 (0.1)                  | 4 (0.2)                  | 3 (0.4%)                   | 1 (0.1%)                 | 4 (0.2%)                 |
| Other                                     | 3 (0.3)                    | 6 (0.7)                  | 9 (0.5)                  | 3 (0.4%)                   | 5 (0.6%)                 | 8 (0.5%)                 |
| Missing c                                 | 10 (1.1)                   | 8 (0.9)                  | 18 (1.0)                 | 8 (1.0%)                   | 8 (1.0%)                 | 16 (1.0%)                |

a There were no patients from South Africa in the study.

Age was calculated as the patient's age at randomisation.

'Not reported', 'Not recorded', and 'Unknown' are included as missing.

bd = twice daily; FAS = full analysis set; gBRCAm = germline BRCA mutations; N = total number of patients; SD = standard deviation.

<div style=\"page-break-after: always\"></div>

Baseline patient characteristics of height, weight, BMI, menopausal status, and ECOG performance status for the FAS are summarised in Table 9.

Table 9 : Baseline patient characteristics (FAS)

|                               | 0laparib300mgbd (N=921)   | Placebo (N=915)   | Overall (N=1836)   |
|-------------------------------|---------------------------|-------------------|--------------------|
| Height (cm)                   |                           |                   |                    |
| Mean                          | 162.9                     | 163.1             | 163.0              |
| SD                            | 6.75                      | 6.91              | 6.83               |
| Median                        | 162.2                     | 163.0             | 163.0              |
| Min                           | 143                       | 117               | 117                |
| Max                           | 183                       | 185               | 185                |
| Missing                       | 3 (0.3%)                  | 3(0.3%)           | 6(0.3%)            |
| Weight (kg)                   |                           |                   |                    |
| Mean                          | 68.1                      | 69.2              | 68.7               |
| SD                            | 16.56                     | 16.38             | 16.47              |
| Median                        | 65.0                      | 65.4              | 65.0               |
| Min                           | 39                        | 38                | 38                 |
| Max                           | 162                       | 146               | 162                |
| Missing                       | 1 (0.1%)                  | (0.0%)            | 1 (0.1%)           |
| Weight group (kg)             |                           |                   |                    |
| <55 kg                        | 179 (19.4%)               | 149 (16.3)        | 328 (17.9%)        |
| [55 - 75 kg)                  | 487 (52.9%)               | 489 (53.4)        | 976 (53.2%)        |
| >= 75 kg                      | 254 (27.6%)               | 277 (30.3%)       | 531 (28.9%)        |
| Missing                       | 1 (0.1%)                  | 0 (0.0%)          | 1 (0.1%)           |
| Body mass index (kg/m2） [1]   |                           |                   |                    |
| Mean                          | 25.6                      | 25.9              | 25.8               |
| SD                            | 5.71                      | 5.58              | 5.65               |
| Median                        | 24.2                      | 24.7              | 24.5               |
| Min                           | 16                        | 16                | 16                 |
| Max                           | 59                        | 57                | 59                 |
| Missing                       | 3 (0.3%)                  | 3(0.3%)           | 6 (0.3%)           |
| Body mass index (kg/m2) group |                           |                   |                    |
| <18.5kg/m2                    | 34 (3.7%)                 | 25 (2.7%)         | 59 (3.2%)          |
| [18.5 kg/m2-25 kg/m2)         | 469 (50.9%)               | 451 (49.3)        | 920 (50.1)         |
| [25 kg/m2 -30 kg/m2)          | 251 (27.38)               | 248 (27.1%)       | 499 (27.2%)        |
| >= 30 kg/m2                   | 164 (17.8)                | 188 (20.5%)       | 352 (19.2%)        |
| Missing                       | 3(0.3%)                   | 3 (0.3%)          | 6 (0.3%)           |
| Menopausal status [2]         |                           |                   |                    |
| Premenopausal                 | 572 (62.1%)               | 553 (60.4%)       | 1125 (61.3)        |
| Postmenopausal                | 347 (37.7%)               | 358 (39.18)       | 705 (38.4%)        |
| Male                          | 2 (0.2%)                  | 4 (0.4%)          | 6 (0.3%)           |
| Missing                       | 0 (0.0%)                  | 0 (0.0%)          | 0 (0.0%)           |
| ECoGperformancestatus         |                           |                   |                    |
| 0:Fully Active                | 824 (89.5%)               | 804 (87.98)       | 1628 (88.7%)       |
| 1:Restricted work             | 97 (10.5)                 | 111 (12.1)        | 208 (11.3%)        |
| 2:Ambulatory                  | 0 (0.0%)                  | 0 (0.0%)          | 0 (0.0%)           |
| 3: Limited self-care          | (0.0%)                    | 0 (0.0%)          | 0 (0.0%)           |
| 4:Disabled                    | 0 (0.0%)                  | 0 (0.0%)          | 0 (0.0%)           |
| Missing [3]                   | 0 (0.0%)                  | 0 (0.0%)          | 0 (0.0%)           |

[2] Menopausal status is collected at screening.

[1] Body Mass Index = weight (kg) (height (m)~2)

[3]

<div style=\"page-break-after: always\"></div>

The baseline patient and disease characteristics of FAS are summarised in

Table 10 .

Table 10 : Baseline Patient and Disease Characteristics (FAS)

|                                                   | Number (%o) Patients       | Number (%o) Patients   | Number (%o) Patients   |
|---------------------------------------------------|----------------------------|------------------------|------------------------|
|                                                   | Olaparib 300 mg bd (N=921) | Placebo (N=915)        | Total (N=1836)         |
| Hormone Receptor Status                           |                            |                        |                        |
| TNBC a                                            | 753 (81.8)                 | 758 (82.8)             | 1511 (82.3)            |
| ER and/or PgR positive, HER2-negative             | 168 (18.2)                 | 157 (17.2)             | 325 (17.7)             |
| Prior Platinum                                    |                            |                        |                        |
| No                                                | 674 (73.2)                 | 677 (74.0)             | 1351 (73.6)            |
| Yes                                               | 247 (26.8)                 | 238 (26.0)             | 485 (26.4)             |
| Prior Chemotherapy                                |                            |                        |                        |
| Adjuvant                                          | 461 (50.1)                 | 455 (49.7)             | 916 (49.9)             |
| Neoadjuvant                                       | 460 (49.9)                 | 460 (50.3)             | 920 (50.1)             |
| Prior Chemotherapy by Hormone Receptor Status     |                            |                        |                        |
| Adjuvant TNBC                                     | 397 (43.1)                 | 390 (42.6)             | 787 (42.9)             |
| Adjuvant ER and/or PgR positive, HER2-negative    | 64 (6.9)                   | 65 (7.1)               | 129 (7.0)              |
| Neoadjuvant TNBC a                                | 356 (38.7)                 | 368 (40.2)             | 724 (39.4)             |
| Neoadjuvant ER and/or PgR positive, HER2-negative | 104 (11.3)                 | 92 (10.1)              | 196 (10.7)             |
| BaselineBRCA Status                               |                            |                        |                        |
| BRCA1                                             | 656 (71.2)                 | 669 (73.1)             | 1325 (72.2)            |
| BRCA2                                             | 260 (28.2)                 | 238 (26.0)             | 498 (27.1)             |
| BRCA1&2                                           | 2 (0.2)                    | 5 (0.5)                | 7 (0.4)                |

<div style=\"page-break-after: always\"></div>

|                                                                   | Number (%o)Patients                                               | Number (%o)Patients                                               | Number (%o)Patients                                               |
|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
|                                                                   | Olaparib 300 mg bd (N=921)                                        | Placebo (N=915)                                                   | Total (N=1836)                                                    |
| No gBRCA mutation                                                 | 2 (0.2)                                                           | 3 (0.3)                                                           | 5 (0.3)                                                           |
| Missing                                                           | 1 (0.1)                                                           | 0                                                                 | 1 (0.1)                                                           |
| Prior Neoadjuvant/Adjuvant Chemotherapy for Primary Breast Cancer | Prior Neoadjuvant/Adjuvant Chemotherapy for Primary Breast Cancer | Prior Neoadjuvant/Adjuvant Chemotherapy for Primary Breast Cancer | Prior Neoadjuvant/Adjuvant Chemotherapy for Primary Breast Cancer |
| Anthracycline and taxane regimen                                  | 871 (94.6)                                                        | 849 (92.8)                                                        | 1720 (93.7)                                                       |
| Anthracycline regimen (without taxane)                            | 7 (0.8)                                                           | 13 (1.4)                                                          | 20 (1.1)                                                          |
| Taxane regimen (without anthracycline)                            | 43 (4.7)                                                          | 52 (5.7)                                                          | 95 (5.2)                                                          |
| Missing                                                           | 0                                                                 | 1 (0.1)                                                           | 1 (0.1)                                                           |
| PrimaryBreastCancerSurgeryPriortoRandomisation                    | PrimaryBreastCancerSurgeryPriortoRandomisation                    | PrimaryBreastCancerSurgeryPriortoRandomisation                    | PrimaryBreastCancerSurgeryPriortoRandomisation                    |
| Primary breast cancer surgery                                     | 921 (100.0)                                                       | 913 (99.8)                                                        | 1834 (99.9)                                                       |
| Non-conservative surgery                                          | 698 (75.8)                                                        | 673 (73.6)                                                        | 1371 (74.7)                                                       |
| Conservative surgery                                              | 223 (24.2)                                                        | 240 (26.2)                                                        | 463 (25.2)                                                        |
| Unknown b                                                         | 0                                                                 | 2 (0.2)                                                           | 2 (0.1)                                                           |

Post randomisation 2 patients (included as TNBC) were found not to have confimed negative HER2 status. These patients were captured as important protocol deviations in category *No histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast'.

- E106578 (placebo) was reported to have right mastectomy (DCIS) in 2001 in the concomitant procedure of the eCRF, the patient received axillary lymph node dissection (pN1) prior to entering OlympiA study. tumour in the breast per MRI; the patient received axillary lymph node dissection (pN1) prior to entering OlympiA study.

bd = twice daily; BRCA = breast cancer susceptibility gene; eCRF = electronic case report form; ER = oestrogen receptor; gBRCA = germline BRCA; HER2 = human epidermal growth factor receptor 2; N = total number of

Source: Table 14.1.6. Table 14.1.7. Table 14.1.15.1, and Appendix 16.1.13, Table 2838.1, and Table 2842.2.

<div style=\"page-break-after: always\"></div>

Pathological characteristics of primary breast cancer are summarised in Table 11.

<!-- image -->

Table 11 : Pathological Characteristics of Primary Breast Cancer at Baseline (FAS Population)

| Number (%) of patients               | Number (%) of patients    | Number (%) of patients   | Number (%) of patients   |
|--------------------------------------|---------------------------|--------------------------|--------------------------|
|                                      | Full analysis set         | Full analysis set        | Full analysis set        |
|                                      | Olaparib 300 mgbd (N=921) | Placebo (N=915)          | Total (N=1836)           |
| Clinicalstageofdistantmetastases     |                           |                          |                          |
| MO                                   | 826 (89.7)                | 815 (89.1)               | 1641 (89.4)              |
| M1                                   | 0                         | 0                        | 0                        |
| Missing                              | 95 (10.3)                 | 100 (10.9)               | 195 (10.6)               |
| Clinical AJCC stage                  |                           |                          |                          |
| IA                                   | 103 (11.2)                | 85 (9.3)                 | 188 (10.2)               |
| IB                                   | 0                         | 0                        | 0                        |
| IIA                                  | 329 (35.7)                | 334 (36.5)               | 663 (36.1)               |
| IIB                                  | 190 (20.6)                | 195 (21.3)               | 385 (21.0)               |
| IIIA                                 | 128 (13.9)                | 111 (12.1)               | 239 (13.0)               |
| IIIB                                 | 28 (3.0)                  | 30 (3.3)                 | 58 (3.2)                 |
| IIIC                                 | 42 (4.6)                  | 56 (6.1)                 | 98 (5.3)                 |
| IV                                   | 0                         | 0                        | 0                        |
| Missing                              | 101 (11.0)                | 104 (11.4)               | 205 (11.2)               |
| Pathologicalstageofdistantmetastases |                           |                          |                          |
| MO                                   | 921 (100)                 | 915 (100)                | 1836 (100)               |
| M1                                   | 0                         | 0                        | 0                        |
| Missing                              | 0                         | 0                        | 0                        |

mutations; N = total number of patients; NOS = not otherwise specified.

Source:Table 14.1.17.1 and Table 14.1.17.1.2

<div style=\"page-break-after: always\"></div>

The concordance between overall hormone receptor status by local versus central laboratory result is presented in Table 12.

Table 12 : OlympiA: Central ER/PgR Expression Levels in Patients Locally identified as TNBC and Hormone Receptor Positive (FAS Population)

|                                                | Local TNBC (per eCRF) N=1509   | Local Hormone Receptor Positive (per eCRF) N=325   |
|------------------------------------------------|--------------------------------|----------------------------------------------------|
| Central hormone receptor positive, n (%)       | 106 (7.0)                      | 240 (73.8)                                         |
| Central ER 1% to = 10%                         | 37 (2.5)                       | 13 (4.0)                                           |
| Cental ER ≥ 10%                                | 33 (2.2)                       | 222 (68.3)                                         |
| Central ER negative but PgR positive           | 36 (2.4)                       | 5 (1.5)                                            |
| Central hormone receptor negative, n (%)       | 1064 (70.5)                    | 40 (12.3)                                          |
| Central hommone receptor status missing, n (%) | 339 (22.5)                     | 45 (13.8)                                          |
| Cental ER% ,n                                  | 1183                           | 282                                                |
| Mean (Std Dev)                                 | 1.3 (8.9)                      | 62.0 (39.2)                                        |
| Median (Q1 -Q3)                                | 0 (0 -0)                       | 80.0 (15.0- 95.0)                                  |
| min-max                                        | 0-99                           | 0-99                                               |
| Central PgR%², n                               | 1174                           | 277                                                |
| Mean (Std Dev)                                 | 0.6 (4.8)                      | 29.6 (35.0)                                        |
| Median (Q1 -Q3)                                | 0 (0-0)                        | 10.0 (0-60.0)                                      |
| min-max                                        | 0-99                           | 0-99                                               |

Hormone receptor positive is defined as ER-positive and/or PgR positive

Summary statistics for central ER% and PgR% include all central results.

Two patients are excluded from the summary of the TNBC subset because they do not have confirmed HER2-negative status.

eCRF = electronic case report fomm; ER = oestrogen receptor, FAS = fuill analysis set; PgR = progesterone

Central laboratory results were not available in China.

receptor; Q1-Q3 = interquartile range; StdDev = standard deviation; TNBC = tiple negative breast cancer. Source EMT 3056.1, Appendix C.

A total of 50 patients were centrally identified as ER low (1% to 10% expression). Out of these 50 patients, the majority (41 patients [82%]) did not receive any concurrent endocrine therapy. 37 patients (74.0%) were identified as local TNBC patients and 13 (26.0%) as local Hormone Positive patients.

<div style=\"page-break-after: always\"></div>

Previous disease-related cytotoxic chemotherapy treatments are summarised in Table 13 and prior and concurrent hormonal therapies in Table 14.

Table 13: Prior Chemotherapy, Bisphosphonates and Immunotherapy for Primary Breast Cancer in ≥5% of Patients Overall (FAS)

Each treatment was counted a maximum of once per patient.

<!-- image -->

Patients received adjuvant endocrine therapy per local policy and/or international guidelines. Overall, 291 (89.5%) of  the  ER  and/or  PgR  positive,  HER2  negative  patients  received  concurrent  hormone  therapy including 146 patients (86.9%) in the olaparib arm and 145 patients (92.4%) in the placebo arm.

<div style=\"page-break-after: always\"></div>

Table 14 : Prior and/or Concurrent Hormone Therapy for Primary Breast Cancer in the ER and/or PgR Positive, HER2 Negative Subgroup in ≥10% of Patients Overall (FAS)

|                                                   | 0laparib300mgbd (N=168)   | Placebo (N=157)     | Overall (N=325)      |
|---------------------------------------------------|---------------------------|---------------------|----------------------|
| All HR+/HER2-patients [1]                         | 168 (100.0%)              | 157 (100.0%)        | 325 (100.0%)         |
| Any prior and/or concurrent hormone therapy       | 146 (86.9%)               | 145 5(92.48)        | 291 (89.58)          |
| Diagnostic agents                                 | 1 (0.6%)                  | 0 (0.0%)            | 1 (0.3%)             |
| Tests for fertility disturbances                  | 1 (0.68)                  | 0 (0.0%)            | 1 (0.38)             |
| Gonadorelin                                       | 1 (0.6%)                  | 0 (0.0%)            | 1 (0.38)             |
| Endocrine therapy                                 | 146 (86.98)               | 145 (92.48)         | 291 (89.58)          |
| Anti-estrogens                                    | 73 (43.5%)                | 64 (40.8%)          | 137 (42.2%)          |
| Tamoxifen                                         | 73 (43.58)                | 62 (39.58)          | 135 (41.5%)          |
| Toremifene                                        | 0 (0.0%)                  | 2 (1.38)            | 2 (0.68)             |
| Aromatase inhibitors                              | 85 (50.6%)                | 68 (56.78)          | 174 (53.58)          |
| Anastrozole                                       | 26 (15.58)                | 31 (19.78)          | 57 (17.58)           |
| Exemestane                                        | 23 (13.78)                | 27 (17.2%)          | 50 (15.48)           |
| Letrozole                                         | 43 (25.6%)                | 39 (24.8%)          | 82 (25.28)           |
| Gonadotropin releasinghormoneanalogues            | 37 (22.08)                | 35 (22.38)          | 72 (22.28)           |
| Goserelin                                         | 28 (16.7%)                | 20 (12.7%)          | 48 (14.8%)           |
| Goserelin acetate                                 | 0 (0.0%)                  | (0.68)              | 1 (0.38)             |
| Leuprorelin                                       | 8 (4.8%)                  | 12 2(7.6%)          | 20 (6.2%)            |
| Triptorelin                                       | 1 (0.68)                  | 3 (1.98)            | 4 (1.2%)             |
| Triptorelin acetate                               | 2 (1.28)                  | 0 (0.0%)            | 2 (0.6%)             |
| Pituitary and hypothalamichormones and analogues  | 4 (2.4%)                  | 2 (1.38)            | 6 (1.8%)             |
| Gonadotropin-releasing hormones                   | 4 (2.4%)                  | 2 (1.3%)            | 6 (1.8%)             |
| Gonadorelin                                       | 2 (1.2%)                  | 2 (1.38)            | 4 (1.2%)             |
| Gonadotropin-releasing hormones                   | 2 (1.28)                  | 0 (0.0%)            | 2 (0.6%)             |
| Any prior hormone therapy                         | 8 (4.8%)                  | 11 (7.0%)           | 19 (5.8%) (5.8%)     |
| Endocrine therapy                                 | 8 (4.8号) 1 (0.6%)         | 11 (7.08) 3 (1.9%)  | 19 4 (1.2%)          |
| Anti-estrogens Tamoxifen                          | 1 (0.6%)                  | 3 (1.98)            | 4 (1.28)             |
| Aromatase inhibitors                              | 4 (2.4%)                  | 3 (1.98)            | 7 (2.28)             |
| Anastrozole                                       | 1 (0.6%)                  | 0 (0.0%)            | 1 (0.38)             |
| Exemestane                                        | 0 (0.0%)                  | (1.38)              | 2 (0.6%)             |
| Letrozole                                         | 3 (1.8%)                  | 1 (0.6%)            | 4 (1.2%)             |
| Gonadotropin releasing hormone analogues          | 3 (1.8%)                  | 5 (3.28)            | 8 (2.58)             |
| Goserelin                                         | 3 (1.8%)                  | 3(1.98)             | 6 (1.88)             |
| Leuprorelin                                       | 0 (0.0%)                  | 1 (0.68)            | 1 (0.3%)             |
| Triptorelin                                       | 0 (0.0%)                  | 1 (0.6%)            | (0.3%)               |
| Anyconcurrenthormone therapy                      | 146 (86.9%)               | 145 (92.48)         | 291 (89.58)          |
| Diagnostic agents                                 | 1 (0.6%)                  | 0 (0.0%)            | 1 (0.38)             |
| Tests for fertility disturbances                  | 1 (0.6%)                  | 0 (0.0%)            | 1 (0.3%)             |
| Gonadorelin                                       | 1 (0.68)                  | 0 (0.0%)            | 1 (0.3%)             |
| Endocrine therapy                                 | 146 (86.98)               | 145 (92.48)         | 291 (89.58)          |
| Anti-estrogens                                    | 72 (42.98)                | 61 (38.98)          | 133 (40.98)          |
| Tamoxifen                                         | 72 (42.9%)                | 59 (37.68) 2 (1.3%) | 131 (40.38)          |
| Toremifene Aromatase inhibitors                   | 0 (0.0%) 83 (49.4%)       | 88 (56.1%)          | 2 (0.6%) 171 (52.6%) |
| Anastrozole                                       | 25 (14.98)                | 31 (19.7%)          | 56                   |
| Exemestane                                        | 23 (13.78)                | 25 (15.98)          | (17.28) 48           |
| Letrozole                                         | 41 (24.48)                | 38 (24.28)          | (14.88) 79 (24.3%)   |
| Gonadotropin releasing hormone analogues          | 35 (20.8%)                | 32 (20.4%)          | 67 (20.6%)           |
| Goserelin                                         | 25 (14.98)                | 18 (11.58)          | 43 (13.28)           |
| Goserelin acetate                                 | 0 (0.0%)                  | 1 (0.68)            | 1 (0.3%)             |
| Leuprorelin                                       | 8 (4.88)                  | 11 (7.0%)           | 19 (5.88)            |
| Triptorelin                                       | 1 (0.6%)                  | 2 (1.38)            | 3 (0.9%)             |
| Triptorelin acetate                               | 2                         | 0 (0.0%)            | 2 (0.6%)             |
|                                                   | (1.28)                    |                     |                      |
| Pituitary and hypothalamic hormones and analogues | 4 (2.48)                  | 2 (1.3%)            | 6 (1.8%)             |
| Gonadotropin-releasing hormones Gonadorelin       | 4 (2.48) 2 2(1.2%)        | 2 (1.3%) 2 (1.3%)   | 6 (1.8%) 4 (1.2%)    |
|                                                   | 2 2(1.28)                 | 0                   | 2 (0.6%)             |
| Gonadotropin-releasing hormones                   |                           | (0.0%)              |                      |

<div style=\"page-break-after: always\"></div>

## Numbers analysed

The analysis sets and the number of patients in each analysis set are summarised in Table 15.

Table 15 : Analysis sets and number of patients in each analysis set

|                                                           | 0laparib300mgbd (N=921)   | Placebo (N=915)   | Overall (N=1836)   |
|-----------------------------------------------------------|---------------------------|-------------------|--------------------|
| Patients randomised                                       | 921 (100.0%)              | 915 (100.0%)      | 1836 (100.0%)      |
| Patients in full analysis set                             | 921 (100.0%)              | 915 (100.0%)      | 1836 (100.0%)      |
| Patients not in full analysis set                         | 0 (0.0%)                  | 0 (0.0%)          | 0 (0.0%)           |
| Patients in safety analysis set                           | 911 (98.9%)               | 904 (98.8%)       | 1815 (98.9%)       |
| Patients not in safety analysis set                       | 10 (1.1)                  | 11 (1.2)          | 21 (1.1)           |
| No treatment received                                     | 10 (1.1%)                 | 11 (1.2%)         | 21 (1.1%)          |
| Patients in the mature cohort                             | 449 (48.8%)               | 451 (49.3%)       | 006 (49.0%)        |
| Patients consented for PK assessments                     | 06 (9.8%)                 | 98 (10.7)         | 188 (10.2%)        |
| Patients included in PK analysis set                      | 71 (7.7%)                 | 0 (0.0%)          | 71 (3.9%)          |
| Patients not included in PK analysis set                  | 19 (2.1%)                 | 98 (10.7)         | 117 (6.4%)         |
| No pharmacokinetic analysis done                          | 17 (1.8)                  | 0 (0.0%)          | 17 (0.9%)          |
| No treatment received                                     | 2 (0.2%)                  | 0 (0.0%)          | 2 (0.1%)           |
| Not on olaparib                                           | 0 (0.0%)                  | 98 (10.7%)        | 98 (5.3%)          |
| Patients consented for PRo assessments                    | 806 (98.6%)               | 897 (98.0%)       | 1805 (98.3%)       |
| Patients included in PRo analysis set                     | 876 (95.1%)               | 875 (95.6%)       | 1751 (95.4)        |
| Patients not included in PRo analysis set                 | 32 (3.5%)                 | 22 (2.4%)         | 54 (2.9%)          |
| No evaluable baseline QoL questionnaire                   | 22 (2.4)                  | 11 (1.2)          | 33 (1.8)           |
| No treatment received                                     | 10 (1.1%)                 | 11 (1.2%)         | 21 (1.1%)          |
| Protocol version at randomisation (full analysis set) RoW |                           |                   |                    |
| Version 1                                                 | 178 (19.3%)               | 182 (19.9%)       | 360 (19.6%)        |
| Version                                                   | 266 (28.9%)               | 254 (27.8%)       | 520 (28.3%)        |
| Version 4                                                 | 263 (28.68)               | 263 (28.7%)       | 526 (28.6%)        |
| Version 5                                                 | 103 (11.2%)               | 107 (11.7%)       | 210 (11.4%)        |
| US                                                        |                           |                   |                    |
| Version                                                   | 23 (2.5%)                 | 25 (2.7%)         | 48 (2.6%)          |
| Version 2                                                 | 35 (3.8%)                 | 36 (3.9%)         | 71 (3.9%)          |
| Version 3                                                 | 7 (0.8%)                  | 8 (0.9%)          | 15 (0.8%)          |
| Version5                                                  | 30 (3.3%)                 | 33 (3.6%)         | 63 (3.48)          |
| Version 6                                                 | 16 (1.7%)                 | 7 (0.8%)          | 23 (1.3)           |

Mature cohort analysis set - first 9oo randomised patients only. PRO analysis set -patients who consent to participate in the Patient Reported Outcome （PRo)assessment portion of the study, who started treatment and completed at least the baseline PRo questionnaire. Safety analysis set-allpatientswhoreceivedat least one dose of study treatment. PK analysis set -patients who signed the optional PK informed consent form, were randomised to the olaparib arm, received at least one dose of study treatment and had at least one PK sample collected. QoL-Quality of life

Full analysis set - All randomised patients with a signed informed consent.

## Outcomes and estimation

## Primary variable

Primary endpoint: IDFS by investigator assessment (FAS, DCO 27 March 2020, 15.5% maturity )

As the pre-defined statistical threshold for superiority of olaparib versus placebo for IDFS was met at the interim analysis (2-sided, 0.005 significance level), the superiority interim analysis reported constitutes the primary IDFS analysis for this study.

Median duration of follow-up was 2.3 years in the olaparib arm and 2.5 years in the placebo arm. The IDFS status based on investigator assessment at the time of the DCO is presented in Table 16.

<div style=\"page-break-after: always\"></div>

Table 16 : Summary of Type of First IDFS Event (FAS)

|                                            | Number (%) of patients     | Number (%) of patients   |
|--------------------------------------------|----------------------------|--------------------------|
|                                            | Olaparib 300 mg bd (N=921) | Placebo (N=915)          |
| IDFS events                                | 106 (11.5)                 | 178 (19.5)               |
| DistantCNSrecurrence                       | 22 (2.4)                   | 36 (3.9)                 |
| Brain metastasis                           | 21 (2.3)                   | 36 (3.9)                 |
| Meningitis carcinomatosa                   | 1 (0.1)                    | 0                        |
| Distant excl.CNS recurrence                | 50 (5.4)                   | 84 (9.2)                 |
| Bone                                       | 5 (0.5)                    | 14 (1.5)                 |
| Skin nodes (other than local or regional)  | 0                          | 0                        |
| Lymph nodes (other than local or regional) | 5 (0.5)                    | 9 (1.0)                  |
| Lung                                       | 16 (1.7)                   | 34 (3.7)                 |
| Liver                                      | 20 (2.2)                   | 23 (2.5)                 |
| Pleural effusion                           | 3 (0.3)                    | 4 (0.4)                  |

|                                                     | Number (%) of patients     | Number (%) of patients   |
|-----------------------------------------------------|----------------------------|--------------------------|
|                                                     | Olaparib 300 mg bd (N=921) | Placebo (N=915)          |
| Other                                               | 1 (0.1)                    | 0                        |
| Regional (ipsilateral) recurrence                   | 6 (0.7)                    | 14 (1.5)                 |
| Axillary lymph nodes                                | 6 (0.7)                    | 9 (1.0)                  |
| Infraclavicular lymph nodes                         | 0                          | 0                        |
| Supraclavicular lymphnodes                          | 0                          | 3 (0.3)                  |
| Internal mammary lymph nodes                        | 0                          | 1 (0.1)                  |
| Skin or soft tissue within the regional area        | 0                          | 1 (0.1)                  |
| Local (ipsilateral) recurrence                      | 7 (0.8)                    | 11 (1.2)                 |
| Breast surgical scaf                                | 1 (0.1)                    | 3 (0.3)                  |
| Breast                                              | 3 (0.3)                    | 4 (0.4)                  |
| Anterior chest wall                                 | 2 (0.2)                    | 2 (0.2)                  |
| Skin or soft tissue within the local area           | 1 (0.1)                    | 2 (0.2)                  |
| Contralateralinvasivebreastcancer                   | 8 (0.9)                    | 12 (1.3)                 |
| New primary cancer's                                | 11 (1.2)                   | 21 (2.3)                 |
| New primary invasive non-breast ovarian cancer      | 2 (0.2)                    | 8 (0.9)                  |
| Ovarian cancer                                      | 1 (0.1)                    | 4 (0.4)                  |
| Fallopian tube cancer                               | 1 (0.1)                    | 4 (0.4)                  |
| Peritoneal cancer                                   | 0                          | 0                        |
| New primary invasive non-breast non-ovarian cancers | 9 (1.0)                    | 13 (1.4)                 |
| Deaths without a prior IDFS event                   | 2 (0.2)                    | 0                        |

If 2recurrence eventswere reportedwithin 2months of eachother, thiswasreferred to as asimultaneous event and was considered to be a single event.In this situation the worst case was taken as the event ^typebut the date of recurrence was the earliest date of the 2 events.

bd = twice daily; CNS = central nervous system; FAS =full analysis set; IDFS =invasive disease free survival. Source: Table 14.2.1.

<div style=\"page-break-after: always\"></div>

Table 17 : Analysis of IDFS (FAS)

|                                                            | Olaparib 300 mg bd (N=921)   | Placebo (N=915)   |
|------------------------------------------------------------|------------------------------|-------------------|
| Olaparib vs placebo                                        |                              |                   |
| Number of events (%)                                       | 106 (11.5)                   | 178 (19.5)        |
| Estimate ofHR a                                            | 0.581                        | 0.581             |
| 99.5% CI for HR b, c                                       | 0.409, 0.816                 | 0.409, 0.816      |
| 95% CI for HR c. d                                         | 0.455,0.737                  | 0.455,0.737       |
| log-rank test: p-value e                                   | 0.0000073                    | 0.0000073         |
| Median clinical follow-up time, years f                    | 2.3                          | 2.5               |
| Minimum/Maximum                                            | 0/5.5                        | 0/5.5             |
| Percentage (95% C1) of patients invasive disease free at * |                              |                   |
| 1 year                                                     | 93.3 (91.4, 94.8)            | 88.4 (86.1, 90.4) |
| 2 years                                                    | 89.2 (86.8, 91.3)            | 81.5 (78.6, 84.0) |
| 3 years                                                    | 85.9 (82.8, 88.4)            | 77.1 (73.7, 80.1) |

Estimate of the treatment HR was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo arm. Stratification factors were the same as those used in the stratified log-rank test.

- Inferential, according to the alpha spending rules for the interim analysis.
- The CI for the HR was estimated using the profile likelihood approach.
- d Exploratory, not inferential.
- P-value from a stratified log-rank test. Stratification was by chemotherapy type (2 levels: adjuvant versus neoadjuvant), hormone receptor status (2 levels: ER and/or PgR positive, HER2 negative versus TNBC), and prior platinum therapy (2 levels: yes versus no). Stratification factors were based upon the categories used in the randomisation system and were chosen by the pooling strategy. Once the pooling strategy was applied, only the hormone receptor status stratification factor was selected.
- Median clinical follow-up was calculated using the reverse censoring method.
- g Percentage of patients were from the KM estimates and the 95% CIs were calculated using Greenwood's formula

bd = twice daily; CI = confidence interval; FAS = full analysis set; ER = oestrogen receptor; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio; IDFS = invasive disease free survival;

S p   =    =  n =

Source: Table 14.2.3.

<div style=\"page-break-after: always\"></div>

<!-- image -->

FAS = full analysis set; IDFS = invasive disease free survival.

Source: Figure 14.2.1.

Figure 6 : Kaplan-Meier Plot of IDFS (FAS)

<div style=\"page-break-after: always\"></div>

## Secondary variables

## DDFS by investigator assessment (FAS, DCO 27 March 2020, 13% maturity)

Table 18 : Analysis of DDFS (FAS)

|                                                           | Olaparib300mgbd (N=921)                                   | Placebo (N=915)   |
|-----------------------------------------------------------|-----------------------------------------------------------|-------------------|
| Olaparibvs placebo                                        |                                                           |                   |
| Number of events (%)                                      | 89 (9.7)                                                  | 152 (16.6)        |
| Estimate of HR a                                          | 0.574                                                     | 0.574             |
| 99.5% CI for HR b, c                                      | 0.392, 0.831                                              | 0.392, 0.831      |
| 95% CI for HR b, d                                        | 0.441, 0.744                                              | 0.441, 0.744      |
| log-rank test: p-value e                                  | 0.0000257                                                 | 0.0000257         |
| Median clinical follow-up time,year's                     | 2.3                                                       | 2.5               |
| Minimum/Maximum                                           | 0/5.5                                                     | 0/5.5             |
| Percentage (95% CI) of patients distant disease free at f | Percentage (95% CI) of patients distant disease free at f |                   |
| 1 year                                                    | 94.3 (92.4, 95.6)                                         | 90.2 (88.1, 92.0) |
| 2 years                                                   | 90.0 (87.6, 92.0)                                         | 83.9 (81.2, 86.3) |
| 3 years                                                   | 87.5 (84.6, 89.9)                                         | 80.4 (77.2, 83.3) |

Estimate of the treatment HR was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo arm. Stratification factors were the same as those used in the stratified log-rank test.

b The CI for the HR was estimated using the profile likelihood approach.

- C Inferential, according to the alpha spending rules for the interim analysis.
- d Exploratory, not inferential.
- P-value from a stratified log-rank test. Stratification was by chemotherapy type (2 levels: adjuvant versus neoadjuvant), hormone receptor status (2 levels: ER and/or PgR positive, HER2 negative versus TNBC), and prior platinum therapy (2 levels: yes versus no). Stratification factors were based upon the categories used in the randomisation system and were chosen by the pooling strategy. Once the pooling strategy was applied, only the hormone receptor status stratification factor was selected.
- Percentage of patients were from the KM estimates and the 95% CIs were calculated using Greenwood's formula.

bd = twice daily; CI = confidence interval; DDFS = distant disease free survival; ER = oestrogen receptor;

FAS = full analysis set; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio;

KM = Kaplan-Meier; PgR = progesterone receptor; TNBC = triple negative breast cancer.

Source: Table 14.2.10.

<div style=\"page-break-after: always\"></div>

<!-- image -->

DDFS = distant disease free survival; FAS = full analysis set.

Source: Figure 14.2.20.1.

Figure 7 : Kaplan-Meier plot of DDFS (FAS)

## OS by investigator assessment (FAS, DCO2 12 July 2021, 10% maturity)

The MAH provided updated OS results from the second planned interim analysis (DCO2 12 July 2021). Median duration of follow-up for OS was 3.5 years in the olaparib arm and 3.6 years in the placebo arm.

<div style=\"page-break-after: always\"></div>

Table 19 : Updated Analysis of OS (FAS)

<!-- image -->

|                                               |                                               | DCOl: 27March 2020         | DCOl: 27March 2020   | DC02 12 July 2021          | DC02 12 July 2021   |
|-----------------------------------------------|-----------------------------------------------|----------------------------|----------------------|----------------------------|---------------------|
|                                               |                                               | Olaparib 300 mg bd (N=921) | Placebo (N=915)      | Olaparib 300 mg bd (N=921) | Placebo (N=915)     |
|                                               | 4 years                                       |                            |                      | 86.5 (83.8, 88.8)          | 79.1 (76.0, 81.8)   |
| OS                                            |                                               |                            |                      |                            |                     |
| Number of events/total mumber of patients (%) | Number of events/total mumber of patients (%) | 59/921 (6.4)               | 86/915 (9.4)         | 75/921 (8.1)               | 109/915 (11.9)      |
| Hazardratio b                                 | Hazardratio b                                 | 0.683                      | 0.683                | 0.678                      | 0.678               |
| 99% CI for hazard ratio cd                    | 99% CI for hazard ratio cd                    | 0.438, 1.053               | 0.438, 1.053         |                            |                     |
| 98.5% CI for hazard ratio cd                  | 98.5% CI for hazard ratio cd                  |                            |                      | 0.468, 0.973               | 0.468, 0.973        |
| 95% CI for hazard ratio 4e                    | 95% CI for hazard ratio 4e                    | 0.488, 0.950               | 0.488, 0.950         | 0.503, 0.907               | 0.503, 0.907        |
| p-value, 2-sided                              | p-value, 2-sided                              | 0.0236                     | 0.0236               | 0.0091                     | 0.0091              |
| Median survival follow-up time, years ?       | Median survival follow-up time, years ?       | 2.4                        | 2.5                  | 3.5                        | 3.6                 |
| Percentage (95% CI) of patients alive ath     | 1 year                                        | 98.1 (96.9, 98.8)          | 96.9 (95.5, 97.9)    | 98.0 (96.9, 98.8)          | 96.9 (95.5, 97.9)   |
| Percentage (95% CI) of patients alive ath     | 2 years                                       | 94.8 (93.0, 96.2)          | 92.3 (90.1, 94.0)    | 95.0 (93.3, 96.2)          | 92.8 (90.9, 94.3)   |
| Percentage (95% CI) of patients alive ath     | 3 years                                       | 92.0 (89.6, 93.9)          | 88.3 (85.4, 90.7)    | 92.8 (90.8, 94.4)          | 89.1 (86.7, 91.0)   |
| Percentage (95% CI) of patients alive ath     | 4 years                                       |                            |                      | 89.8 (87.2, 91.9)          | 86.4 (83.6, 88.7)   |

Invasive disease ffee suuvival is defined as time from randomisation to date of first recuurence, where recurence is defined (per STEEP definition) as loco-regional, distant recurence, contralateral invasive breast cancer, second primary non-breast invasive malignancy, or death from any cause.

Estimate of the treatment hazard ratio was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower nisk with olaparib compared with placebo anm.Stratification factors were the same as those used in the shratified log-rank test.

Inferential, according to the alpha spending nles for each DCO, pre-defined in the statistical analysis plan (Table 10, Section 5).

The CI for the hazard ratio was estimated using the profile likelihood approach.

Exploratory, not inferential.

P-value from a stratified log-rank test. Stratification was by chemotherapy type (2 levels: adjuvant versus neoadjuvant), hormone receptor status (2 levels: ER and/or PgR positive, HER2 negative versus TNBC), and prior platinum therapy (2 levels: yes versus no). Stratification factors were based upon the categories used in the randomisation system and were chosen by the pooling strategy. Once the pooling strategy was applied, only the hormone receptor status shratification factor was selected.

- P-value from a stratified log-rank test. Stratification was by chemotherapy type (2 levels: adjuvant versus neoadjuvant), hoimone receptor status (2 levels: ER and/or PgR positive, HER2 negative versus TNBC), and prior platinum therapy (2 levels: yes versus no). Stratification factors were based upon the categories used in the randomisation system and were chosen by the pooling strategy. Once the pooling strategy was applied, only the hormone receptor status stratification factor was selected.
- Percentage of patients were from the KM estimates and the 95% CIs were calculated using Greenwood's formula.

bd = twice daily; CI = confidence interval; ER = oestrogen receptor positive; FAS = full analysis set; HER2 = human epidermal growth factor receptor 2; HR = hazard ratio; KM = Kaplan Meier; OS = overall survival; PgR = progesterone receptor positive; TNBC = triple negative breast cancer.

Source: Table 14.2.7.

## Cancers Occurring Post Randomisation

Table 20 presents all cancers occurring post randomisation (COPRs), which included not only the incidence of cancers of special interest as listed in the secondary efficacy endpoint, but also the incidence of new primary non-breast, non-ovarian cancers including MDS/AML.

New primary malignancies (NPM) are those that are not the primary reason for the administration of the study treatment and have developed after the inclusion of the patient into the study. Invasive non-breast new primary cancers  were  confirmed  by  clinical  or  radiological  examination,  with  positive  histology  or cytology when the lesion was easily accessible for biopsy. These events were captured in eCRF on the 'Second Primary Malignancy' form.

In comparison, breast cancer relapses in the OlympiA study includes ipsilateral invasive breast tumour recurrence, regional invasive breast cancer recurrence, distant recurrence, and contralateral invasive breast

<div style=\"page-break-after: always\"></div>

cancer if determined as recurrence by the investigator. Locoregional recurrence of the disease (ipsilateral, regional and contralateral invasive breast cancer) should be cytologically/histologically confirmed. Distant recurrence  were  diagnosed  by  radiological  examination  and/or  histopathological  confirmation  when metastatic lesion was easily accessible for biopsy.

Table 20 : Summary of Cancers Occurring Post-Randomisation (FAS)

|                                                     | Olaparib 300 mg bd (N=921)   | Placebo (N=915)   |
|-----------------------------------------------------|------------------------------|-------------------|
| Number (%) of patients with:                        |                              |                   |
| Contralateral invasive breast cancer                | 12 (1.3)                     | 14 (1.5)          |
| Contralateral non-invasive breast cance1            | 2 (0.2)                      | 3 (0.3)           |
| New primary ovarian a                               | 2 (0.2) b                    | 8 (0.9)           |
| New primary ovarian cancer                          | 1 (0.1)                      | 4 (0.4)           |
| New primaiy fallopian tube cancer                   | 1 (0.1)                      | 4 (0.4)           |
| New primary peritoneal cancer                       | 0                            | 0                 |
| New primary invasive non-breast non-ovarian cancers | 9 (1.0)                      | 14 (1.5)          |

a Includes new primary ovarian, fallopian, and peritoneal cancers, without considering competing risks.

b One patient was captured in the database with ovarian cancer recurrence.

Summary of cancers without considering competing risks.

For contralateral breast cancers, this includes all cancers, both new and recurrent.

bd = twice daily; FAS = full analysis set.

Source: Table 14.2.14.

## Health-related Quality of Life

FACIT-Fatigue  score  and  EORTC  QLQ-C30  global  health  status/QoL  score  were  secondary  outcome measures.

PRO analyses were based on the PRO analysis set (N=876 patients in the olaparib arm and N=875 in the placebo arm).

<div style=\"page-break-after: always\"></div>

Table 21 : Compliance Rate for QoL Questionnaires by Group and Visit (PRO Analysis Set)

|                  | Compliance rate (%o) a   | Compliance rate (%o) a   | Compliance rate (%o) a   | Compliance rate (%o) a   | Compliance rate (%o) a   |
|------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                  | Baseline                 | 6 Months                 | 12 Months                | 18 Months                | 24 Months                |
| Olaparib (N=876) |                          |                          |                          |                          |                          |
| FACIT-Fatigue    | 99.4                     | 84.0                     | 81.8                     | 72.2                     | 66.8                     |
| EORTC QLQ-C30    | 100                      | 84.8                     | 82.2                     | 72.4                     | 66.8                     |
| Placebo (N=875)  |                          |                          |                          |                          |                          |
| FACIT-Fatigue    | 99.7                     | 90.9                     | 86.0                     | 73.6                     | 68.7                     |
| EORTC QLQ-C30    | 99.9                     | 91.6                     | 86.9                     | 74.2                     | 69.3                     |

Number of evaluable forms divided by the number of expected forms.

EORTC QLQ-30 = European Organisation for Research and Treatment of Cancer quality of life questionnaire; FACIT-Fatigue = Functional Assessment of Chronic Illness Therapy-Fatigue Measurement questionnaire; PRO = patient reported outcome; QoL = quality of life.

Source: Table 14.2.25.02.

## FACIT-Fatigue

The  FACIT-Fatigue  score  ranges  from  0  to  52  with  higher  scores  indicating  less  fatigue,  and  a  score difference of 3 points defined as clinically meaningful. Separate analyses were conducted for patients who had  received  prior  neoadjuvant  chemotherapy  and  patients  who  had  received  standard  post-surgical adjuvant chemotherapy because the timing of chemotherapy had the potential to impact fatigue outcome differently.

Change from baseline at 6 and 12 months for FACIT-Fatigue in patients receiving neoadjuvant and adjuvant chemotherapy is presented in Table 22.

Regarding FACIT-Fatigue Score, differences that were detected were not clinically meaningful (adjusted LS mean change scores between the olaparib and placebo at Months 6 and 12 for both the prior neoadjuvant (-1.3 at 6 months; p=0.024 [nominal], -1.5 at 12 months; p=0.025 [nominal]) and adjuvant (-1.3 at 6 months; p=0.017 [nominal], and -1.3 at 12 months; p=0.027 [nominal]) treatment groups).

Table  22  :  Change  from  Baseline  for  FACIT-Fatigue  Score  at  6  and  12  Months  (MMRM;  PRO Analysis Set) - Neoadjuvant

|                                                     | 6 months                                            | 6 months                                            | 12 months                                           | 12 months                                           |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Parameter                                           | LS Mean                                             | 95% CI                                              | LS Mean                                             | 95% CI                                              |
| Patients who had completed neoadjuvant chemotherapy | Patients who had completed neoadjuvant chemotherapy | Patients who had completed neoadjuvant chemotherapy | Patients who had completed neoadjuvant chemotherapy | Patients who had completed neoadjuvant chemotherapy |
| Olaparib 300 mg bd (n=371)                          | -1.5                                                | -2.2, -0.7                                          | -1.5                                                | -2.4, -0.6                                          |
| Placebo (n=356)                                     | -0.2                                                | -1.0, 0.6                                           | 0.0                                                 | -0.9, 0.9                                           |
| Difference                                          | -1.3                                                | -2.4, -0.2                                          | -1.5                                                | -2.8, -0.2                                          |
| P-value                                             | 0.024                                               | 0.024                                               | 0.025                                               | 0.025                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

FACIT-Fatigue score ranges from 0 to 52 with higher score indicating less fatigue; a score difference of 3 points was defined as clinically meaningful. Adjusted LS mean changes and 95% CI are obtained from MMRM analysis of the change from baseline. The model includes treatment, time and treatment by time interaction, corresponding baseline score and the baseline score by time interaction.

CI = confidence interval; FACIT-Fatigue = Functional Assessment of Chronic Illness Therapy-Fatigue Measurement questionnaire; LS = least squares; MMRM = mixed model for repeated measures; PRO = patient reportedoutcome.

Source: Figure 14.2.24.01.

## Figure  8:  Mean  Change  from  Baseline  for  FACIT-Fatigue  (Prior  Neoadjuvant  Patients;  PRO Analysis Set)

Table  23  :  Change  from  Baseline  for  FACIT-Fatigue  Score  at  6  and  12  Months  (MMRM;  PRO Analysis Set) - Adjuvant

|           | 6 months   | 6 months   | 12 months   | 12 months   |
|-----------|------------|------------|-------------|-------------|
| Parameter | LS Mean    | 95% CI     | LS Mean     | 95% CI      |

| Patients whohad completed adjuvant chemotherapy   |   Patients whohad completed adjuvant chemotherapy | Patients whohad completed adjuvant chemotherapy   |   Patients whohad completed adjuvant chemotherapy | Patients whohad completed adjuvant chemotherapy   |
|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
| Olaparib 300 mg bd (n=375)                        |                                            -0.7   | -1.4, 0.1                                         |                                            -0.8   | -1.6, -0.0                                        |
| Placebo (n=403)                                   |                                             0.6   | -0.1, 1.3                                         |                                             0.5   | -0.3, 1.2                                         |
| Difference                                        |                                            -1.3   | -2.3,-0.2                                         |                                            -1.3   | -2.4, 0.1                                         |
| P-value                                           |                                             0.017 | 0.017                                             |                                             0.027 | 0.027                                             |

Only patients with an evaluable baseline form were included.

Adjusted least-square mean changes, p-values (2-sided) and 95% CI were obtained from MMRM analysis of the change from baseline. The model included treatment, time and treatment by time interaction, corresponding baseline score, and the baseline score by time interaction.

FACIT-Fatigue ranges from 0 to 52 with higher score indicating less fatigue.

Difference was the values for olaparib minus placebo.

bd = twice daily; CI = confidence interval; FACIT = functional assessment of chronic illness therapy; LS = least squares; MMRM = mixed model for repeated measures; PRO = patient reported outcome.

Source:Table 14.2.25.11 and Table 14.2.25.12.

<div style=\"page-break-after: always\"></div>

<!-- image -->

FACIT-Fatigue score ranges from 0 to 52 with higher score indicating less fatigue a score difference of 3 points defined as clinically meaningful. Adjusted LS mean changes and 95% CI are obtained from MMRM analysis of the change from baseline. The model includes treatment, time and treatment by time interaction, corresponding baseline score and the baseline score by time interaction.

CI = confidence interval; FACIT = functional assessment of chronic illness therapy; LS = least squares; MMRM = mixed model for repeated measures; PRO = patient reported outcome.

Source: Figure 14.2.24.02.

Figure 9 : Mean Change from Baseline for FACIT-Fatigue (Prior Adjuvant Patients; PRO Analysis Set)

## EORTC QLQ-C30

All EORTC QLQ-C30 scales range in score from 0 to 100, with higher scores on HRQoL and functioning scores indicating better HRQoL/functioning and higher scores on symptom scales indicating worse symptom severity.

Mean (SD) EORTC QLQ-C30 global health status/QoL and functioning subscale scores generally remained stable for both the olaparib and placebo arms at Months 6 and 12. Small improvements from baseline were observed in global health status/QoL, role functioning, and social functioning in both arms at Months 18 and 24, with no statistical meaningful differences.

Mean (SD) EORTC QLQ-C30 GI symptom scores (nausea/vomiting) were increased in the olaparib arm versus the placebo arm after 6 and 12 months of treatment as expected given the known safety profile of olaparib. At Months 18 and 24, scores returned to baseline and were comparable between the olaparib and placebo arms, with no clinically meaningful differences observed ( Table 24 ). For the prior neoadjuvant group, small increases in scores for diarrhoea were observed in the olaparib arm versus the placebo arm after 6 and 12 months of treatment, with scores returning to baseline and comparable to placebo at 18 and 24 months. For the adjuvant group, diarrhoea scores generally remained stable for both the olaparib and placebo arms across all timepoints.

Change from baseline for EORTC QLQ-C30 subscale scores in patients receiving neoadjuvant and adjuvant chemotherapy are presented in Table 24.

<div style=\"page-break-after: always\"></div>

Table  24  :  Model  Based  Change  from  Baseline  for  EORTC  QLQ-C30  Subscale  Measures  (PRO Analysis Set) - Neoadjuvant

|                                                 | 6 months                                        | 6 months                                        | 12 months                                       | 12 months                                       | 18 months                                       | 18 months                                       | 24 months                                       | 24 months                                       |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Parameter                                       | Mean                                            | 95% CI                                          | Mean                                            | 95% CI                                          | Mean                                            | 95% CI                                          | Mean                                            | I0 %S6                                          |
| Patientswhohadcompletedneoadjuvantchemotherapy  | Patientswhohadcompletedneoadjuvantchemotherapy  | Patientswhohadcompletedneoadjuvantchemotherapy  | Patientswhohadcompletedneoadjuvantchemotherapy  | Patientswhohadcompletedneoadjuvantchemotherapy  | Patientswhohadcompletedneoadjuvantchemotherapy  | Patientswhohadcompletedneoadjuvantchemotherapy  | Patientswhohadcompletedneoadjuvantchemotherapy  | Patientswhohadcompletedneoadjuvantchemotherapy  |
| EORTC QLQ-C30 Global health status QoL          | EORTC QLQ-C30 Global health status QoL          | EORTC QLQ-C30 Global health status QoL          | EORTC QLQ-C30 Global health status QoL          | EORTC QLQ-C30 Global health status QoL          | EORTC QLQ-C30 Global health status QoL          | EORTC QLQ-C30 Global health status QoL          | EORTC QLQ-C30 Global health status QoL          | EORTC QLQ-C30 Global health status QoL          |
| Olaparib 300 mg bd (n=380)                      | -0.2                                            | -2.0, 1.6                                       | 0.4                                             | -1.7, 2.4                                       | 3.6                                             | 1.4, 5.7                                        | 2.3                                             | -0.3, 5.0                                       |
| Placebo (n=358)                                 | 0.5                                             | -1.3, 2.4                                       | 2.8                                             | 0.8, 4.8                                        | 4.2                                             | 2.0, 6.4                                        | 6.9                                             | 4.2, 9.7                                        |
| Difference                                      | -0.7                                            | -3.3, 1.9                                       | -2.5                                            | -5.3, 0.4                                       | -0.6                                            | -3.7,2.5                                        | -4.6                                            | -8.4, -0.8                                      |
| P-value                                         | 0.590                                           | 0.590                                           | 0.090                                           | 0.090                                           | 0.688                                           | 0.688                                           | 0.018                                           | 0.018                                           |
| EORTC QLQ-C30 Nausea and vomiting symptom scale | EORTC QLQ-C30 Nausea and vomiting symptom scale | EORTC QLQ-C30 Nausea and vomiting symptom scale | EORTC QLQ-C30 Nausea and vomiting symptom scale | EORTC QLQ-C30 Nausea and vomiting symptom scale | EORTC QLQ-C30 Nausea and vomiting symptom scale | EORTC QLQ-C30 Nausea and vomiting symptom scale | EORTC QLQ-C30 Nausea and vomiting symptom scale | EORTC QLQ-C30 Nausea and vomiting symptom scale |
| Olaparib 300 mg bd (n=383)                      | 7.6                                             | 6.2, 9.0                                        | 7.3                                             | 6.0, 8.7                                        | 0.7                                             | -0.4, 1.8                                       | 1.3                                             | 0.0, 2.6                                        |
| Placebo (n=359)                                 | 1.6                                             | 0.2, 3.1                                        | 1.0                                             | -0.4, 2.4                                       | 0.4                                             | -0.8, 1.5                                       | -0.1                                            | -1.5, 1.2                                       |
| Difference                                      | 6.0                                             | 4.0, 8.0                                        | 6.3                                             | 4.4, 8.2                                        | 0.4                                             | -1.2,1.9                                        | 1.4                                             | -0.4, 3.3                                       |
| P-value                                         | <0.001                                          | <0.001                                          | <0.001                                          | <0.001                                          | 0.664                                           | 0.664                                           | 0.120                                           | 0.120                                           |
| EORTC QLQ-C30 Diarrhoea symptom scale           | EORTC QLQ-C30 Diarrhoea symptom scale           | EORTC QLQ-C30 Diarrhoea symptom scale           | EORTC QLQ-C30 Diarrhoea symptom scale           | EORTC QLQ-C30 Diarrhoea symptom scale           | EORTC QLQ-C30 Diarrhoea symptom scale           | EORTC QLQ-C30 Diarrhoea symptom scale           | EORTC QLQ-C30 Diarrhoea symptom scale           | EORTC QLQ-C30 Diarrhoea symptom scale           |
| Olaparib 300 mg bd (n=380)                      | 1.6                                             | -0.0, 3.3                                       | 4.0                                             | 1.9, 6.1                                        | 2.7                                             | 0.5, 4.9                                        | 1.3                                             | -1.0, 3.5                                       |
| Placebo (n=357)                                 | 1.3                                             | -0.4, 3.0                                       | 2.0                                             | -0.1, 4.1                                       | 1.5                                             | -0.7, 3.8                                       | -0.5                                            | -2.9, 1.8                                       |
| Difference                                      | 0.3                                             | -2.0, 2.7                                       | 2.0                                             | -1.0, 4.9                                       | 1.1                                             | -2.0, 4.3                                       | 1.8                                             | -1.5, 5.0                                       |
| P-value                                         | 0.776                                           | 0.776                                           | 0.187                                           | 0.187                                           | 0.488                                           | 0.488                                           | 0.282                                           | 0.282                                           |

|                                               | 6 months                                      | 6 months                                      | 12 months                                     | 12 months                                     | 18 months                                     | 18 months                                     | 24 months                                     | 24 months                                     |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Parameter                                     | Mean                                          | 10 %S6                                        | Mean                                          | 10 %S6                                        | Mean                                          | 1D %S6                                        | Mean                                          | 1D %S6                                        |
| Patientswhohadcompleted adjuvant chemotherapy | Patientswhohadcompleted adjuvant chemotherapy | Patientswhohadcompleted adjuvant chemotherapy | Patientswhohadcompleted adjuvant chemotherapy | Patientswhohadcompleted adjuvant chemotherapy | Patientswhohadcompleted adjuvant chemotherapy | Patientswhohadcompleted adjuvant chemotherapy | Patientswhohadcompleted adjuvant chemotherapy | Patientswhohadcompleted adjuvant chemotherapy |
| EORTC QLQ-C30 Global health status QoL        | EORTC QLQ-C30 Global health status QoL        | EORTC QLQ-C30 Global health status QoL        | EORTC QLQ-C30 Global health status QoL        | EORTC QLQ-C30 Global health status QoL        | EORTC QLQ-C30 Global health status QoL        | EORTC QLQ-C30 Global health status QoL        | EORTC QLQ-C30 Global health status QoL        | EORTC QLQ-C30 Global health status QoL        |
| Olaparib 300 mg bd (n=383)                    | -0.4                                          | -2.1, 1.3                                     | 0.7                                           | -1.0, 2.5                                     | 2.8                                           | 1.0, 4.7                                      | 4.1                                           | 1.8, 6.3                                      |
| Placebo (n=406)                               | 2.3                                           | 0.7, 3.9                                      | 3.3                                           | 1.6, 5.0                                      | 5.5                                           | 3.6, 7.4                                      | 4.9                                           | 2.6, 7.1                                      |
| Difference                                    | -2.7                                          | -5.0, -0.4                                    | -2.5                                          | -5.0, -0.1                                    | -2.6                                          | -5.3, 0.0                                     | -0.8                                          | -4.0, 2.4                                     |
| P-value                                       | 0.023                                         | 0.023                                         | 0.043                                         | 0.043                                         | 0.053                                         | 0.053                                         | 0.619                                         | 0.619                                         |
| EORTCQLQ-C30Nausea andvomiting symptomscale   | EORTCQLQ-C30Nausea andvomiting symptomscale   | EORTCQLQ-C30Nausea andvomiting symptomscale   | EORTCQLQ-C30Nausea andvomiting symptomscale   | EORTCQLQ-C30Nausea andvomiting symptomscale   | EORTCQLQ-C30Nausea andvomiting symptomscale   | EORTCQLQ-C30Nausea andvomiting symptomscale   | EORTCQLQ-C30Nausea andvomiting symptomscale   | EORTCQLQ-C30Nausea andvomiting symptomscale   |
| Olaparib 300 mg bd (n=385)                    | 6.9                                           | 5.5, 8.2                                      | 5.5                                           | 4.2, 6.7                                      | 0.7                                           | -0.5, 1.8                                     | -0.0                                          | -1.3, 1.3                                     |
| Placebo (n=406)                               | 1.6                                           | 0.3, 2.9                                      | 1.0                                           | -0.2, 2.1                                     | 1.0                                           | -0.2, 2.1                                     | 0.6                                           | -0.6, 1.9                                     |
| Difference                                    | 5.3                                           | 3.4, 7.2                                      | 4.5                                           | 2.8, 6.2                                      | -0.3                                          | -1.9, 1.3                                     | -0.6                                          | -2.5, 1.2                                     |
| P-value                                       | <0.001                                        | <0.001                                        | <0.001                                        | <0.001                                        | 0.718                                         | 0.718                                         | 0.481                                         | 0.481                                         |
| EORTC QLQ-C30 Diarrhoea symptom scale         | EORTC QLQ-C30 Diarrhoea symptom scale         | EORTC QLQ-C30 Diarrhoea symptom scale         | EORTC QLQ-C30 Diarrhoea symptom scale         | EORTC QLQ-C30 Diarrhoea symptom scale         | EORTC QLQ-C30 Diarrhoea symptom scale         | EORTC QLQ-C30 Diarrhoea symptom scale         | EORTC QLQ-C30 Diarrhoea symptom scale         | EORTC QLQ-C30 Diarrhoea symptom scale         |
| Olaparib 300 mg bd (n=384)                    | 0.0                                           | -1.7, 1.8                                     | 1.5                                           | -0.1, 3.1                                     | -0.2                                          | -1.8, 1.4                                     | -1.6                                          | -3.2, 0.1                                     |
| Placebo (n=406)                               | 1.7                                           | 0.1, 3.4                                      | 1.4                                           | -0.2, 3.0                                     | -0.6                                          | -2.2, 1.0                                     | -0.6                                          | -2.2, 1.1                                     |
| Difference                                    | -1.7                                          | -4.1, 0.7                                     | 0.1                                           | -2.2,2.4                                      | 0.4                                           | -1.9, 2.7                                     | -1.0                                          | -3.4, 1.4                                     |
| P-value                                       | 0.167                                         | 0.167                                         | 0.901                                         | 0.901                                         | 0.736                                         | 0.736                                         | 0.405                                         | 0.405                                         |

Only patients with an evaluable baseline form were included.

Adjusted least-square mean changes, p-values (2-sided) and 95% CI were obtained from MMRM analysis of the change from baseline. The model included treatment, time and treatment by time interaction, corresponding baseline score, and the baseline score by time interaction.

All EORTC QLQ-C30 scales range in score from 0 to 100. Higher score indicates better QoL/functioning or worse symptom severity. Difference was the values for olaparib minus placebo.

bd = twice daily; CI = confidence interval; EORTC QLQ-30 = European Organisation for Research and Treatment of Cancer quality of life questionnaire; MMRM = mixed model for repeated measures; PRO = patient reported outcome; QoL = quality of life.

Source: Table 14.2.25.15 and Table 14.2.25.16.

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Sensitivity Analyses

## Table 25 : Sensitivity Analyses of IDFS (FAS) (DCO1: 27 March 2020)

|                                                    |                    |     | Treatmenteffect             | Treatmenteffect           | Treatmenteffect           |
|----------------------------------------------------|--------------------|-----|-----------------------------|---------------------------|---------------------------|
|                                                    |                    |     | Number (%) of patients with | Comparison betveen groups | Comparison betveen groups |
| Analysis                                           | Group              | Na  | events                      | HR                        | 95% CI                    |
| Patients with central pathology review data b      | Olaparib300mg bd   | 732 | 86 (11.7)                   | 0.535c                    | 0.409, 0.696 d            |
|                                                    | Placebo            | 720 | 151 (21.0)                  | 0.535c                    | 0.409, 0.696 d            |
| Unadjusted analysis(unstratified Cox model fitted) | Olaparib 300 mg bd | 921 | 106 (11.5)                  | 0.581 e                   | 0.455, 0.737 d            |
| Unadjusted analysis(unstratified Cox model fitted) | Placebo            | 915 | 178 (19.5)                  | 0.581 e                   | 0.455, 0.737 d            |
| Interval censoring f                               | Olaparib 300 mg bd | 921 | 106 (11.5)                  | 0.580 c                   | 0.456, 0.738              |
| Interval censoring f                               | Placebo            | 915 | 178 (19.5)                  | 0.580 c                   | 0.456, 0.738              |

Number of patients included in sensitivity analysis.

- Includes patients that had both central and local hormone receptor status results. Central pathology review data were not available for China.See Table 14.1.8.3for tabulation of the concordance between central and local results. Stratification factors for hormone receptor status was according to the central pathology review.
- Estimate of the treatment HR was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo arm.
- P The 95% CI for the HR was estimated using the profile likelihood approach.
- Estimate of the treatment HR was based on the unstratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo arm.
- For patients experiencing an event, and without follow-up according to the CSP (defined as over 18 months between the event and the last visit), the interval from the last date at which the subject was known to be IDFS free to the date of recurrence or death, was used.

The 95%Wald CI for theHR.

Percentages are of the number of patients in the population subgroup in question.

Mis-stratification sensitivity analysis was not triggered as ≤5% of randomised patients were incorrectly stratified (ie, randomisation system data did not match intended disease or indication; did not receive any randomised therapy) was not triggered as ≤10% of patients in either treatment group had important protocol deviations.

bd = twice daily; CI = confidence interval; CSP = Clinical Study Protocol; FAS = full analysis set; HR = hazard ratio; IDFS = invasive disease free survival. Source: Table 14.2.6.2.

<div style=\"page-break-after: always\"></div>

Table 26 : Sensitivity Analyses of DDFS (FAS) (DCO1: 27 March 2020)

|                                               | Olaparib 300 mg bd (N=921)   | Placebo (N=915)      |
|-----------------------------------------------|------------------------------|----------------------|
| Patients with central pathology review data * |                              |                      |
| Olaparib vs placebo, n (%) b                  | 732                          | 720                  |
| Number of events (%)                          | 71 (9.7)                     | 127 (17.6)           |
| Estimate of HR (95% CI) cd                    | 0.530 (0.395,0.706)          | 0.530 (0.395,0.706)  |
| Unadjusted analysis e                         |                              |                      |
| Olaparib vs placebo, n (%) b                  | 921                          | 915                  |
| Number of events (%)                          | 89 (9.7)                     | 152 (16.6)           |
| Estimate of HR (95% CI) d.f                   | 0.575 (0.441, 0.745)         | 0.575 (0.441, 0.745) |

Includes patients that had both central and local hormone receptor status results. Central pathology review data were not available for China. See Table 14.1.8.3 for the concordance between central and local results.

- b Number of patients included in sensitivity analysis.
- Estimate of the treatment HR was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo arm. Stratification factors for prior platinum therapy and chemotherapy were the same as those used in the analysis of DDFS, stratification factor for hormone receptor status was according to the central pathology review.
- The 95% CI for the HR was estimated using the profile likelihood approach.
- An unstratified Cox model was fitted.
- 工 Estimate of the treatment HR was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo am. Cox model was unstratified.

Percentages are of the number of patients in the population subgroup in question.

See Table 14.2.10 for the main analysis of DDFS.

bd = twice daily; CI = confidence interval; DDFS = distant disease ffree survival; FAS = full analysis set; HR = hazard ratio.

Source: Table 14.2.12.2.

<div style=\"page-break-after: always\"></div>

## Subgroup analyses

Subgroup Analyses of IDFS (DCO1: 27 March 2020)

<!-- image -->

Hazard Ratio (Olaparib/Placebo)

HR+ was defined as ER positive and/or PgR positive.

2 TwopatientswereexcludedfromthesummaryoftheTNBCsubsetbecausetheydidnothaveconfirmednegativeHER2status.

Breast conservation was defined aspartial mastectomy/breast quadrantectomy/breast segmentectomy/breast lumpectomy and breast re-excision of margins.

4 Unilateral mastectomy was defined as modified radical mastectomy, radical mastectomy (Halsted), or simple mastectomy.

5 Triple negative breast cancer, adjuvant patients only, with sentinel node sampling of axillary node dissection.

6 Post-neoadjuvant group only.

Not Ashkenazi Jewish means that the patient was either Jewish but not Ashkenazi Jewish, not Jewish, or descent recorded as unknown.

Note: Ten olaparib-treated patients and 8 placebo-treated patients in the missing race category (see Table 14.1.4.1) were analysed in race subgroup \"other\".

Figure 10 : Forest Plot of IDFS Subgroup Analyses (FAS) (DCO1: 27 March 2020)

<div style=\"page-break-after: always\"></div>

Table 27: OlympiA: Summary of IDFS by Hormone Receptor Status (DCO1: 27 March 2020)

<!-- image -->

|                                                                                                 | DFS                                                                                             | DFS                                                                                             | DFS                                                                                             |
|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Population                                                                                      | Number of Events/Number of Patients (%)                                                         | Number of Events/Number of Patients (%)                                                         | IDFS Hazard Ratio                                                                               |
|                                                                                                 | Olaparib 300 mg bd                                                                              | Placebo                                                                                         | (95% CI)                                                                                        |
| FAS (local ER/PgR/HER2 status)                                                                  |                                                                                                 |                                                                                                 |                                                                                                 |
| TNBC (N=1509)                                                                                   | 87/751 (11.6)                                                                                   | 153/758 (20.2)                                                                                  | 0.563 (0.431, 0.730)                                                                            |
| ER amd/or PgR positive, HER2 negative (N=325)                                                   | 19/168 (11.3)                                                                                   | 25/157 (15.9)                                                                                   | 0.701 (0.381, 1.268)                                                                            |
| Hormone Receptor Status by Central Pathology Review b                                           | Hormone Receptor Status by Central Pathology Review b                                           | Hormone Receptor Status by Central Pathology Review b                                           | Hormone Receptor Status by Central Pathology Review b                                           |
| TNBC (N=1106)                                                                                   | 70/563 (12.4)                                                                                   | 117/543 (21.5)                                                                                  | 0.548 (0.406, 0.735)                                                                            |
| ER and/or PgR positive, HER2 negative (N=346)                                                   | 16/169 (9.5)                                                                                    | 34/177 (19.2)                                                                                   | 0.486 (0.261, 0.864)                                                                            |
| ER expression level by Central Pathology Review  (Central Hormone Receptor Positive Population) | ER expression level by Central Pathology Review  (Central Hormone Receptor Positive Population) | ER expression level by Central Pathology Review  (Central Hormone Receptor Positive Population) | ER expression level by Central Pathology Review  (Central Hormone Receptor Positive Population) |
| ER negative: ER = 1% (N=41)                                                                     | 3/20 (15.0)                                                                                     | 4/21 (19.0)                                                                                     | NC                                                                                              |
| ER low: ER  1% and ≤ 10% (N=50)                                                                 | 4/17 (23.5)                                                                                     | 13/33 (39.4)                                                                                    | NC                                                                                              |
| ER strongly positive: ER ≥ 10% (N=255)                                                          | 9/132 (6.8)                                                                                     | 17/123 (13.8)                                                                                   | 0.463 (0.197, 1.016)                                                                            |

Exploratory, not inferential.

Excludes patients recruited in China.

Two patients are excluded from the summary of the TNBC subset because they do not have confimed hormone receptor negative status.

bd = twice daily; CI= confidence interval; ER =oestrogenreceptor; FAS =Full Analysis Set; HER2 =human epidermal growth factor receptor 2; IDFS = invasive disease free suuvival; NC = Not calculated;

PgR = progesterone receptor; TNBC = triple negative breast cancer.

Source: Table 14.2.13.1, OlympiA CSR, Module 5.3.5.1; IEMT 2848.2.1, Efficacy Outputs, Module 5.3.5.3.

Hazard Ratios are not presented for any subgroup levels with less than 5 events in either treatment anm.

IEMT 3079.1; (DC01: 27 March 2020).

<div style=\"page-break-after: always\"></div>

## Subgroup Analyses of IDFS (DCO2: 12 July 2021)

<!-- image -->

- [1] HR+ is defined as ER positive and/or PgR positive.

[3]Breast conservation defined as partial mastectomy/ breast quadrantectomy/ breast segmentectomy/ breast lumpectomy and breast re-excision of margins.

- [2] Two patients are excluded from the summary of the TNBC subset because they do not have confirmed negative HER2 status.
- [4] Unilateral mastectomy defined as modified radical mastectomy, radical mastectomy (Halsted) or simple mastectomy.

[6] Post neoadjuvant group only.

[5] TNBC, adjuvant patients only,

,with sentinel node sampling or axillary node dissection.

- [7] Not Ashkenazi Jewish can mean that the patient is either Jewish but not Ashkenazi Jewish, not Jewish or descent recorded as unknown.

<!-- image -->

[1] HR+ is defined as ER positive and/or PgR positive.

- [3]Breast conservation defined as partial mastectomy/ breast quadrantectomy/ breast segmentectomy/breastlumpectomy and breast re-excision of margins.
- [2] Two patients are excluded from the summary of the TNBC subset because they do not have confirmed negative HER2 status.
- [4] Unilateral mastectomy defined as modified radical mastectomy, radical mastectomy (Halsted) or simple mastectomy.

[6] Post neoadjuvant group only.

- [5]] TNBc, adjuvant patients only, with sentinel node sampling or axillary node dissection.
- [7] Not Ashkenazi Jewish can mean that the patient is either Jewish but not Ashkenazi Jewish,not Jewish or descent recorded as unknown.

Figure 11 : Forest Plot of IDFS (FAS) (DCO2: 12 July 2021)

<div style=\"page-break-after: always\"></div>

## Subgroup Analyses of DDFS (DCO1: 27 March 2020)

<!-- image -->

| Subgroup                                                             | N                                | Events                           | HR (95& CI)                      |
|----------------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                                                      | 0laparib/PlaceboOlaparib/Placebo | 0laparib/PlaceboOlaparib/Placebo | 0laparib/PlaceboOlaparib/Placebo |
| saaa                                                                 |                                  |                                  |                                  |
| Overa11                                                              | 921/915                          | 89/152                           | 0.574 (CI 0.441 - 0.744)         |
| Prior Chumo                                                          |                                  |                                  |                                  |
| Adjuvant                                                             | 461/455                          | 28/47                            | 0.603 (CI 0.373 -0.956)          |
| Neoadjuvant                                                          | 460/460                          | 61/105                           | 0.551 (CI 0.400 - 0.753)         |
| Prior Platinum.                                                      |                                  |                                  |                                  |
| Yes                                                                  | 247/239                          | 31/39                            | 0.783 (CI 0.485 - 1.252)         |
| No                                                                   | 674/676                          | 58/113                           | 0.504 (CI 0.365 -0.688)          |
| HR status                                                            |                                  |                                  |                                  |
| HR+/HER2- [1]                                                        | 168/157                          | 17/23                            | 0.686 (CI 0.361 1.279)           |
| TNBC[2]                                                              | 751/158                          | 72/129                           | 0.556 (CI 0.415 - 0.740)         |
| BRCA mutation type                                                   |                                  |                                  |                                  |
| BRCA1                                                                | 558/558                          | 59/103                           | 0.548 (CI 0.396 -0.752)          |
| BRCA2                                                                | 230/209                          | 10/34                            | 0.444 (CI 0.247 - 0.770)         |
| BRCA1/2 both                                                         | 1/3                              | 0/0                              |                                  |
| BRCA status by prior platinum therapy setting                        |                                  |                                  |                                  |
| DRCA1 with prior platinum therapy for current breast cancer          | 174/179                          | 24/32                            | 0.758 (CI 0.442 -1.282)          |
| BRCA1 with no priox platinum therapy for current breast cancer       | 384/379                          | 35/71                            | 0.461 (CI 0.305 -0.686)          |
| BRCA2 with prior platinum therapy for current breast cancer          | 53/40                            | 4/7                              |                                  |
| DnCa2 with no priox platLnum thevapy for ouvrent breaat oanoer       | 177/169                          | 14/29                            | D,440 (CT 0.226 ∩. R1A)          |
| BRCAl/2both with prior platinum therapy for current breast cancer    | /1                               | 0/0                              |                                  |
| BRCAl/2both with no prior platinum therapy for current breast cancer | 1/2                              | 0/0                              |                                  |
| HR etatue by prior ohomothorapy cotting                              |                                  |                                  |                                  |
| HR+/HER2- with neoadjuvant chemotherapy [1]                          | 104/92                           | 12/19                            | 0.522 (CI 0.246 1.063)           |
| HR+/HER2- with adjuvant chemotherapy [1]                             | 64/65                            | 5/4                              |                                  |
| TNBC with neoadjuvant chemotherapy [2]                               | 354/368                          | 49/86                            | 0.565 (CI 0.355 0.755)           |
| TNBC with adjuvant chemotherapy [2]                                  | 397/390                          | 23/43                            | 0.535 (CI 0.310 - 0.879)         |
| IdexouaououoqueanCpe/zueanCproou xorxdzoeds                          |                                  |                                  |                                  |
| Pclor anthzacyclle alone                                             | 7/13                             | 0/2                              |                                  |
| Prlor taxane alone                                                   | 43/52                            | 2/7                              |                                  |
| Prloz anthracycline and Laxane                                       | 871/849                          | 87/143                           | 0.589 (CI 0.450 - 0.767)         |
| Type of breaot ourgery prior to randomioation                        |                                  |                                  |                                  |
| Breast conservation [3]                                              | 223/240                          | 13/37                            | 0.374 (CI 0.191 -0.685)          |
| Unilateral mastectomy [4]                                            | 366/356                          | 43/59                            | 0.712 (CI 0.478 -1.052)          |
| Bilateral mastectomy                                                 | 332/317                          | 33/55                            | 0.556 (CI 0.357 -0.850)          |

Hazard Ratio(Olaparib/Placebo)

<!-- image -->

| Subgroup                                                        | N                                | Events                           | HR (95& CI)                      |                                  |
|-----------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
|                                                                 | 0laparib/PlaceboOlaparib/Placebo | 0laparib/PlaceboOlaparib/Placebo | 0laparib/PlaceboOlaparib/Placebo | 0laparib/PlaceboOlaparib/Placebo |
| Overa11                                                         | 921/915                          | 89/152                           | 0.574 (CI 0.441 - 0.744)         |                                  |
| Have both ovaries been removed prior to first dose of treatment |                                  |                                  |                                  |                                  |
| No bilateral oophorectomy                                       | 732/739                          | 77/119                           | 0.642 (CI 0.480 -0.853)          |                                  |
| Bilateral oophorectomy                                          | 189/176                          | 12/33                            | 0.343 (CI 0.170 - 0.645)         |                                  |
| Axillary nodal status at surgory prior to randomisation [2][5]  |                                  |                                  |                                  |                                  |
|                                                                 | 203/192                          | 7/16                             | 0.443 (CI 0.170 -1.039)          |                                  |
| Node positive                                                   | 174/177                          | 14/24                            | 0.582 (CI 0.294 - 1.111)         |                                  |
| CPS+EG score at baseline [6]                                    |                                  |                                  |                                  |                                  |
| CPS+EG score of 2,3 or 4                                        | 398/387                          | 48/87                            | 0.502 (CI 0.351 - 0.711)         |                                  |
| CPS+EG score of 5 or 6                                          | 22/15                            | 10/10                            | 0.417 (CI 0.171 - 1.019)         |                                  |
| Age at randomisation                                            |                                  |                                  |                                  |                                  |
| Age<50years                                                     | 699/673                          | 66/113                           | 0.553 (CI 0.406 -0.746)          |                                  |
| Age50-64years                                                   | 193/210                          | 19/34                            | 0.564(CI 0.317-0.970)            |                                  |
| Age >=65 years                                                  | 29/32                            | 4/3                              |                                  |                                  |
| Race                                                            |                                  |                                  |                                  |                                  |
| White                                                           | 626/599                          | 65/105                           | 0.575 (CI 0.420 - 0.780)         |                                  |
| Black/African-American                                          | 19/29                            | 4/4                              |                                  |                                  |
| Asian                                                           | 259/272                          | 19/40                            | 0.512 (CI 0.290 - 0.871)         |                                  |
| other                                                           | 17/15                            | 1/3                              |                                  |                                  |
| Ethnicity                                                       |                                  |                                  |                                  |                                  |
| Hispanic or Latino                                              | 34/24                            | 5/6                              | 0.538(CT0.155 -1.787)            |                                  |
| Not Hispanic or Latino                                          | 805/812                          | 74/132                           | 0.565 (CI0.423 0.749)            |                                  |
| Not known, not recorded or refused                              | 82/79                            | 10/14                            | 0.604 (CI 0.260 1.351)           |                                  |
| Jewish descant                                                  |                                  |                                  |                                  |                                  |
| Yes, of Ashkenazi descent                                       | 41/36                            | 5/9                              | 0.406 (CI 0.125 1.177)           |                                  |
| No, not of Ashkenazi descent [7]                                | 948/088                          | 84/143                           | 0.502 (CI 0.443 -0.760)          |                                  |
| Sponsor                                                         |                                  |                                  |                                  |                                  |
| AstraZeneca (A7.)                                               | 810/806                          | 78/135                           | 0.571 (CI 0.430-0.752)           |                                  |
| NRG                                                             | 111/109                          | 11/17                            | 0.605 (CI 0.275 -1.278)          |                                  |
| Geographic region                                               |                                  |                                  |                                  |                                  |
| North America                                                   | 122/132                          | 11/22                            | 0.510 (CI 0.238 - 1.030)         |                                  |
| South America                                                   | 16/12                            | 2/4                              |                                  |                                  |
| Europe                                                          | 481/452                          | 53/77                            | 0.635 (CI 0.446 -0.899)          |                                  |
| Asia Pacific and South Africa                                   | 302/319                          | 23/49                            | 0.502 (CI 0.300 -0.814)          |                                  |

HR+was defined asERpositive and/orPgRpositive.

- 2 TwopatientswereexcludedfromthesummaryoftheTNBCsubsetbecausetheydidnothaveconfirmednegativeHER2status.
- 3
- 4 Unilateral mastectomywas defined as modifiedradical mastectomy,radical mastectomy(Halsted),or simple mastectomy.
- Triple negative breast cancer, adjuvant patients only, with sentinel node sampling or axillary node dissection.
- 6 Post-neoadjuvant group only.

NotAshkenaziJewish means that thepatientwas eitherJewishbut notAshkenaziJewish,not Jewish, or descentrecorded as unknown.

BRCA =breast cancer susceptibility gene; CI = confidence interval; CPS+EG = clinical stage (CS), oestrogen receptor status (E), nuclear grade (G), and post-treatment pathologic stage (PS) - a disease scoring system; DDFS = distant disease free survival; ER = oestrogen receptor; FAS = full analysis set; HER2=human epidermal growth factorreceptor 2;HR=hazard ratio;HR+=hormone receptor positive;HR status =hormone receptor status; PgR = progesterone receptor; TNBC = triple negative breast cancer.

Source:Figure14.2.22.2.1.

Figure 12 : Forest Plot of DDFS (FAS) (DCO1: 27 March 2020)

Hazard Ratio (0laparib/Placebo)

<div style=\"page-break-after: always\"></div>

## Subgroup Analyses of OS (DCO1: 27 March 2020)

<!-- image -->

Hazard Ratio (olaparib/Placebo)

<!-- image -->

| Subgroup                                                                    | N                                | Events.                          |                                  | HR（95&CI)                                         |
|-----------------------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|---------------------------------------------------|
|                                                                             | 0laparib/PlaceboOlaparib/Placebo | 0laparib/PlaceboOlaparib/Placebo | 0laparib/PlaceboOlaparib/Placebo |                                                   |
| OS Overa11                                                                  | 921/915                          | 59/86                            |                                  | 0.603 (CI 0.400 - 0.950)                          |
| Have both ovaries been renoved pzior ta first dose of treatment             |                                  |                                  |                                  |                                                   |
| No bilatoral oophorootomy                                                   | 732/139                          | 49/7C                            |                                  | 0.692 (CI 0.478 - 0.995)                          |
| Bilateral oophorectomy                                                      | 184/176                          | 10/16                            |                                  | 0.619 (CI 0.271 - 1.344)                          |
|                                                                             | 203/192                          | 5/4                              |                                  |                                                   |
| Axillary nodal status at surgery prior to randomisation [2][5]              |                                  |                                  |                                  |                                                   |
| Node negative                                                               | 174/177                          | /14                              |                                  | 0.559 (CI 0.223 - 1.306)                          |
| Node positive CPS+EG score at baseline [6]                                  |                                  |                                  |                                  |                                                   |
| CPS+EG score of 2, 3 or 4                                                   | 398/387                          | 33/54                            |                                  | 0.564 (CI 0.362 - 0.864)                          |
| CPS+EG score of 5 or 6 Ago at randomieation                                 | 22/15                            | 7/7                              |                                  | 0.513 (CI 0.175 - 1.502)                          |
| Age < 50 yeare                                                              | 699/673                          | 43/65 13/21                      |                                  | 0.636 (CI 0.430 0.531)                            |
| Age 50 - 64 years                                                           | 193/210 29/32                    |                                  |                                  | 0.651 (CI 0.310 - 1.24)                           |
|                                                                             |                                  | 3/0                              |                                  |                                                   |
| Age >=65 years Race                                                         |                                  |                                  |                                  |                                                   |
| White                                                                       | 626/599                          | 44/66 3/4                        |                                  |                                                   |
| Dlack/Afzican-Amezlcan Asian Other                                          | 19/29 259/272                    | 12/14 0/2                        |                                  | 0.616 (CI 0.418 - 0.898) 0.950 (CI 0.432 - 2.059) |
| Ethnicity                                                                   | 17/15                            |                                  |                                  |                                                   |
|                                                                             |                                  | 4/5                              |                                  |                                                   |
| Hispanic or Latino Not Hispanic or Latino Not known,not recorded or refused | 34/24 805/812 82/79              | 48/7C 7/11                       |                                  | 0.700 (CI 0.482 - 1.007) 0.515 (CI 0.189 - 1.308) |
| Yes, of Ashkenazi descent No, not of Ashkenazi descent [7]                  | 41/36                            | 4/5 55/81                        |                                  |                                                   |
| Jewish descent.                                                             |                                  |                                  |                                  |                                                   |
|                                                                             | 880/876                          |                                  |                                  | D.678 (CI 0.479 - 0.953)                          |
| Sponsor AstraZeneca (AZ) NR                                                 | 10/606                           | 50/76 9/10                       |                                  | 0.653 (CI 0.455 - 0.931) 0.862 (CI 0.342 - 2.139) |
|                                                                             | 111/109                          |                                  |                                  |                                                   |
| Geographic region                                                           |                                  |                                  |                                  |                                                   |
| North America                                                               | 122/132                          | 9/12                             |                                  | 0.774 (CI 0.316 - 1.828)                          |
|                                                                             | 16/12                            | 1/ 4                             |                                  | 0.650 (CI 0.419 - 1.000)                          |
| South America                                                               | 481/452                          |                                  | <--Favors                        |                                                   |
| Europe                                                                      |                                  | 35/49                            |                                  |                                                   |
| Asia Pacific and South Africa                                               | 302/319                          | 1.4/21                           |                                  | 0.737 (CI 0.366 - 1.456)                          |
|                                                                             |                                  |                                  | 0laparib                         |                                                   |
|                                                                             |                                  |                                  | 0.5 1. 0 1.5                     |                                                   |

Hazard Ratio

(olaparib/Placebo)

Figure 13 : Forest Plot of OS Subgroup Analyses (DCO1: March 2020)

<div style=\"page-break-after: always\"></div>

## Subgroup Analyses of OS (DCO2: 12 July 2021)

<!-- image -->

- [2] Two patients are excluded from the summary of the TNBC subset because they do not have confirmed negative HER2 status.

[4] Unilateral mastectomy defined as modified radical mastectomy, radical mastectomy (Halsted) or simple mastectomy.

[9] Post neoadjuvant group only.

- [5] TNBC, adjuvant patients only, with sentinel node sampling or axillary node dissection.
- [7] Not Ashkenazi Jewish can mean that the patient is either Jewish but not Ashkenazi Jewish, not Jewish or descent recorded as unknown.

<!-- image -->

| Subgroup                                                        | N                                | Events                           |                                  | HR (95CI)                |
|-----------------------------------------------------------------|----------------------------------|----------------------------------|----------------------------------|--------------------------|
|                                                                 | 0laparib/Placebo0laparib/Placebo | 0laparib/Placebo0laparib/Placebo | 0laparib/Placebo0laparib/Placebo |                          |
| Overal1                                                         | 921/915                          | 75/109                           |                                  | 0.678 (CI 0.503 - 0.907) |
| ·ave both ovaries been renoved prior to firat dose of treatnent |                                  |                                  |                                  |                          |
| No bflateral oophorectony                                       | 732/739                          | 62/89                            |                                  | 0.694 (CI 0.500 -0.957)  |
| Bilateral oophorectony                                          | 189/176                          | 13/20                            |                                  | 0.619 (CI 0.300 -1.231)  |
| ·Axillary nodal status at surgery prior to randomisation [2][5] |                                  |                                  |                                  |                          |
| Node negative                                                   | 203/192                          | 6/7                              |                                  | 0.887 (CI 0.285 -2.670)  |
| Node positive                                                   | 174/177                          | 10/16                            |                                  | 0.603 (CI 0.264 1.311)   |
| ·CPS+Eo score at baseline [6]                                   |                                  |                                  |                                  |                          |
| CPS+8G score of 2, 3 or 4                                       | 398/387                          | 39/68                            |                                  | 0.539 (CI 0.361 - 0.795) |
| CPS+EG score of 5 or 6                                          | 22/15                            | 10/10                            |                                  | 0.474 (CI 0.194 - 1.158) |
| Age at randomisation                                            |                                  |                                  |                                  |                          |
| Age c 50 years                                                  | 699/673                          | 54/84                            |                                  | 0.614 (CI 0.434 0.861)   |
| Age 50- 64 yaars                                                | 193/210                          | 18/24                            |                                  | 0.803 (CI 0.430 -1.473)  |
| Age >=65 years                                                  | 29/32                            | 3/1                              |                                  |                          |
| R4Ce                                                            |                                  |                                  |                                  |                          |
| White                                                           | 626/599                          | 56/79                            |                                  | 0.659 (CI 0.466 - 0.926) |
| Black/African=American                                          | 19/29                            | 3/4                              |                                  |                          |
| Aaian                                                           | 259/272                          | 14/23                            |                                  | 0.661 (CI 0.332 - 1.269) |
| other                                                           | 17/15                            | 2/3                              |                                  |                          |
| gthnioity                                                       |                                  |                                  |                                  |                          |
| Hispanie or Latino                                              | 34/24                            | 5/6                              |                                  | 0.540 (CI 0.156 1.794)   |
| Not Hispanic or Latino                                          | 805/812                          | 59/91                            |                                  | 0.655 (CI 0.470 -0.907)  |
| Not known, not recorded or refused                              | 82/79                            | 11/12                            |                                  | 0.795 (C1 0.345 - 1.814) |
| · Jewish descent                                                |                                  |                                  |                                  |                          |
| Yes, of Ashkenazl descent                                       | 41/36                            | 5/6                              |                                  | 0.593 (CI 0.171 1.969)   |
| No, not of Ashkenazi descent [7]                                | 880/876                          | 70/103                           |                                  | 0.678 (CI 0.499 0.917)   |
| Sponsor                                                         |                                  |                                  |                                  |                          |
| Astrazeneca (Az)                                                | 810/806                          | 65/98                            |                                  | 0.659 (CI 0.480 - 0.900) |
| NRG                                                             | 111/109                          | 10/11                            |                                  | 0.848 (CI 0.353 - 2.010) |
| Gecgraphic reqion                                               |                                  |                                  |                                  |                          |
| North Anerica                                                   | 122/132                          | 10/14                            |                                  | 0.728 (CI 0.314 - 1.626) |
| South Anerica                                                   | 16/12                            | 2/5                              |                                  |                          |
| Rurope                                                          | 481/452                          | 46/60                            |                                  | 0.713 (CI 0.483 - 1.044) |
| Asia Pacific and South Africa                                   | 302/319                          | 17/30                            |                                  | 0.608 (C1 0.328 -1.089)  |
|                                                                 |                                  |                                  | Favors                           |                          |
|                                                                 |                                  |                                  | 0laparib                         |                          |
|                                                                 |                                  |                                  | 0.5 1.0 5 5                      |                          |
|                                                                 |                                  |                                  | Hazard Ratio (0laparib/Placebo)  |                          |

[2] Two patients are excluded from the summary of the TNBC subset because they do not have confirmed negative HER2 status.

[1] HR+ is defined as ER positive and/or PgR positive.

[3]Breast conservation defined as partial mastectomy / breast quadrantectomy / breast segmentectomy / breastlumpectomy and breast re-excision of margins.

[5]

[4] Unilateral mastectomy defined as modified radical mastectomy, radical mastectomy (Halsted) or simple mastectomy.

[6] Post neoadjuvant group only.

TNBC, adjuvant patients only,

,with sentinel node sampling or axillary node dissection.

- [7] Not Ashkenazi Jewish can mean that the patient is either Jewish but not Ashkenazi Jewish, not Jewish or descent recorded as unknown.

Figure 12: Forest Plot of OS Subgroup Analyses (DCO2: 12 July 2021)

<div style=\"page-break-after: always\"></div>

## Descriptive analyses of IDFS (DCO2: 12 July 2021)

Updated descriptive analyses of IDFS based on more mature data (with median follow-up of 3.5 years) conducted at the time of the pre-planned second OS interim analysis (DCO2: 12 July 2021) were provided. These were undertaken in the overall ITT population including the subgroup analysis of patients with ER and/or PgR positive, HER2-negative status who had received adjuvant chemotherapy.

Table 28: OlympiA: Summary of IFDS by hormone receptor status (per local status) and prior chemotherapy

<!-- image -->

|                                                                       | DFS                                                          | DFS                                                          | DFS                                                          |
|-----------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                                                                       | Number of Events/Number of Patients (%)                      | Number of Events/Number of Patients (%)                      | IDFS Hazard Ratio                                            |
| Population                                                            | Olaparib 300 mg bd                                           | Placebo                                                      | (95% CI)                                                     |
| Primary Amalysis IDFS Subgroup analysis (DCO1 27 March 2020)          | Primary Amalysis IDFS Subgroup analysis (DCO1 27 March 2020) | Primary Amalysis IDFS Subgroup analysis (DCO1 27 March 2020) | Primary Amalysis IDFS Subgroup analysis (DCO1 27 March 2020) |
| Overall population                                                    | 106/921 (11.5)                                               | 178/915 (19.5)                                               | 0.581 (0.455, 0.737)                                         |
| TNBC                                                                  | 87/751 (11.6)                                                | 153/758 (20.2)                                               | 0.563 (0.431, 0.730)                                         |
| TNBC prior neoadjuvant chemotherapy                                   | 57/354 (16.1)                                                | 97/368 (26.4)                                                | 0.571 (0.410,0.789)                                          |
| TNBC prior adjuvant chemotherapy                                      | 30/397 (7.6)                                                 | 56/390 (14.4)                                                | 0.537 (0.341,0.830)                                          |
| ER and/or PgR positive, HER2 negative                                 | 19/168 (11.3)                                                | 25/157 (15.9)                                                | 0.701 (0.381, 1.268)                                         |
| ER and/or PgR positive, HER2 negative, prior neoadjuvant chemotherapy | 13/104 (12.5)                                                | 20/92 (21.7)                                                 | 0.521 (0.253, 1.036)                                         |
| ER and/or PgR positive, HER2 negative, prior adjuvant chemotherapy    | 6/64 (9.4)                                                   | 5/65 (7.7)                                                   | 1.357 (0.409,4.710)                                          |
| Updated IDFS subgroup analysis (DC02 12 July 2021)                    | Updated IDFS subgroup analysis (DC02 12 July 2021)           | Updated IDFS subgroup analysis (DC02 12 July 2021)           | Updated IDFS subgroup analysis (DC02 12 July 2021)           |
| Overall population                                                    | 134/921 (14.5)                                               | 207/915 (22.6)                                               | 0.628 (0.504 - 0.779)                                        |
| TNBC                                                                  | 109/751 (14.5)                                               | 173/758 (22.8)                                               | 0.620 (0.487 - 0.787)                                        |
| TNBC prior neoadjuvant chemotherapy                                   | 69/354 (19.5)                                                | 107/368 (29.1)                                               | 0.628 (0.462 - 0.848)                                        |
| TNBC prior adjuvant chemotherapy                                      | 40/397 (10.1)                                                | 66/390 (16.9)                                                | 0.602 (0.403 -0.887)                                         |
| ER and/or PgR positive, HER2 negative                                 | 25/168 (14.9)                                                | 34/157 (21.7)                                                | 0.680 (0.402 - 1.134)                                        |
| ER amd/or PgR positive, HER2 negative, prior neoadjuvant chemotherapy | 19/104 (18.3)                                                | 25/92 (21.7)                                                 | 0.621 (0.338 -1.124)                                         |
| ER and/or PgR positive, HER2 negative, prior adjuvant chemotherapy    | 6/64 (9.4)                                                   | 9/65 (13.8)                                                  | 0.736 (0.247 -2.042)                                         |

Two patients are excluded from the summary of the TNBC subset because they do not have confinmed hormone receptor negative status.

bd = twice daily; CI = confidence interval; ER = oestrogen receptor; FAS = Full Analysis Set; HER2 = human epidermal growth factor receptor 2; PgR = progesterone receptor; TNBC = tiple negative breast cancer. Source: Table 14.2.13.1, OlympiA CSR (D001: 27 March 2020); Figure 14.2.22.1.1 in Appendix B

(DC02: 12 July 2021).

<div style=\"page-break-after: always\"></div>

## Myriad gBRCAm Patients

## Table 29: Supportive Analyses of IDFS, DDFS, and OS in Confirmed Myriad gBRCAm Patients (FAS) (DCO2: 12 July 2021)

|                                                            | Olaparib 300 mg bd (N=816)                                 | Placebo (N=807)   |
|------------------------------------------------------------|------------------------------------------------------------|-------------------|
| IDFS                                                       |                                                            |                   |
| Number of events (%)                                       | 117 (14.3)                                                 | 193 (23.9)        |
| Estimate of HR a                                           | 0.571                                                      | 0.571             |
| 95% CI for HR b                                            | 0.453, 0.717                                               | 0.453, 0.717      |
| Median clinical follow-up time, years c                    | 3.5                                                        | 3.5               |
| Minimum/Maximum                                            | 0/6.7                                                      | 0/6.6             |
| Percentage (95% CI) of patients invasive disease free at d | Percentage (95% CI) of patients invasive disease free at d |                   |
| 1 year                                                     | 93.4 (91.4, 95.0)                                          | 87.9 (85.3, 90.0) |
| 2 years                                                    | 89.8 (87.4, 91.7)                                          | 80.2 (77.2, 82.8) |
| 3 years                                                    | 86.3 (83.5, 88.7)                                          | 75.7 (72.4, 78.6) |
| 4 years                                                    | 82.9 (79.6, 85.7)                                          | 74.0 (70.6, 77.2) |
| DDFS                                                       |                                                            |                   |
| Number of events (%)                                       | 94 (11.5)                                                  | 159 (19.7)        |
| Estimate of HR a                                           | 0.561                                                      | 0.561             |
| 95% CI for HR b                                            | 0.433,0.722                                                | 0.433,0.722       |
| Median clinical follow-up time, years c                    | 3.5                                                        | 3.5               |
| Minimum/Maximum                                            | 0/6.7                                                      | 0/6.6             |
| Percentage (95% CI) of patients distant disease free at d  | Percentage (95% CI) of patients distant disease free at d  |                   |
| 1 year                                                     | 94.4 (92.6, 95.9)                                          | 89.8 (87.4, 91.7) |
| 2 years                                                    | 90.8 (88.5, 92.7)                                          | 83.0 (80.1, 85.5) |
| 3 years                                                    | 88.5 (85.9, 90.6)                                          | 79.7 (76.6, 82.5) |
| 4 years                                                    | 86.8 (83.9, 89.2)                                          | 78.0 (74.7, 81.0) |

<div style=\"page-break-after: always\"></div>

|                                            | Olaparib 300 mg bd (N=816)   | Placebo (N=807)   |
|--------------------------------------------|------------------------------|-------------------|
| OS                                         |                              |                   |
| Number of events (%)                       | 65 (8.0)                     | 103 (12.8)        |
| Estimate of HR a                           | 0.607                        | 0.607             |
| 95% CI for HR b                            | 0.443,0.826                  | 0.443,0.826       |
| Median clinical follow-up time, years c    | 3.5                          | 3.5               |
| Minimum/Maximum                            | 0/6.8                        | 0/6.7             |
| Percentage (95% CI) of patients alive at d |                              |                   |
| 1 year                                     | 98.0 (96.8, 98.8)            | 96.8 (95.3, 97.8) |
| 2 years                                    | 94.9 (93.0, 96.2)            | 92.2 (90.1, 93.9) |
| 3 years                                    | 92.9 (90.8, 94.5)            | 87.9 (85.3, 90.1) |
| 4 years                                    | 90.2 (87.5, 92.4)            | 85.2 (82.1, 87.7) |

- Estimate of the treatment HR was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo arm. Stratification factors were the same as those used in the analysis ofIDFS, DDFS,or OSin the FAS.
- b The 95% CI for the HR was estimated using the profile likelihood approach.
- C Median clinical follow-up was calculated using the reverse censoring method.
- d Percentage of patients were from the KM estimates and the 95% CIs were calculated using Greenwood's formula.

Excludes patients with only a local or Beijing Genomics Institute result. Myriad data was not available for China. Percentages are of the number of patients in the population subgroup in question.

bd = twice daily; CI = confidence interval; DDFS = distant disease free survival; FAS = fuill analysis set; gBRCAm = germline BRCA mutated; HR = hazard ratio; IDFS = invasive disease free survival; KM = Kaplan-Meier; N = total number of patients; OS = overall survival.

Source: Table 14.2.6.1, Table 14.2.9.1, and Table 14.2.12.1.

<div style=\"page-break-after: always\"></div>

## Summary of main study

The following table summarise the efficacy results from the main study OlympiA supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table 30: Summary of Key Efficacy Outcome Variables (FAS)

| Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OlympiA).   | Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OlympiA).   | Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OlympiA).   | Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OlympiA).   | Title: A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OlympiA).   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                                        | D081CC00006                                                                                                                                                                                                                                                                                                                                                                             | D081CC00006                                                                                                                                                                                                                                                                                                                                                                             | D081CC00006                                                                                                                                                                                                                                                                                                                                                                             | D081CC00006                                                                                                                                                                                                                                                                                                                                                                             |
| Design                                                                                                                                                                                                                                                                                                                                                                                  | Randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study                                                                                                                                                                                                                                                                                               | Randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study                                                                                                                                                                                                                                                                                               | Randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study                                                                                                                                                                                                                                                                                               | Randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study                                                                                                                                                                                                                                                                                               |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                              | Superiority (interim analysis)                                                                                                                                                                                                                                                                                                                                                          | Superiority (interim analysis)                                                                                                                                                                                                                                                                                                                                                          | Superiority (interim analysis)                                                                                                                                                                                                                                                                                                                                                          | Superiority (interim analysis)                                                                                                                                                                                                                                                                                                                                                          |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                       | Olaparib                                                                                                                                                                                                                                                                                                                                                                                | Olaparib                                                                                                                                                                                                                                                                                                                                                                                | 300 mg (2 x 150 mg tablets) orally bd continuous N=921 (FAS)                                                                                                                                                                                                                                                                                                                            | 300 mg (2 x 150 mg tablets) orally bd continuous N=921 (FAS)                                                                                                                                                                                                                                                                                                                            |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                                       | Placebo                                                                                                                                                                                                                                                                                                                                                                                 | Placebo                                                                                                                                                                                                                                                                                                                                                                                 | Matching placebo N=915 (FAS)                                                                                                                                                                                                                                                                                                                                                            | Matching placebo N=915 (FAS)                                                                                                                                                                                                                                                                                                                                                            |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                               | Primary endpoint                                                                                                                                                                                                                                                                                                                                                                        | IDFS (Invasive Disease Free Survival)                                                                                                                                                                                                                                                                                                                                                   | IDFS (Invasive Disease Free Survival)                                                                                                                                                                                                                                                                                                                                                   | Time from randomisation to invasive disease recurrence or death due to any cause                                                                                                                                                                                                                                                                                                        |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                      | DDFS (Distant Disease Free Survival)                                                                                                                                                                                                                                                                                                                                                    | DDFS (Distant Disease Free Survival)                                                                                                                                                                                                                                                                                                                                                    | Time from randomisation to distant recurrence or death due to any cause                                                                                                                                                                                                                                                                                                                 |
| Endpoints and definitions                                                                                                                                                                                                                                                                                                                                                               | Secondary endpoint                                                                                                                                                                                                                                                                                                                                                                      | OS (Overall Survival)                                                                                                                                                                                                                                                                                                                                                                   | OS (Overall Survival)                                                                                                                                                                                                                                                                                                                                                                   | Time from randomisation to death due to any cause                                                                                                                                                                                                                                                                                                                                       |
| Results and Analysis                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                         | FAS                                                                                                                                                                                                                                                                                                                                                                                     | FAS                                                                                                                                                                                                                                                                                                                                                                                     | FAS                                                                                                                                                                                                                                                                                                                                                                                     | FAS                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                         | Olaparib                                                                                                                                                                                                                                                                                                                                                                                | Olaparib                                                                                                                                                                                                                                                                                                                                                                                | Placebo (N=915)                                                                                                                                                                                                                                                                                                                                                                         | Placebo (N=915)                                                                                                                                                                                                                                                                                                                                                                         |
| IDFS (15.5% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                     | IDFS (15.5% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                     | IDFS (15.5% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                     | IDFS (15.5% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                     | IDFS (15.5% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                     |
| Number of events/total number of patients (%)                                                                                                                                                                                                                                                                                                                                           | 106/921 (11.5)                                                                                                                                                                                                                                                                                                                                                                          | 106/921 (11.5)                                                                                                                                                                                                                                                                                                                                                                          | 178/915 (19.5)                                                                                                                                                                                                                                                                                                                                                                          | 178/915 (19.5)                                                                                                                                                                                                                                                                                                                                                                          |
| HR a (99.5% CI) b                                                                                                                                                                                                                                                                                                                                                                       | 0.581 (0.409, 0.816) c                                                                                                                                                                                                                                                                                                                                                                  | 0.581 (0.409, 0.816) c                                                                                                                                                                                                                                                                                                                                                                  | 0.581 (0.409, 0.816) c                                                                                                                                                                                                                                                                                                                                                                  | 0.581 (0.409, 0.816) c                                                                                                                                                                                                                                                                                                                                                                  |
| 95% CI b,d                                                                                                                                                                                                                                                                                                                                                                              | (0.455, 0.737)                                                                                                                                                                                                                                                                                                                                                                          | (0.455, 0.737)                                                                                                                                                                                                                                                                                                                                                                          | (0.455, 0.737)                                                                                                                                                                                                                                                                                                                                                                          | (0.455, 0.737)                                                                                                                                                                                                                                                                                                                                                                          |
| p-value (2-sided) e                                                                                                                                                                                                                                                                                                                                                                     | 0.0000073                                                                                                                                                                                                                                                                                                                                                                               | 0.0000073                                                                                                                                                                                                                                                                                                                                                                               | 0.0000073                                                                                                                                                                                                                                                                                                                                                                               | 0.0000073                                                                                                                                                                                                                                                                                                                                                                               |
| Patients invasive disease free at 36 months (%) f (95% CI)                                                                                                                                                                                                                                                                                                                              | 85.9 (82.8, 88.4)                                                                                                                                                                                                                                                                                                                                                                       | 85.9 (82.8, 88.4)                                                                                                                                                                                                                                                                                                                                                                       | 77.1 (73.7, 80.1)                                                                                                                                                                                                                                                                                                                                                                       | 77.1 (73.7, 80.1)                                                                                                                                                                                                                                                                                                                                                                       |
| DDFS (13% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                       | DDFS (13% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                       | DDFS (13% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                       | DDFS (13% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                       | DDFS (13% maturity in FAS) - DCO1 (25 March 2020)                                                                                                                                                                                                                                                                                                                                       |
| Number of events/total number of patients (%)                                                                                                                                                                                                                                                                                                                                           | 89/921 (9.7)                                                                                                                                                                                                                                                                                                                                                                            | 89/921 (9.7)                                                                                                                                                                                                                                                                                                                                                                            | 152/915 (16.6)                                                                                                                                                                                                                                                                                                                                                                          | 152/915 (16.6)                                                                                                                                                                                                                                                                                                                                                                          |
| HR a (99.5% CI) b,c                                                                                                                                                                                                                                                                                                                                                                     | 0.574 (0.392, 0.831)                                                                                                                                                                                                                                                                                                                                                                    | 0.574 (0.392, 0.831)                                                                                                                                                                                                                                                                                                                                                                    | 0.574 (0.392, 0.831)                                                                                                                                                                                                                                                                                                                                                                    | 0.574 (0.392, 0.831)                                                                                                                                                                                                                                                                                                                                                                    |
| 95% CI b,d                                                                                                                                                                                                                                                                                                                                                                              | (0.441, 0.744)                                                                                                                                                                                                                                                                                                                                                                          | (0.441, 0.744)                                                                                                                                                                                                                                                                                                                                                                          | (0.441, 0.744)                                                                                                                                                                                                                                                                                                                                                                          | (0.441, 0.744)                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| p-value (2-sided) e                                      | 0.0000257                                        | 0.0000257                                        |
|----------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Patients distant disease free at 36 months (%) f (95%CI) | 87.5 (84.6, 89.9)                                | 80.4 (77.2, 83.3)                                |
| OS (10.0% maturity in FAS) - DCO2 (12 July 2021)         | OS (10.0% maturity in FAS) - DCO2 (12 July 2021) | OS (10.0% maturity in FAS) - DCO2 (12 July 2021) |
| Number of events/total number of patients (%)            | 75/921 (8)                                       | 109/915 (12)                                     |
| HR a (98.5% CI) b,c                                      | 0.68 (0.47, 0.97)                                | 0.68 (0.47, 0.97)                                |
| p-value (2-sided) e                                      | 0.0091                                           | 0.0091                                           |
| Percentage (95% CI) of patients alive at 3 years f       | 92.8 (09.8, 94.4)                                | 89.1 (86.7, 91.0)                                |
| Percentage (95% CI) of patients alive at 4 years f       | 89.8 (87.2, 91.9)                                | 86.4 (83.6, 88.7)                                |

a Estimate of the treatment HR was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo arm. Stratification factors were the same as those used in the stratified log-rank test.

- b The CI for the HR was estimated using the profile likelihood approach.
- c Inferential, according to the alpha spending rules for the interim analysis.
- d Exploratory, not inferential
- e P-value from a stratified log-rank test. Stratification was by chemotherapy type (2 levels: adjuvant vs neoadjuvant), hormone receptor status (2 levels: ER and/or PgR positive, HER2 negative vs TNBC), and prior platinum therapy (2 levels: yes vs no). Stratification factors were based upon the categories used in the randomisation system and were chosen  by  the  pooling  strategy.  Once  the  pooling  strategy  was  applied,  only  the  hormone  receptor  status stratification factor was selected.
- f Percentages of patients were from the Kaplan-Meier estimates and the 95% CIs were calculated using Greenwood's formula.

CI = confidence interval; DDFS = distant disease free survival; FAS = full Analysis Set; HR = hazard ratio; IDFS = invasive disease free survival; N = total number of patients; OS = overall survival

## Supportive studies

The pivotal study OlympiA only included patients with germline mutations of BRCA (gBRCAm). The MAH submitted additional clinical evidence to support the claimed indication that included patients with both germline and somatic BRCA mutations.

Table 31 summarises efficacy data for olaparib and other PARP inhibitors in gBRCAm, tBRCAm, and sBRCAm metastatic breast cancer patients.

<div style=\"page-break-after: always\"></div>

Table 31: Summary of Clinical Outcomes by Germline/Somatic BRCA Status in Metastatic Breast Cancer Patients

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Study                          | Subtype                  | BRCAm status              | Number of patients       | Prior lines of chemotherapy for metastatic disease   | Treatment                  | Median PFS months            | ORR                      | Additional information                  |
|--------------------------------|--------------------------|---------------------------|--------------------------|------------------------------------------------------|----------------------------|------------------------------|--------------------------|-----------------------------------------|
| RUBY (Patsouris et al 2021)    | TNBC and ER and/or PgR   | sBRCAm                    | 5                        | 12                                                   | Rucaparib monotherapy      | NA                           | 20%                      | 1 additional patient had stable disease |
| Vinayak et al 2019             | INBC                     | tBRCAm                    | 15                       | 0-3                                                  | Nirapanb + Pembrolizumab   | 8.3 (95% CI: 2.1, NA)        | 47% (90% CI: 24%, 70%)   |                                         |
| Vinayak et al 2019             | INBC                     | sBRCAm (out of 15 tBRCAm) | 2                        | 0-3                                                  | Niraparib + Pembrolizumab  | NA                           | 100% (1 CR and 1 PR)     |                                         |
| RealWorldEvidenceStudies       | RealWorldEvidenceStudies | RealWorldEvidenceStudies  | RealWorldEvidenceStudies | RealWorldEvidenceStudies                             | RealWorldEvidenceStudies   | RealWorldEvidenceStudies     | RealWorldEvidenceStudies | RealWorldEvidenceStudies                |
| Real World Clinico- Genomic    | TNBC and ER and/or PgR   | gBRCAm                    | 44                       | [4+                                                  | PARPi or PARPi combination | IwPFS 5.5 (range: 4.3, 7.2)  | NA                       |                                         |
| Database (Batalini et al 2021) | TNBC and ER and/or PgR   | SBRCAm                    |                          | 14+                                                  | PARPi or PARPi combination | rwPFS 7.1 (range: 1.4, 12.4) | NA                       |                                         |

All patients in the combination arms had a full dose of Olaparib monotherapy.

ORR data are forconfimmedresponses (byBICR); these were defined as a recorded response of either confirmed orpartial response,confimed byrepeat imaging not less than 4 weeks after the visit when the response was first observed.

sBRCAm wasdetemined byFouudationMedicineIncSGZcomputational validated algorithm(Sumet al 2018).

- Unconfinmed ORR as confinmation of response was not required in VIOLETTE.

ORRdata aredeterminedbyinvestigators.

BICR =blinded independent central review; BRCA = breast cancer susceptibility gene; BRCAm=BRCA mutated; CI = confidence interval; CR =complete response; DDRi =DNA damage response imhibitor, ER = oestrogen receptor, gBRCAm = gemline BRCA mutated; HER2 = human epidermal growth factor receptor 2; NA =not available/computable; NE =not evaluable; ORR = objective response rate; PARP = poly adenosine diphosphate-nibose polymerase; PARPi = PARP inhibitor; PFS = progression free suvival; PgR = progesterone receptor; PR = partial response; rwPFS = real world progression free suvival; sBRCAm=somaticBRCAmutatedtBRCAm=tuumourBRCAmutated;TDT=timetodiscontimuationofstudytreatment;TNBC=triplenegativebreastcancer.

## 2.7.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

The applicant provided data from the randomised, double blind, controlled, multi-centre phase III study OlympiA to support the proposed use of olaparib as monotherapy for the adjuvant treatment of adult patients  with  BRCA1/2-mutations (germline / somatic) who have HER2 negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy.

The dose of olaparib in OlympiA (300 mg bd tablets) was selected based on data from the Phase I study, D0810C00024  (Study  24).  Study  24  was  a  formulation  comparison  study  and  the  findings  provided information on the efficacy, PK/PD, safety and tolerability profiles of the olaparib tablet. Study 24 explored the safety data and tumour shrinkage data across a number of different doses and schedules of olaparib tablet  or  capsule  in  an  advanced  gBRCA  mutated  ovarian  cancer  population.  The  results  of  this  study supported the use of 300 mg bd tablet dose for Phase III studies.

On 28 February 2019 (EMEA/H/C/003726/II/0020) Olaparib 100mg/150mg tablets were approved in a breast  cancer  indication  for  the  treatment  in  monotherapy  of  adult  patients  with  germline  BRCA1/2mutations, who have HER2 negative locally advanced or metastatic breast cancer (based on the results of the pivotal study OlympiAD).

Considering the data from study OlympiA, the proposed recommended dose of Lynparza in monotherapy or in combination with endocrine therapy in the treatment of early breast cancer is 300 mg (two 150 mg tablets) taken twice daily, equivalent to a total daily dose of 600 mg (see SmPC section 4.2). The 100 mg tablet is available for dose reduction. Prescribers should refer to the full product information of the endocrine

<div style=\"page-break-after: always\"></div>

therapy combination partner(s) (aromatase inhibitor/anti-oestrogen agent and/or LHRH)  for the recommended posology.

For  what  concern  treatment  duration,  the  choice  of  the  one-year  duration  was  based  on  the  available efficacy and safety information (due to potential safety issues, e.g. MDS/AML) at the time of the study design in the early breast cancer setting. Therefore, it is recommended that patients are treated for up to 1 year, or until disease recurrence, or unacceptable toxicity, whichever occurs first.

OlympiA study was designed as a comparative study of olaparib monotherapy versus placebo. At the time of study onset, endocrine therapies for patients with HR+/HER2- breast cancer were the only available treatment options after completion of neoadjuvant/adjuvant, anthracycline/taxane chemotherapy. Patients with  HR+/HER2-  breast  cancer  included  in  OlympiA  were  allowed  to  have  concurrent  treatment  with endocrine  therapy  as  per  local  guidelines.  Overall,  89.5%  of  them  received  an  endocrine  concomitant therapy during study (see discussion below). The control arm of OlympiA study for RH+/HER2- patients is therefore considered to be placebo + endocrine therapy for this group of patients.

The choice of comparator was also discussed in light of available results from a clinical trial evaluating capecitabine in the adjuvant treatment of TNBC breast cancer (Masuda et al 2017, CREATE-X study). Based on the results of the CREATE-X trial (a trial in Asian patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy [containing anthracycline, taxane, or both]), the NCCN guidelines and ESMO guidelines for early breast cancer were updated to recommend that capecitabine may be offered to  high  risk  TNBC  patients  following  optimal  neoadjuvant  chemotherapy  (Cardoso  et  al  2019,  NCCN Guidelines 2021). However, these results were published three years after the initiation of study OlympiA and the use of additional adjuvant therapy after randomised therapy was not permitted in study OlympiA. Capecitabine is not approved in the EU as adjuvant treatment for breast cancer. Overall, the choice of comparator arm in study OlympiA is acceptable.

The OlympiA study was double blinded which is expected to minimise the risk of bias that could affect the interpretation of the IDFS primary endpoint. A somewhat significant rate of premature unblinding was observed, with a twice higher rate in the placebo arm as compared to olaparib arm. However, these treatments disclosures were compliant to protocol rules and mainly due to treatment discontinuations. A differential efficacy and the need to adequately treat patients' condition when their allocated treatment was stopped could explain this imbalance in unblinding rates.

Patient distribution was generally well balanced between the 2 treatment arms with regard to baseline demographics, disease characteristics, prior medication and therapy.

The  majority  of  hormone  receptor  positive  patients  received  concurrent  endocrine  therapy  (86.9%  in olaparib  arm  and  92.4%  in  placebo  arm)  mainly  based  on  aromatase  inhibitors  (52.6%,  n=171)  and tamoxifen (40.3%, n=131). This is consistent with clinical practice and the most recent ESMO Guideline (Cardoso et al 2019) and NCCN Guidelines (NCCN Guidelines 2021). The 34 (10.5%) hormone receptor positive patients who did not receive endocrine therapy were mostly primarily ER zero/PgR positive or ER low (1 to 10%). Current clinical practice guidelines recommend the use of endocrine therapy in ER positive breast cancer defined as ≥1% by immunohistochemistry (IHC) (ESMO, 2019). It is acknowledged that there is currently limited data on the overall benefit of endocrine therapies for patients with low level (1% to 10%) ER expression (Iwamoto et al 2012; Allison et al 2020 ; Burstein et al 2021 ; Schrodi et al 2021; Villegas et al 2021) and the clinical decision to treat with endocrine therapy in OlympiA was made by the treating physician. To adequately reflect the studied population the indication has been reworded to include the use of olaparib is either as monotherapy or in combination with endocrine therapy (see SmPC section 4.1).

<div style=\"page-break-after: always\"></div>

The  imbalances  between  arms  recorded  in  the  use  of  individual  endocrine  therapy  agents  in  hormone receptor positive patients in OlympiA are not considered to introduce any major biases on the efficacy results of the study.

The definitions of high risk of recurrence for patients who received adjuvant chemotherapy (inclusion criteria #3A) and for TNBC patients who received neoadjuvant therapy (inclusion criteria #3B1) are considered acceptable. In OlympiA, high risk early breast cancer patients were selected as follows:

- patients who received prior neoadjuvant chemotherapy: patients with either triple negative breast cancer (TNBC) or hormone receptor positive breast cancer must have had residual invasive cancer in the breast and/or the resected lymph nodes (non-pathologic complete response) at the time of surgery. Additionally, patients with hormone receptor positive breast cancer must have had a CPS&amp;EG score of ≥3 based on pre-treatment clinical and post-treatment pathologic stage (CPS), estrogen receptor (ER) status and histologic grade as shown in Table 9 of the SmPC.

- patients who have received prior adjuvant chemotherapy: triple negative breast cancer (TNBC) patients must have had node positive disease or node negative disease with a ≥2 cm primary tumour; HR positive, HER2negative patients must have had ≥4 pathologi cally confirmed positive lymph nodes.

The MAH provided clarifications regarding the CPS&amp;EG scoring system and its use as a prognostic score following neoadjuvant chemotherapy in several retrospective studies including a large population of patients (Mittendorf et al 2011, Abdelsattar et al 2016, Marmé et al 2016). This staging system globally showed a statistically significant stepwise reduction in breast cancer-specific survival with increasing CPS&amp;EG score and was able to separate patients into more refined subgroups. The SmPC has been revised to provide more details about the CPS&amp;EG Scoring and transparent instructions on how high-risk ER and/or PgR positive, HER2-negative breast cancer patients were selected in OlympiA in the neoadjuvant setting (see SmPC section 5.1).

The primary objective of OlympiA was to evaluate the effect of adjuvant treatment with olaparib for patients with  HER2-negative  (HR+/HER2-  or  TNBC)  early-stage  breast  cancer  on  IDFS  which  is  considered acceptable.  A  multiple  testing  procedure  was  employed  across  the  IDFS,  DDFS,  and  OS  endpoints  to strongly control the overall type I error at 5% 2-sided, accounting for any interim analyses on IDFS, DDFS and OS. At the DCO1 date (27 March 2020), a 2-sided significance level of 0.005 was assigned to the analysis for IDFS and DDFS and a 2-sided significance level of 0.01 was assigned to the analysis for OS. Secondary efficacy endpoints included DDFS, OS and PRO collected on pertinent scales regarding olaparib safety profile and olaparib indication (FACIT-Fatigue, EORTC QLQ-C30).

A  protocol  amendment  was  put  in  place  in  2015  (ROW  CSP  3.0  [21  Oct  2015])  to  update  the  target population to include HR+/HER2- patients. Prior to this amendment only TNBC patients were included. Only 17.7% of HR+/HER2- patients were included in OlympiA representing a total of 325 patients. It is agreed that  this  amendment  is  not  considered  to  have  affected  the  interpretation  of  study  results  since  IDFS HR+/HER2- subgroup analyses showed HR point estimate consistent with overall IDFS results (HR 0.70; 95% CI: 0.38, 1.27 and HR 0.59; 95% CI: 0.46, 0.74 respectively).

Important  protocol  deviations  were  reported  in  252  patients  (13.7%)  and  were  balanced  between  the treatment arms (130 patients [14.1%] and 122 patients [13.3%] in the olaparib arm and placebo arm, respectively). The most common important deviation observed in both treatment arms was no staging or insufficient staging as required by exclusion criterion 4 with 67 patients (7.3%) in the olaparib arm and 66 patients (7.2%) in the placebo arm not having all the required tests performed prior to randomisation. A total of 10.2% of patients with AJCC clinical stage IA were included in the study. This population is not covered by the claimed indication. A post hoc analysis was provided excluding all patients with an important protocol deviations related to eligibility (n=223) (data not shown). Results of this post hoc exploratory

<div style=\"page-break-after: always\"></div>

analysis of IDFS suggested a consistent treatment effect in the intended study population, when compared with the FAS (HR 0.52; 95% CI 0.40, 0.68; p&lt;0.001).

## Efficacy data and additional analyses

OlympiA met its primary endpoint showing a statistically significant improvement in IDFS for olaparibtreated patients compared to placebo-treated patients, reducing the risk of recurrence of disease at any given point in time by 42% in patients with gBRCAm, high risk early-stage breast cancer after standard of care  neo/adjuvant  chemotherapy  and  surgery  (HR  0.58;  99.5%  CI:  0.41,  0.82;  p=0.0000073).  The difference in the proportion of patients free of invasive disease at 3 years was 8.8% (95%CI, 4.5%-13.0%) in favour of olaparib. This benefit is considered clinically meaningful.

The results of the sensitivity analyses of IDFS (including only patients with central pathology review data for hormone receptor status [ER and PgR], using unadjusted analysis, using interval censoring, and using RMST method) are considered consistent with the primary analysis of IDFS.

The subgroup analyses showed consistent effects with the primary analysis of IDFS in the FAS with a treatment  benefit  of  olaparib  over  placebo  evidenced  across  most  of  the  pre-defined  subgroups.  The subgroup of patients with HR+/HER2- status who had received adjuvant chemotherapy (6 events in 64 olaparib-treated patients vs 5 events in 65 placebo-treated patients) showed a HR point estimate &gt;1 (HR 1.36; 95% CI: 0.41, 4.71) at DCO 1 (27 March 2020).

Updated descriptive analyses of IDFS based on more mature data (with median follow-up of 3.5 years) conducted at the time of the pre-planned second OS interim analysis (DCO2: 12 July 2021) were provided. The updated analysis with increased number of events in the hormone receptor positive prior adjuvant subgroup (9.4% and 13.8% events for the olaparib and placebo arm respectively) showed an improved hazard ratio for IDFS of 0.736 (95% CI: 0.247, 2.042). The hazard ratio in this subgroup of patients with longer follow up and increased maturity of events is consistent with the ITT outcome supporting a treatment benefit for olaparib in these patients.

Treatment with olaparib compared to placebo conferred a numerical benefit in DDFS supporting the positive outcome of IDFS.

The MAH provided updated OS results from the second planned interim analysis (DCO2 12 July 2021). Median duration of follow-up for OS was 3.5 years in the olaparib arm and 3.6 years in the placebo arm. The OS results showed statistically 32.2% numerical reduction in the risk of death at any given point in time (HR 0.68, 98.5% CI: 0.47, 0.97, p=0.0091). At all-time points, a higher proportion of patients in the olaparib arm compared with the placebo arm remained alive (1 year [98.0%], 2 years [95.0%], 3 years [92.8%]  and  4  years  [89.8%]  compared  with  96.9%,  92.8%,  89.1%  and  86.4%  respectively).  The subgroup analyses showed consistent effects with the analysis of OS in the FAS, with a treatment benefit of  olaparib  over  placebo  evidenced  across  all  the  pre-defined  subgroups  (including  the  HR+/HER2population).

The incidences of contralateral breast cancers (invasive and non-invasive), new primary ovarian cancer, new primary fallopian tube cancer, and new primary peritoneal cancer without considering competing risks were numerically lower in the olaparib arm compared with the placebo arm. However, it remains difficult to draw conclusion based on this low number of cases, in addition longer follow up would be necessary to assess if this potential benefit persists on long term.

No  clinically  meaningful  differences  in  HRQoL  were  observed  between  patients  receiving  olaparib  and placebo over the course of the study especially on adverse events of special interest (nausea/vomiting and diarrhea) and fatigue scores based on results collected on pertinent scales regarding olaparib safety profile (FACIT-Fatigue, EORTC QLQ-C30). However, no formal hypothesis testing was performed regarding PROs.

<div style=\"page-break-after: always\"></div>

Methodologically robust PRO data are needed to be able to conclude on a potential clinical benefit (The use of  patient-reported outcome (PRO) measures in oncology studies - Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man; 1 April 2016 EMA/CHMP/292464/2014).

The MAH submitted a justification to support the claimed indication that include patients with both germline and somatic BRCA mutations. The MAH presented data available with olaparib in the metastatic setting and data available from other PARP inhibitors. These data support a strong biological rationale and suggest antitumour activity in patients with sBRCA in this adjuvant setting. In addition, similarities between the target population (sBRCAm in adjuvant setting) and the studied population are acknowledged. However, the extrapolation of the efficacy associated with olaparib observed in patients with germline BRCA mutations to patients with tumours with somatic BRCA mutations in the early breast cancer setting is considered premature considering the remaining uncertainties. Further evidence to support efficacy in patients with sBRCAm and to address uncertainties related to safety is required including clinical data with longer follow-up (see also discussion on clinical safety). The indication is thus restricted to germline BRCAm patients only (see SmPC section 4.1). Section 4.2 of the SmPC has been updated accordingly reflecting that patients must have confirmation of deleterious or suspected deleterious g BRCA1/2 mutation using a validated test before Lynparza treatment is initiated for adjuvant treatment of HER2 negative high risk early breast cancer.

## 2.7.3. Conclusions on the clinical efficacy

A  clinically  relevant  benefit  of  olaparib  has  been  shown  for  both  the  subgroups  of  TNBC  patients  in monotherapy and HR+/HER2- patients in association with endocrine therapy as adjuvant treatment of adult patients with germline BRCA1/2-mutations who have high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy.

Since  patients  with  a  somatic  mutation  were  excluded  from  study  OlympiA  due  to  unavailability  of  an appropriate diagnostic test based on tissue analysis at that time, there are no clinical data available on the responsiveness of breast tumours with sBRCA mutation to olaparib in the early setting. The benefit remains uncertain in patients with sBRCA1/2 mutations treated in early breast cancer setting. In the absence of data  supporting  extrapolation  to  patients  with  somatic  mutation  the  indication  has  been  restricted  to germline BRCAm patients only.

## 2.8. Clinical safety

## Introduction

Across the entire clinical programme, as of 15 June 2021, approximately 17923 patients are estimated to have received treatment with olaparib.

The safety assessment was based primarily on data from OlympiA, the pivotal Phase III study in gBRCAm primary breast cancer patients, where 911 patients received olaparib (300 mg bd tablet).

Data from OlympiA was supported by data from a pooled safety database of olaparib 300 mg bd tablet data from 17 AstraZeneca sponsored monotherapy studies (n=3045 [including 911 patients from OlympiA]) as described in Table 32 and larger pools of olaparib studies (olaparib monotherapy combined therapeutic dose pool, n=3988) at the DCO 27 March 2020 (DCO1). The MAH provided updated safety data with the DCO 12 July 2021 (DCO2). At DCO2, safety data from 18 studies were pooled to provide data for a total of 3155 patients with advanced solid tumours, 1289 of whom had breast cancer. Between DCO1 and DCO2,

<div style=\"page-break-after: always\"></div>

the total number of patients in the 300 mg bd pool has increased by 110 patients; this was due to addition of data from patients who received olaparib 300 mg bd monotherapy in the VIOLETTE study. Data have also been updated for the OlympiA and SOLO3 studies.

The primary comparison of safety was between the olaparib and placebo arms within the OlympiA study and the olaparib 300 mg bd tablet pool. In addition, data were presented for the larger therapeutic dose pool of olaparib studies in summaries of MDS/AML and important potential risks.

Table 32: Number of Patients in the 300 mg bd Pool (DCO: 12 July 2021)

| Study/pooled dataset                                                                                                                                                                                                | Number of patients intended for the 300 mg bd cohort and received olaparib (all tumour types)   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Total exposed                                                                                                                                                                                                       | 3155                                                                                            |
| D081CC00006 (OlympiA): Phase III gBRCA1/2m HER2 negative high-risk early breast cancer patients who have completed definitive local treatment and either neoadjuvant or adjuvant chemotherapy                       | 911                                                                                             |
| D0818C00001 (SOLO1): Phase III FIGO Stage III-IV ovarian cancer SOLO1 China cohort a                                                                                                                                | 260 40                                                                                          |
| D0816C00002 (SOLO2): Phase III platinum-sensitive serous ovarian                                                                                                                                                    | 195 22                                                                                          |
| cancer SOLO2: China cohort a                                                                                                                                                                                        |                                                                                                 |
| Study D0816C00010 (SOLO3): Phase III gBRCAm ≥ third line ovarian cancer patients D0819C00003 (OlympiAD): Phase III HER2-negative breast cancer                                                                      | 178                                                                                             |
| patients with gBRCA1/2 mutation Study D081DC00007 (PROfound): Phase III HRRm metastatic                                                                                                                             | 205                                                                                             |
| castration-resistant prostate cancer (mCRPC)                                                                                                                                                                        | 256                                                                                             |
| Study D081FC00001 (POLO): Phase III gBRCAm metastatic pancreatic adenocarcinoma patients whose disease has not progressed on first- line platinum-based chemotherapy.                                               | 90                                                                                              |
| Study D0816C00020 (OPINION): Phase IIIb, patients with platinum-sensitive relapsed non-germline BRCA mutated ovarian cancer                                                                                         | 279                                                                                             |
| Study D0816L00003 (LIGHT): Phase II, patients with different HRD tumour status and with platinum-sensitive and endometrioid ovarian, fallopian tube, or primary peritoneal cancer                                   | 271                                                                                             |
| Study D5336C00001 (VIOLETTE): Phase II, second- or third-line metastatic TNBC patients stratified by alterations in HRR related genes (including BRCA1/2 ) (Patient Population E [Stratum A]; olaparib monotherapy) | 110                                                                                             |
| Study 24: Phase I Relative Bioavailability (300 mg tablet bd patients only, Groups 4 and 6)                                                                                                                         | 24                                                                                              |

<div style=\"page-break-after: always\"></div>

| Study/pooled dataset                               |   Number of patients intended for the 300 mg bd cohort and received olaparib (all tumour types) |
|----------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Study 06: Phase I Renal impairment study           |                                                                                              43 |
| Study 07: Phase I CYP3A4 inhibition and QT         |                                                                                              56 |
| Study 08: Phase I CYP induction                    |                                                                                              19 |
| Study D081CC00001: Phase I anti-hormonal PK study  |                                                                                              69 |
| Study D081BC00001: Phase I Japan Monotherapy study |                                                                                              19 |
| D0816C00005: Phase I hepatic impairment study      |                                                                                              31 |
| D081BC00002: China PK study                        |                                                                                              20 |

## Patient exposure

## Overall Extent of Exposure: OlympiA Study

All except for 21 of the 1836 randomised patients in OlympiA received study treatment (10 patients randomised to olaparib and 11 patients randomised to placebo). The OlympiA Safety Analysis Set (SAS) consists of 1815 patients (911 who received olaparib and 904 who received placebo).

The DCO for the interim analysis for OlympiA was 27 March 2020 (DCO1). At the time of the DCO1, 1353 patients (73.7%) had completed study treatment per protocol and 39 patients (2.1%) were still receiving study treatment (19 patients [2.1%] in the olaparib arm and 20 patients [2.2%] in the placebo arm). At the time of the DCO2 (12 July 2021), no patients remained on study treatment in OlympiA; 1389 patients (75.7% of those randomised) had completed treatment per protocol and 426 patients (23.2% of those randomised) had discontinued study treatment. In total, 674 patients (73.2% of those randomised) in the olaparib arm and 715 patients (78.1% of those randomised) in the placebo arm completed treatment per protocol. As observed at DCO1, the most common reason for early discontinuation in the olaparib arm was AEs (98 patients [10.6%] in the olaparib versus 41 patients [4.5%] in the placebo arm) and in the placebo arm it was recurrence of disease (80 patients [8.7%] in the placebo arm versus 40 patients [4.3%] in the olaparib arm). A lower proportion of patients in the olaparib arm than the placebo arm died on study (75 patients [8.1%] versus 106 patients [11.6%] in the FAS, respectively ( Table 44 ).

The treatment duration in OlympiA was capped at 12 months. A summary of the number of patients receiving treatment by months is presented in Table 33 . A similar proportion of patients in both treatment arms continued to receive treatment over 12 months treatment duration.

The majority of patients (76.1% in the olaparib arm and 81.7% in the placebo arm) received ≥11 months with most patients discontinuing treatment after 11.5 months (73.9% in the olaparib arm and 79.4% in the placebo arm). Only a small number of patients rec eived ≥12.5 months of randomised treatment (1.9% of patients in the olaparib arm and 0.9% of patients in the placebo arm).

<div style=\"page-break-after: always\"></div>

Table 33:  OlympiA: Overall Extent of Exposure (SAS)

|                                          | Number (%) of patients     | Number (%) of patients     | Number (%) of patients   | Number (%) of patients   |
|------------------------------------------|----------------------------|----------------------------|--------------------------|--------------------------|
|                                          | Olaparib 300 mg bd (N=911) | Olaparib 300 mg bd (N=911) | Placebo (N=904)          | Placebo (N=904)          |
| Cumulative exposure over time (months) a | 27 Mar 2020 DCO            | 12 Jul 2021 DCO            | 27 Mar 2020 DCO          | 12 Jul 2021 DCO          |
| >0 months                                | 910 (99.9)                 | 910 (99.9)                 | 903 (99.9)               | 903 (99.9)               |
| ≥1 month                                 | 848 (93.1)                 | 848 (93.1)                 | 872 (96.5)               | 872 (96.5)               |
| ≥2 months                                | 824 (90.5)                 | 824 (90.5)                 | 847 (93.7)               | 847 (93.7)               |
| ≥3 months                                | 801 (87.9)                 | 801 (87.9)                 | 836 (92.5)               | 836 (92.5)               |
| ≥4 months                                | 782 (85.8)                 | 782 (85.8)                 | 821 (90.8)               | 821 (90.8)               |
| ≥5 months                                | 769 (84.4)                 | 769 (84.4)                 | 805 (89.0)               | 805 (89.0)               |
| ≥6 months                                | 757 (83.1)                 | 757 (83.1)                 | 794 (87.8)               | 794 (87.8)               |
| ≥7 months                                | 752 (82.5)                 | 752 (82.5)                 | 782 (86.5)               | 782 (86.5)               |
| ≥8 months                                | 739 (81.1)                 | 739 (81.1)                 | 771 (85.3)               | 771 (85.3)               |
| ≥9 months                                | 719 (78.9)                 | 719 (78.9)                 | 758 (83.8)               | 758 (83.8)               |
| ≥10 months                               | 706 (77.5)                 | 707 (77.6)                 | 753 (83.3)               | 753 (83.3)               |
| ≥11 months                               | 685 (75.2)                 | 693 (76.1)                 | 733 (81.1)               | 739 (81.7)               |
| 12 months                                | 401 (44.0)                 | 414 (45.4)                 | 449 (49.7)               | 465 (51.4)               |

g Rows are cumulative and patients were included if they had taken treatment up to and including that day.

Patients with partial treatment end dates were excluded.

bd = Twice daily; CSR = Clinical study report; DCO = Data cut-off; N = Total number of patients; SAS = Safety analysis set.

Source: Table 14.3.1.3, OlympiA CSR, Module 5.3.5.1 and Safety Update Table 14.3.1.3.

<div style=\"page-break-after: always\"></div>

Table 34: OlympiA: Duration of Exposure (SAS)

| Treatment                               |                           | Olaparib 300 mg bd (N=911)   | Olaparib 300 mg bd (N=911)   | Placebo (N=904)   | Placebo (N=904)   |
|-----------------------------------------|---------------------------|------------------------------|------------------------------|-------------------|-------------------|
|                                         |                           | 27 Mar 2020 DCO              | 12 Jul 2021 DCO              | 27 Mar 2020 DCO   | 12 Jul 2021 DCO   |
| Total intended exposure (days) a        | Mean (standard deviation) | 306.5 (114.80)               | 307.2 (115.02)               | 322.4 (97.54)     | 323.1 (97.72)     |
| Total intended exposure (days) a        | Median (range)            | 364.0 (1-492)                | 364.0 (1-492)                | 364.0 (2- 414)    | 365.0 (2- 414)    |
| Actual treatment exposure (days) b      | Mean (standard deviation) | 294.4 (113.90)               | 295.0 (114.09)               | 315.1 (97.59)     | 315.7 (97.77)     |
| Actual treatment exposure (days) b      | Median (range)            | 350.0 (1-420)                | 350.0 (1-420)                | 358.0 (2- 404)    | 359.0 (2- 404)    |
| Number of days on 300 mg treatment bd c | Mean (standard deviation) | 245.2 (141.68)               | 245.8 (142.05)               | 306.3 (107.51)    | 307.0 (107.67)    |
| Number of days on 300 mg treatment bd c | Median (range)            | 338.0 (1-420)                | 341.0 (1-420)                | 358.0 (2- 404)    | 358.0 (2- 404)    |

h

Total intended exposure (days) = (last dose date - first dose date + 1).

Actual treatment exposure (days) = intended exposure - total duration of dose interruptions, where intended exposure was calculated as above.

Number of days on 300 mg olaparib/placebo bd (actual exposure for the assigned starting dose).

Patients with partial treatment end dates were excluded.

bd = Twice daily; CSR = Clinical study report; DCO = Data cut-off; N = Total number of patients; SAS = Safety analysis set.

Source: Table 14.3.1.1, OlympiA CSR, Module 5.3.5.1 and Safety Update Table 14.3.1.1.

<div style=\"page-break-after: always\"></div>

The proportion of patients with dose interruptions or reductions was higher in the olaparib arm than in the placebo arm. The majority of patients in the olaparib arm had ≤2 interruptions and 79 patients (8.7%) had ≥3 interruptions. In both arms, AEs were the most common reason for dose reductions. The most common reason for dose interruption were AEs in the olaparib arm and surgery in the placebo arm.

Table 35 : Treatment dose reductions (SAS) (DCO 12 July 2021)

|                                    | olaparib300mgbd (N=911)   | Placebo (N=904)   |
|------------------------------------|---------------------------|-------------------|
| Patientswithnodosereduction        | 683（75.0%)                | 857(94.8%)        |
| Patients with a dose reduction     | 228(25.0%)                | 47(5.2%)          |
| Totalnumberofdosereductions        | 287                       | 54                |
| Numberofpatientswithadosereduction |                           |                   |
| 1dosereduction                     | 170(18.7)                 | 40（4.4)           |
| 2 dose reductions                  | 57(6.3%)                  | 7(0.8%)           |
| 3ormoredose reductions             | 1 (0.1)                   | 0 (0.0)           |
| Reason for reduction [2]           |                           |                   |
| Adverse event                      | 222 2（24.4)               | 35 (3.98)         |
| Dosing error                       | 6 (0.7%)                  | 10 (1.1%)         |
| Administrative reasons             | 2 (0.2$)                  | 1 (0.1$)          |
| other                              | 0 (0.0%)                  | 1 (0.1%)          |

[1] Dose reductionsare based on investigator initiated decisions,reductions due to'Subject non-compliance'are omitted.

[2]Reasons for dose reductions are not mutuallyexclusive forpatients withmultiplereductionsalthough are counted only once per category.

Table 36 :  Treatment dose interruptions (SAS) (DCO 12 July 2021)

|                                                           | olaparib300mgbd (N=911)   | Placebo (N=904)   |
|-----------------------------------------------------------|---------------------------|-------------------|
| Patientswithnodoseinterruption                            | 401(44.0%)                | 500（55.3)         |
| Patientswithadoseinterruption                             | 510 (56.0%)               | 404 (44.7%)       |
| Patients with a dose interruption lasting at least 3 days | 400 (43.9%)               | 279 (30.9%)       |
| Numberof patients with adoseinterruption                  |                           |                   |
| 1dose interruption                                        | 300 (32.9%)               | 272 (30.1%)       |
| 2 dose interruptions                                      | 131 (14.4%)               | 92 (10.2%)        |
| 3ormoredoseinterruptions                                  | 79 (8.7%)                 | 40 (4.4%)         |
| Reason for interruption [2]                               |                           |                   |
| Adverse event                                             | 323 (35.5%)               | 126 (13.9%)       |
| Surgery                                                   | 224 (24.6%)               | 236 (26.1%)       |
| Recurrence of disease                                     | 38 (4.2%)                 | 79 (8.7%)         |
| Dosing error                                              | 0 (0.0%)                  | 3 (0.3%)          |
| Administrative reasons                                    | 20(2.2%)                  | 25 (2.8%)         |
| Other                                                     | 6 (0.7%)                  | 11 (1.2%)         |

[1] Dose interruptions are based on investigator initiated decisions,interruptions due to Subject non-compliance' are omitted.

[2]Reasons for dose interruptions are not mutually exclusive for patients with multiple interruptions although are counted only once per category.

<div style=\"page-break-after: always\"></div>

Table 37 : 300 mg bd Pool: Overall Extent of Exposure (SAS)

|                  | Number (%)ofpatients Olaparib300 mgbd (N=3155)   | Number (%)ofpatients Olaparib300 mgbd (N=3155)   |
|------------------|--------------------------------------------------|--------------------------------------------------|
| Treatment period | 27Mar2020DCO                                     | 12 Jul 2021 DCO                                  |
| uou 0<           | 3045 (100)                                       | 3155 (100)                                       |
| ≥1 month         | 2887 (94.8)                                      | 2981 (94.5)                                      |
| ≥3 months        | 2520 (82.8)                                      | 2577 (81.7)                                      |
| ≥6 months        | 2077 (68.2)                                      | 2107 (66.8)                                      |
| ≥12 months       | 983 (32.3)                                       | 996 (31.6)                                       |
| ≥18 months       | 548 (18.0)                                       | 548 (17.4)                                       |
| ≥24 months       | 365 (12.0)                                       | 366 (11.6)                                       |
| ≥36 months       | 109 (3.6)                                        | 117 (3.7)                                        |
| ≥48 months       | 82 (2.7)                                         | 92 (2.9)                                         |
| ≥60 months       | 58 (1.9)                                         | 65 (2.1)                                         |
| ≥72 months       | 9 (0.3)                                          | 9 (0.3)                                          |

Patients ongoing treatment at study closure may not necessarily appear in the final treatment day category as total treatment duration differs across patients.

Rows are cumulative and patients were included if they had taken treatment up to that day.

bd = Twice daily; DCO = Data cut-off; N = Total number of patients; SAS = Safety analysis set.

Source: Safety Update Table 2.7.4.1.9.2.

In OlympiA, patients were treated for a maximum of 12 months in comparison to the 300 mg bd pool where studies allowed patients to be treated for 24 months or until disease progression if they were continuing to receive benefit.

## Demographics and Characteristics of Study Population

## OlympiA Study

The demographic and disease characteristics of patients in OlympiA are summarised in Table 8 .

<div style=\"page-break-after: always\"></div>

## Adverse events

## Overview of AE

Comparison with olaparib 300mg bd pool

## Table 38: OlympiA: Number of Events and Number (%) of patients who had at least one AE in any Category (SAS; DCO: 12 July 2021)

|                                                        | Number (%) of patients     | Number (%) of patients   | Number (%) of patients           |
|--------------------------------------------------------|----------------------------|--------------------------|----------------------------------|
|                                                        | OlympiA SAS                | OlympiA SAS              |                                  |
| AE category a                                          | Olaparib 300 mg bd (N=911) | Placebo (N=904)          | Olaparib 300 mg bd pool (N=3155) |
| Any AE                                                 | 836 (91.8)                 | 756 (83.6)               | 3024 (95.8)                      |
| Any AE of CTCAE Grade ≥3                               | 223 (24.5)                 | 102 (11.3)               | 1155 (36.6)                      |
| Any AE with outcome=death                              | 1 (0.1)                    | 2 (0.2)                  | 31 (1.0)                         |
| Any SAE (including events with outcome=death)          | 79 (8.7)                   | 78 (8.6)                 | 616 (19.5)                       |
| AnyAEleadingtodiscontinuation of olaparibor placebo    | 97 (10.6)                  | 42 (4.6)                 | 306 (9.7)                        |
| Any AE leading to dosereduction of olaparib or placebo | 213 (23.4)                 | 33 (3.7)                 | 711 (22.5)                       |
| Any AE leading tointerruption of olaparib or placebo c | 284 (31.2)                 | 99 (11.0)                | 1191 (37.7)                      |

Patients with multiple events in the same category were counted only once in that category. Patients with

IncludesAEs thatled toadoseinterruption/reductionand didnotlead topermanent discontinuation of study treatment.

IncludesAEswith anonset datebetween the date offirst dose and 30daysfollowing thedate oflast dose of study treatment.

<div style=\"page-break-after: always\"></div>

At DCO2 (12 July 2021), AE causally related to olaparib/placebo were reported in 736 patients (80.8%) and 480 patients (53.1%) in the olaparib and placebo arm respectively.

Table 39: OlympiA: Adverse Events and Event Rate Reported in At Least 5% of Patients in Either Treatment Arm Arranged by System Organ Class and Preferred Term (SAS)

|                                                      | Olaparib 300 mg bd (N=911)   | Olaparib 300 mg bd (N=911)      | Olaparib 300 mg bd (N=911)   | Olaparib 300 mg bd (N=911)       | Placebo (N=904)        | Placebo (N=904)                  | Placebo (N=904)        | Placebo (N=904)                 |
|------------------------------------------------------|------------------------------|---------------------------------|------------------------------|----------------------------------|------------------------|----------------------------------|------------------------|---------------------------------|
|                                                      | 27 Mar 2020 DCO              | 27 Mar 2020 DCO                 | 12 Jul 2021 DCO              | 12 Jul 2021 DCO                  | 27 Mar 2020 DCO        | 27 Mar 2020 DCO                  | 12 Jul 2021 DCO        | 12 Jul 2021 DCO                 |
| System organclass/ MedDRA preferred term             | Number (%) of patients       | Event rate (per1000 pt years) a | Number (%) of patients       | Event rate (per 1000 pt years) a | Number (%) of patients | Event rate (per 1000 pt years) a | Number (%) of patients | Eventrate (per 1000 pt years) a |
| Any AE                                               | 835 (91.7)                   | 7774                            | 836 (91.8)                   | 7790                             | 753 (83.3)             | 3530                             | 756 (83.6)             | 3576                            |
| Gastrointestinal disorders                           | 654 (71.8)                   | 2405                            | 654 (71.8)                   | 2393                             | 427 (47.2)             | 827                              | 429 (47.5)             | 830                             |
| Nausea                                               | 518 (56.9)                   | 1340                            | 518 (56.9)                   | 1335                             | 211 (23.3)             | 303                              | 212 (23.5)             | 303                             |
| Vomiting                                             | 206 (22.6)                   | 305                             | 206 (22.6)                   | 304                              | 74 (8.2)               | 91                               | 74 (8.2)               | 90                              |
| Diarrhoea                                            | 160 (17.6)                   | 226                             | 160 (17.6)                   | 225                              | 124 (13.7)             | 161                              | 124 (13.7)             | 160                             |
| Abdominal pain                                       | 86 (9.4)                     | 111                             | 86 (9.4)                     | 111                              | 68 (7.5)               | 83                               | 68 (7.5)               | 83                              |
| Constipation                                         | 84 (9.2)                     | 108                             | 84 (9.2)                     | 108                              | 77 (8.5)               | 95                               | 78 (8.6)               | 96                              |
| Stomatitis                                           | 81 (8.9)                     | 105                             | 81 (8.9)                     | 104                              | 36 (4.0)               | 43                               | 36 (4.0)               | 43                              |
| Dyspepsia                                            | 55 (6.0)                     | 70                              | 55 (6.0)                     | 69                               | 37 (4.1)               | 44                               | 37 (4.1)               | 44                              |
| General disorders and administration site conditions | 505 (55.4)                   | 1131                            | 505 (55.4)                   | 1129                             | 379 (41.9)             | 671                              | 382 (42.3)             | 677                             |
| Fatigue                                              | 365 (40.1)                   | 665                             | 365 (40.1)                   | 662                              | 245 (27.1)             | 363                              | 246 (27.2)             | 364                             |
| Pain                                                 | 68 (7.5)                     | 86                              | 68 (7.5)                     | 86                               | 74 (8.2)               | 91                               | 74 (8.2)               | 90                              |
| Influenza like illness                               | 57 (6.3)                     | 71                              | 58 (6.4)                     | 72                               | 43 (4.8)               | 51                               | 44 (4.9)               | 52                              |
| Pyrexia                                              | 48 (5.3)                     | 60                              | 48 (5.3)                     | 60                               | 41 (4.5)               | 49                               | 41 (4.5)               | 49                              |
| Nervous system disorders                             | 370 (40.6)                   | 689                             | 370 (40.6)                   | 685                              | 298 (33.0)             | 467                              | 297 (32.9)             | 464                             |
| Headache                                             | 180 (19.8)                   | 258                             | 179 (19.6)                   | 255                              | 152 (16.8)             | 202                              | 152 (16.8)             | 201                             |
| Dysgeusia                                            | 107 (11.7)                   | 144                             | 107 (11.7)                   | 144                              | 38 (4.2)               | 45                               | 38 (4.2)               | 45                              |
| Dizziness                                            | 104 (11.4)                   | 137                             | 104 (11.4)                   | 136                              | 67 (7.4)               | 82                               | 66 (7.3)               | 80                              |
| Infections and infestations                          | 284 (31.2)                   | 446                             | 286 (31.4)                   | 448                              | 305 (33.7)             | 467                              | 306 (33.8)             | 468                             |

<div style=\"page-break-after: always\"></div>

|                                                | Olaparib 300 mg bd (N=911)   | Olaparib 300 mg bd (N=911)      | Olaparib 300 mg bd (N=911)   | Olaparib 300 mg bd (N=911)      | Placebo (N=904)        | Placebo (N=904)                 | Placebo (N=904)        | Placebo (N=904)                |
|------------------------------------------------|------------------------------|---------------------------------|------------------------------|---------------------------------|------------------------|---------------------------------|------------------------|--------------------------------|
|                                                | 27 Mar 2020 DCO              | 27 Mar 2020 DCO                 | 12 Jul 2021 DCO              | 12 Jul 2021 DCO                 | 27 Mar 2020 DCO        | 27 Mar 2020 DCO                 | 12 Jul 2021 DCO        | 12 Jul 2021 DCO                |
| System organ class/ MedDRApreferred term       | Number (%) of patients       | Event rate (per 1000 pt years)a | Number (%) of patients       | Event rate (per 1000 pt years)a | Number (%) of patients | Event rate (per 1000 pt years)a | Number (%) of patients | Eventrate (per 1000 pt years)a |
| Upper respiratory tract infection              | 79 (8.7)                     | 101                             | 79 (8.7)                     | 101                             | 75 (8.3)               | 92                              | 75 (8.3)               | 92                             |
| Nasopharyngitis                                | 31 (3.4)                     | 38                              | 31 (3.4)                     | 38                              | 52 (5.8)               | 63                              | 52 (5.8)               | 62                             |
| Investigations                                 | 282 (31.0)                   | 452                             | 285 (31.3)                   | 456                             | 184 (20.4)             | 252                             | 185 (20.5)             | 253                            |
| Neutrophil count decreased                     | 146 (16.0)                   | 200                             | 147 (16.1)                   | 200                             | 59 (6.5)               | 72                              | 59 (6.5)               | 72                             |
| WBC count decreased                            | 143 (15.7)                   | 197                             | 144 (15.8)                   | 197                             | 52 (5.8)               | 63                              | 52 (5.8)               | 63                             |
| Lymphocytecountdecreased                       | 61 (6.7)                     | 78                              | 62 (6.8)                     | 79                              | 15 (1.7)               | 18                              | 15 (1.7)               | 17                             |
| Musculoskeletalandconnective tissue disorders  | 280 (30.7)                   | 445                             | 280 (30.7)                   | 442                             | 307 (34.0)             | 477                             | 307 (34.0)             | 476                            |
| Arthralgia                                     | 84 (9.2)                     | 109                             | 89 (9.8)                     | 115                             | 107 (11.8)             | 135                             | 114 (12.6)             | 145                            |
| Back pain                                      | 62 (6.8)                     | 79                              | 62 (6.8)                     | 78                              | 74 (8.2)               | 90                              | 73 (8.1)               | 89                             |
| Pain in extremity                              | 62 (6.8)                     | 78                              | 61 (6.7)                     | 76                              | 61 (6.7)               | 74                              | 63 (7.0)               | 76                             |
| Myalgia                                        | 49 (5.4)                     | 61                              | 49 (5.4)                     | 61                              | 49 (5.4)               | 59                              | 49 (5.4)               | 59                             |
| Bloodandlymphaticsystem disorders              | 228 (25.0)                   | 339                             | 229 (25.1)                   | 339                             | 43 (4.8)               | 51                              | 43 (4.8)               | 51                             |
| Anaemia                                        | 214 (23.5)                   | 314                             | 215 (23.6)                   | 314                             | 35 (3.9)               | 41                              | 35 (3.9)               | 41                             |
| Respiratory,thoracic and mediastinal disorders | 170 (18.7)                   | 238                             | 171 (18.8)                   |                                 | 163 (18.0)             | 215                             | 164 (18.1)             | 215                            |
| Cough                                          | 77 (8.5)                     | 98                              | 77 (8.5)                     | 98                              | 73 (8.1)               | 89                              | 73 (8.1)               | 89                             |
| Metabolism and nutrition disorders             | 154 (16.9)                   | 214                             | 155 (17.0)                   | 215                             | 88 (9.7)               | 110                             | 88 (9.7)               | 109                            |
| Decreased appetite                             | 119 (13.1)                   | 160                             | 119 (13.1)                   | 159                             | 53 (5.9)               | 64                              | 53 (5.9)               | 64                             |

|                                            | Olaparib 300 mg bd (N=911)   | Olaparib 300 mg bd (N=911)     | Olaparib 300 mg bd (N=911)   | Olaparib 300 mg bd (N=911)     | Placebo (N=904)        | Placebo (N=904)                | Placebo (N=904)        | Placebo (N=904)                 |
|--------------------------------------------|------------------------------|--------------------------------|------------------------------|--------------------------------|------------------------|--------------------------------|------------------------|---------------------------------|
|                                            | 27Mar 2020DCO                | 27Mar 2020DCO                  | 12 Jul2021 DCO               | 12 Jul2021 DCO                 | 27 Mar 2020 DCO        | 27 Mar 2020 DCO                | 12 Jul2021 DCO         | 12 Jul2021 DCO                  |
| System organ class / MedDRA preferred term | Number (%) of patients       | Eventrate (per 1000 pt years)a | Number (%) of patients       | Eventrate (per 1000 pt years)a | Number (%) of patients | Eventrate (per 1000 pt years)a | Number (%) of patients | Event rate (per 1000 pt years)a |
| Vascular disorders                         | 121 (13.3)                   | 163                            | 121 (13.3)                   | 162                            | 136 (15.0)             | 177                            | 135 (14.9)             | 175                             |
| Hot flush                                  | 72 (7.9)                     | 93                             | 72 (7.9)                     | 92                             | 75 (8.3)               | 93                             | 74 (8.2)               | 91                              |
| Psychiatric disorders                      | 118 (13.0)                   | 156                            | 120 (13.2)                   | 158                            | 128 (14.2)             | 164                            | 128 (14.2)             | 163                             |
| Insomnia                                   | 67 (7.4)                     | 85                             | 67 (7.4)                     | 85                             | 60 (6.6)               | 73                             | 60 (6.6)               | 72                              |

2 For any event, each SOC and each PT, the event rate is presented and was defined as the number of patients with that AE (counting AEs from date of first dose up to 30 days followfng the date of last dose of study treatment) divided by the total number of days at risk across all patients in.a.given group multiplied by 365.25 x 1000.The denominator, total number of days at risk, was,(a) for patients who had the event, the number of days between date of first treatment to start date of the first event,(b)for patients who did not have the event,the number of days between date of first treatment and end of safety follow-up (where end of safety follow-up was defined as the minimum of 30 days following last dose of study treatment, withdrawal and death).

There were 12 patients (6 patients in the olaparib arm and 6 patients in the placebo arm) with 13 pre-existing AEs that worsened after treatment was started who wereincorrectly censored in the calculation of the event rate and were not included in this table.

SOCs sorted by decreasing frequency and by decreasing frequency order in the olaparib arm for PT.

Patients with multiple events in the same category were counted only once in that category.Patients with events in more than one category were counted once in each of those categories.

Includes AEs with an onset date on or after the date of first dose and up to and including 30 days following the date of last dose of olaparib/placebo.

CTCAE Version 4.03.MedDRA Version 22.1 used for 27 March 2020 DCO and MedDRA Version 24.0 used for 12 July 2021 DCO.

AE =Adverse event;bd=Twice daily;CSR =Clinical study report;DCO =Data cut-off, MedDRA =Medical Dictionary for Regulatory Activities;N=Total number of patients; PT = Preferred term; Rt = Patient; SAS = Safety analysis set; SOC = System organ class; WBC = White blood cell.

Source: Table 14.3.2.15,OlvmpiA CSR, Module 5.3.5.1, data on file, and Safety Update Tab1e 14.3.2.15.

<div style=\"page-break-after: always\"></div>

## Comparison with olaparib 300mg bd pool

Table 40 : Most Common AEs (Reported in ≥5% of Patients in the Olaparib Arm of OlympiA or the 300 mg bd Pool; DCO: 12 July 2021)

|                                   | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|-----------------------------------|----------------------------|----------------------------|----------------------------------|
|                                   | OlympiA SAS                | OlympiA SAS                | Olaparib 300 mg bd pool (N=3155) |
| Preferred term                    | Olaparib 300 mg bd (N=911) | Placebo (N=904)            | Olaparib 300 mg bd pool (N=3155) |
| Any AE                            | 836 (91.8)                 | 756 (83.6)                 |                                  |
|                                   |                            |                            | 3024 (95.8)                      |
| Nausea                            | 518 (56.9)                 | 212 (23.5)                 | 1842 (58.4)                      |
| Fatigue                           | 365 (40.1)                 | 246 (27.2)                 | 1238 (39.2)                      |
| Anaemia                           | 215 (23.6)                 | 35 (3.9)                   | 1087 (34.5)                      |
| Vomiting                          | 206 (22.6)                 | 74 (8.2)                   | 904 (28.7)                       |
| Headache                          | 179 (19.6)                 | 152 (16.8)                 | 515 (16.3)                       |
| Diarrhoea                         | 160 (17.6)                 | 124 (13.7)                 | 703 (22.3)                       |
| Neutrophil count decreased        | 147 (16.1)                 | 59 (6.5)                   | 281 (8.9)                        |
| WBC count decreased               | 144 (15.8)                 | 52 (5.8)                   | 284 (9.0)                        |
| Decreased appetite                | 119 (13.1)                 | 53 (5.9)                   | 609 (19.3)                       |
| Dysgeusia                         | 107 (11.7)                 | 38 (4.2)                   | 365 (11.6)                       |
| Dizziness                         | 104 (11.4)                 | 66 (7.3)                   | 367 (11.6)                       |
| Arthralgia                        | 89 (9.8)                   | 114 (12.6)                 | 404 (12.8)                       |
| Abdominal pain                    | 86 (9.4)                   | 68 (7.5)                   | 438 (13.9)                       |
| Constipation                      | 84 (9.2)                   | 78 (8.6)                   | 488 (15.5)                       |
| Stomatitis                        | 81 (8.9)                   | 36 (4.0)                   | 207 (6.6)                        |
| Upper respiratory tract infection | 79 (8.7)                   | 75 (8.3)                   | 242 (7.7)                        |
| Cough                             | 77 (8.5)                   | 73 (8.1)                   | 379 (12.0)                       |
| Hot flush                         | 72 (7.9)                   | 74 (8.2)                   | 132 (4.2)                        |
| Pain                              | 68 (7.5)                   | 74 (8.2)                   | 100 (3.2)                        |
| Insomnia                          | 67 (7.4)                   | 60 (6.6)                   | 215 (6.8)                        |
| Back pain                         | 62 (6.8)                   | 73 (8.1)                   | 339 (10.7)                       |
| Lymphocyte count decreased        | 62 (6.8)                   | 15 (1.7)                   | 112 (3.5)                        |
| Pain in extremity                 | 61 (6.7)                   | 63 (7.0)                   | 199 (6.3)                        |
| Influenza like illness            | 58 (6.4)                   | 44 (4.9)                   | 146 (4.6)                        |

<div style=\"page-break-after: always\"></div>

Table 40 : Most Common AEs (Reported in ≥5% of Patients in the Olaparib Arm of OlympiA or the 300 mg bd Pool; DCO: 12 July 2021)

|                            | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|----------------------------|----------------------------|----------------------------|----------------------------|
|                            | OlympiA SAS                | OlympiA SAS                | Olaparib 300 mg bd pool    |
| Preferred term             | Olaparib 300 mg bd (N=911) | Placebo (N=904)            | (N=3155)                   |
| Dyspepsia                  | 55 (6.0)                   | 37 (4.1)                   | 282 (8.9)                  |
| Myalgia                    | 49 (5.4)                   | 49 (5.4)                   | 163 (5.2)                  |
| Pyrexia                    | 48 (5.3)                   | 41 (4.5)                   | 265 (8.4)                  |
| Abdominal pain upper       | 45 (4.9)                   | 35 (3.9)                   | 230 (7.3)                  |
| Urinary tract infection    | 39 (4.3)                   | 43 (4.8)                   | 240 (7.6)                  |
| Dyspnoea                   | 38 (4.2)                   | 30 (3.3)                   | 303 (9.6)                  |
| Nasopharyngitis            | 31 (3.4)                   | 52 (5.8)                   | 186 (5.9)                  |
| Oedema peripheral          | 25 (2.7)                   | 18 (2.0)                   | 210 (6.7)                  |
| Asthenia                   | 23 (2.5)                   | 12 (1.3)                   | 365 (11.6)                 |
| Blood creatinine increased | 18 (2.0)                   | 3 (0.3)                    | 181 (5.7)                  |
| Thrombocytopenia           | 2 (0.2)                    | 0                          | 167 (5.3)                  |
| Neutropenia                | 0                          | 0                          | 259 (8.2)                  |

Sorted by decreasing order of frequency for PT in the olaparib arm of OlympiA, and then by decreasing order of frequency in the placebo arm.

i

Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

MedDRA Version 24.0.

AE = Adverse event; bd = Twice daily; CSR = Clinical study report; DCO = Data cut-off; MedDRA = Medical Dictionary for Regulatory Activities; N = Total number of patients; PT = Preferred term; SAS = Safety analysis set; WBC = White blood cell.

Source: Safety Update Table 14.3.2.15 and Table 2.7.4.1.1.2.

## CTCAE Grade ≥3 Adverse Events

At DCO2, adverse events of CTCAE Grade ≥3 occurred in 24.5% of patients in the olaparib arm and 11.3% of patients in the placebo arm. Anaemia was the only AE of CTCAE Grade ≥3 reported in ≥5% of patients (8.7% of patients in the olaparib arm vs 0.3% of patients in the placebo arm).

<div style=\"page-break-after: always\"></div>

Table 41 : Most Common AEs of CTCAE Grade ≥3 (Reported in ≥3 Patients in the Olaparib Arm of OlympiA or ≥2% of Patients in the 300 mg bd Pool; DCO: 12 July 2021)

|                                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|------------------------------------------------------|----------------------------|----------------------------|----------------------------------|
|                                                      | OlympiA SAS                | OlympiA SAS                | Olaparib 300 mg bd pool (N=3155) |
| System organ class / MedDRA preferred term           | Olaparib 300 mg bd (N=911) | Placebo (N=904)            | Olaparib 300 mg bd pool (N=3155) |
| Patients with AE of CTCAE Grade ≥3                   | 223 (24.5)                 | 102 (11.3)                 | 1155 (36.6)                      |
| Blood and lymphatic system disorders                 | 86 (9.4)                   | 3 (0.3)                    | 548 (17.4)                       |
| Anaemia                                              | 79 (8.7)                   | 3 (0.3)                    | 462 (14.6)                       |
| Febrile neutropenia                                  | 6 (0.7)                    | 0                          | 12 (0.4)                         |
| Neutropenia                                          | 0                          | 0                          | 85 (2.7)                         |
| Investigations                                       | 70 (7.7)                   | 16 (1.8)                   | 207 (6.6)                        |
| Neutrophil count decreased                           | 45 (4.9)                   | 7 (0.8)                    | 94 (3.0)                         |
| WBC count decreased                                  | 27 (3.0)                   | 3 (0.3)                    | 57 (1.8)                         |
| Lymphocyte count decreased                           | 12 (1.3)                   | 0                          | 24 (0.8)                         |
| ALT increased                                        | 3 (0.3)                    | 1 (0.1)                    | 22 (0.7)                         |
| Infections and infestations                          | 21 (2.3)                   | 18 (2.0)                   | 124 (3.9)                        |
| Mastitis                                             | 3 (0.3)                    | 4 (0.4)                    | 3 (0.1)                          |
| Device related infection                             | 3 (0.3)                    | 2 (0.2)                    | 5 (0.2)                          |
| Gastroenteritis                                      | 3 (0.3)                    | 0                          | 7 (0.2)                          |
| General disorders and administration site conditions | 19 (2.1)                   | 10 (1.1)                   | 132 (4.2)                        |
| Fatigue                                              | 16 (1.8)                   | 6 (0.7)                    | 75 (2.4)                         |
| Gastrointestinal disorders                           | 18 (2.0)                   | 9 (1.0)                    | 178 (5.6)                        |
| Nausea                                               | 7 (0.8)                    | 0                          | 34 (1.1)                         |
| Vomiting                                             | 6 (0.7)                    | 0                          | 35 (1.1)                         |
| Diarrhoea                                            | 3 (0.3)                    | 3 (0.3)                    | 24 (0.8)                         |
| Nervous system disorders                             | 12 (1.3)                   | 7 (0.8)                    | 63 (2.0)                         |
| Syncope                                              | 3 (0.3)                    | 2 (0.2)                    | 13 (0.4)                         |
| Vascular disorders                                   | 8 (0.9)                    | 10 (1.1)                   | 49 (1.6)                         |
| Hypertension                                         | 5 (0.5)                    | 9 (1.0)                    | 20 (0.6)                         |
| Embolism                                             | 3 (0.3)                    | 0                          | 9 (0.3)                          |

<div style=\"page-break-after: always\"></div>

## Serious adverse event/deaths/other significant events

## Serious adverse events

Table 42 : Most Common SAEs (Reported in ≥3 Patients in the Olaparib Arm of OlympiA and/or Reported in ≥2% of Patients in the 300 mg bd Pool; DCO: 12 July 2021)

|                                            | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|--------------------------------------------|----------------------------|----------------------------|----------------------------------|
|                                            | OlympiA SAS                | OlympiA SAS                | Olaparib 300 mg bd pool (N=3155) |
| System organ class / MedDRA preferred term | Olaparib 300 mg bd (N=911) | Placebo (N=904)            |                                  |
| Patients with any SAE                      | 79 (8.7%)                  |                            |                                  |
|                                            |                            | 78 (8.6)                   | 616 (19.5)                       |
| Blood and lymphatic system disorders       | 18 (2.0)                   | 1 (0.1)                    | 164 (5.2)                        |
| Anaemia                                    | 15 (1.6)                   | 1 (0.1)                    | 137 (4.3)                        |
| Febrile neutropenia                        | 3 (0.3)                    | 0                          | 8 (0.3)                          |
| Infections and infestations                | 16 (1.8)                   | 15 (1.7)                   | 122 (3.9)                        |
| Device related infection                   | 3 (0.3)                    | 2 (0.2)                    | 4 (0.1)                          |
| Mastitis                                   | 3 (0.3)                    | 6 (0.7)                    | 3 (0.1)                          |

j Sorted by decreasing order of frequency for SOC and PT in the olaparib arm of OlympiA and then by decreasing order of frequency in the placebo arm.

Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

MedDRA Version 24.0.

AE = Adverse event; bd = Twice daily; CSR = Clinical study report; DCO = Data cut-off; MedDRA = Medical Dictionary for Regulatory Activities; N = Total number of patients; PT = Preferred term; SAE = Serious adverse event; SAS = Safety analysis set; SOC = System organ class.

Source: Safety Update Table 14.3.2.23.1 and Table 2.7.4.1.3.1

## Deaths

At DCO2, 181 patients had died; 75 patients (8.1%) in the olaparib arm and 106 patients (11.6%) in the placebo arm. This represents an additional 36 patients (16 in the olaparib arm and 20 in the placebo arm) who died between DCO1 (27 March 2020) and DCO2 (12 July 2021). Consistent with data at DCO1, the majority of deaths reported in the study were related to the disease under investigation (171 of 181 deaths [94.5%]; 70 patients in the olaparib arm and 101 patients in the placebo arm).  At DCO1, four patients experienced an AE with outcome of death (one patient [1.7%] in the olaparib arm [cardiac arrest] and 3 patients [3.5%] in the placebo arm [acute myeloid leukaemia, leukaemia, and ovarian cancer]) during study treatment or after the 30-day follow up. At DCO2 one additional patient experienced an AE with outcome of death after the 30-day follow up period; this patient was in the placebo arm and had a fatal AE of pancreatic carcinoma.

<div style=\"page-break-after: always\"></div>

Table 43 Patients Who Died in OlympiA and the 300 mg bd Pool (DCO: 12 July 2021)

|                                                                                                                 | Number (%) of patients     | Number (%) of patients   | Number (%) of patients           |
|-----------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------|----------------------------------|
|                                                                                                                 | OlympiA SAS                | OlympiA SAS              | Olaparib 300 mg bd pool (N=3155) |
| Category                                                                                                        | Olaparib 300 mg bd (N=911) | Placebo (N=904)          |                                  |
| Total number of deaths                                                                                          | 75 (8.2)                   | 106 (11.7)               | 958 (30.4)                       |
| Death related to disease under investigation only and no AE with outcome of death                               | 70 (7.7)                   | 101 (11.2)               | 857 (27.2)                       |
| Death not related to disease and AE with outcome of death                                                       | 1 (0.1)                    | 2 (0.2)                  | 21 (0.7)                         |
| Death not related to disease and AE with outcome of death (AE start date falling after 30 day follow-up period) | 1 (0.1) a                  | 2 (0.2)                  | 10 (0.3)                         |
| Death related to disease and an AE with outcome of death                                                        | 0                          | 0                        | 10 (0.3)                         |
| Death related to disease and an AE with outcome of death (AE start date falling after 30 day follow-up period)  | 0                          | 0                        | 1 (0.0)                          |
| Deaths not related to disease and no AE with outcome of death b                                                 | 3 (0.3)                    | 1 (0.1)                  | 59 (1.9)                         |

k In the olaparib arm, the AE with outcome of death (AE start date falling after 30 day follow up period) is the case of AML reported for one Patient.

l Patients who died and were not captured in the earlier categories, see Safety Update Table 2.7.4.1.2.4 for details.

Death related to disease under investigation was determined by the investigator.

Rows are mutually exclusive, patients are only reported in one category.

AE = Adverse event; bd = Twice daily; CSR = Clinical study report; DCO = Data cut-off; N = Total number of patients; SAS = Safety analysis set.

Source: Safety Update Table 2.7.4.1.2.5a and Table 2.7.4.1.2.5b.

<div style=\"page-break-after: always\"></div>

Table 44 OlympiA: All Deaths (FAS)

|                                | Number (%) of patients     | Number (%) of patients     | Number (%) of patients   | Number (%) of patients   |
|--------------------------------|----------------------------|----------------------------|--------------------------|--------------------------|
|                                | Olaparib 300 mg bd (N=921) | Olaparib 300 mg bd (N=921) | Placebo (N=915)          | Placebo (N=915)          |
| Category                       | 27 Mar 2020 DCO            | 12 Jul 2021 DCO            | 27 Mar 2020 DCO          | 12 Jul 2021 DCO          |
| Total number of deaths a       | 59 (6.4)                   | 75 (8.1)                   | 86 (9.4)                 | 106 (11.6)               |
| Primary cause of death b       |                            |                            |                          |                          |
| Breast cancer recurrence       | 55 (93.2)                  | 70 (93.3)                  | 82 (95.3)                | 101 (95.3)               |
| Adverse event                  | 1 (1.7)                    | 1 (1.3)                    | 3 (3.5)                  | 4 (3.8)                  |
| Other c                        | 3 (5.1)                    | 3 (4.0)                    | 1 (1.2)                  | 1 (0.9)                  |
| Missing                        | 0                          | 1 (1.3)                    | 0                        | 0                        |
| Time to death from last dose b |                            |                            |                          |                          |
| ≤ 30 days                      | 5 (8.5)                    | 5 (6.7)                    | 4 (4.7)                  | 4 (3.8)                  |
| >30 days                       | 54 (91.5)                  | 70 (93.3)                  | 82 (95.3)                | 102 (96.2)               |

a As reported on the CRF (Death page).

b Percentages were calculated from the number of patients who died.

c In the olaparib arm other includes pulmonary embolism (1 patient), AML (1 patient) and unknown cause of death (1 patient) and in the placebo arm includes 1 patient with an unknown cause of death.

Table is presented for the Full Analysis Set, (ie, showing treatment as randomised).

AE = Adverse event; bd = Twice daily; CRF = Case Report Form; CSR = Clinical study report; DCO = Data cut-off; FAS = Full analysis set; N = Total number of patients.

Source: Table 14.3.3.1 and Listing 14.3.3.3, OlympiA CSR, Module 5.3.5.1 and Safety Update Table 14.3.3.1.

## Adverse drug reaction

When considering an event as an ADR for inclusion in the product information for olaparib, all available sources of data are considered, including: Non-clinical findings; Class effects; Plausibility in light of the drug's pharmacology (eg, PARP inhibition); Clinical data from individual studies, pooled analyses, and postmarketing  reports:  Comparative  incidence  rates  for  the  event  in  placebo-controlled  trials  and  where relevant, exposure-adjusted analyses, Indirect comparisons between single arm olaparib studies, or pooled datasets  from  the  olaparib  arms  of  multiple  studies,  and  epidemiological  data  in  the  breast  cancer population, Individual case/case series reviews, including assessment of time to onset of events and/or de-challenge/re-challenge  data  (where  available),  confounding  factors  (eg,  concurrent  medications; co-morbidities) and/or the presence or absence of single events which are strongly indicative of an ADR.

The safety profile is based on pooled data from 4098 patients with solid tumours treated with Lynparza monotherapy in clinical trials at the recommended dose.

<div style=\"page-break-after: always\"></div>

Table 45: Frequency of AEs for Events Identified as ADRs Associated with Olaparib Treatment (Tablet Pool and Overall)

|                                                                      | Tablet monotherapy pool N=3155   | Tablet monotherapy pool N=3155   | Overall (tablet and capsule) N=4098   | Overall (tablet and capsule) N=4098   | Overall (tablet and capsule) N=4098   | Overall (tablet and capsule) N=4098   |
|----------------------------------------------------------------------|----------------------------------|----------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| System organ class/ Preferred Term                                   | All CTCAE Grades a n (%)         | CTCAE Grades ≥3 b n (%)          | All CTCAE Grades a n (%)              | Frequency descriptor                  | CTCAE Grades ≥3 b n (%)               | Frequency descriptor                  |
| Blood and lymphatic system disorders                                 |                                  |                                  |                                       |                                       |                                       |                                       |
| Anaemia c                                                            | 1110 (35.2)                      | 466 (14.8)                       | 1403 (34.2)                           | Very common                           | 598 (14.6)                            | Very common                           |
| Neutropenia c                                                        | 536 (17.0)                       | 183 (5.8)                        | 613 (15.0)                            | Very common                           | 211 (5.1)                             | Common                                |
| Thrombocytopenia c                                                   | 299 (9.5)                        | 66 (2.1)                         | 369 (9.0)                             | Common                                | 87 (2.1)                              | Common                                |
| Lymphopenia c                                                        | 180 (5.7)                        | 41 (1.3)                         | 193 (4.7)                             | Common                                | 43 (1.0)                              | Common                                |
| Leukopenia c                                                         | 432 (13.7)                       | 83 (2.6)                         | 492 (12.0)                            | Very common                           | 104 (2.5)                             | Common                                |
| Gastrointestinal disorders                                           |                                  |                                  |                                       |                                       |                                       |                                       |
| Nausea                                                               | 1842 (58.4)                      | 34 (1.1)                         | 2414 (58.9)                           | Very common                           | 57 (1.4)                              | Common                                |
| Vomiting                                                             | 904 (28.7)                       | 35 (1.1)                         | 1233 (30.1)                           | Very common                           | 62 (1.5)                              | Common                                |
| Diarrhoea                                                            | 703 (22.3)                       | 24 (0.8)                         | 919 (22.4)                            | Very common                           | 39 (1.0)                              | Uncommon                              |
| Dyspepsia                                                            | 282 (8.9)                        | 1 (0.0)                          | 438 (10.7)                            | Very common                           | 1 (0.0)                               | Rare                                  |
| Abdominal pain upper                                                 | 230 (7.3)                        | 2 (0.1)                          | 318 (7.8)                             | Common                                | 4 (0.1)                               | Rare                                  |
| Stomatitis c                                                         | 256 (8.1)                        | 9 (0.3)                          | 317 (7.7)                             | Common                                | 12 (0.3)                              | Uncommon                              |
| General disorders and administration site conditions                 |                                  |                                  |                                       |                                       |                                       |                                       |
| Fatigue and asthenia c                                               | 1563 (49.5)                      | 111 (3.5)                        | 2129 (52.0)                           | Very common                           | 172 (4.2)                             | Common                                |
| Immune system disorders                                              |                                  |                                  |                                       |                                       |                                       |                                       |
| Hypersensitivity c                                                   | 26 (0.8)                         | 1 (0.0)                          | 34 (0.8)                              | Uncommon                              | 1 (0.0)                               | Rare                                  |
| Angioedema                                                           | 0                                | 0                                | 3 (0.1) d                             | Rare                                  | -                                     | -                                     |
| Investigations                                                       |                                  |                                  |                                       |                                       |                                       |                                       |
| Blood creatinine increased                                           | 181 (5.7)                        | 1 (0.0)                          | 236 (5.8)                             | Common                                | 3 (0.1)                               | Rare                                  |
| Mean cell volume increased                                           | 8 (0.3)                          | 0                                | 8 (0.2)                               | Uncommon                              | 0                                     | -                                     |
| Metabolism and nutrition disorders                                   |                                  |                                  |                                       |                                       |                                       |                                       |
| Decreased appetite                                                   | 609 (19.3)                       | 18 (0.6)                         | 802 (19.6)                            | Very common                           | 24 (0.6)                              | Uncommon                              |
| Neoplasms benign, malignant and unspecified (incl. cysts and polyps) |                                  |                                  |                                       |                                       |                                       |                                       |
| MDS/AML c,e                                                          | 12 (0.4)                         | 12 (0.4)                         | 15 (0.4)                              | Uncommon                              | 15 (0.4)                              | Uncommon                              |
| Nervous system disorders                                             |                                  |                                  |                                       |                                       |                                       |                                       |

<div style=\"page-break-after: always\"></div>

|                                                 | Tablet monotherapy pool N=3155   | Tablet monotherapy pool N=3155   | Overall (tablet and capsule) N=4098   | Overall (tablet and capsule) N=4098   | Overall (tablet and capsule) N=4098   | Overall (tablet and capsule) N=4098   |
|-------------------------------------------------|----------------------------------|----------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| System organ class/ Preferred Term              | All CTCAE Grades a n (%)         | CTCAE Grades ≥3 b n (%)          | All CTCAE Grades a n (%)              | Frequency descriptor                  | CTCAE Grades ≥3 b n (%)               | Frequency descriptor                  |
| Headache                                        | 515 (16.3)                       | 8 (0.3)                          | 668 (16.3)                            | Very common                           | 10 (0.2)                              | Uncommon                              |
| Dysgeusia c                                     | 443 (14.0)                       | 0                                | 566 (13.8)                            | Very common                           | 0                                     | -                                     |
| Dizziness                                       | 367 (11.6)                       | 3 (0.1)                          | 485 (11.8)                            | Very common                           | 6 (0.1)                               | Uncommon                              |
| Respiratory, thoracic and mediastinal disorders |                                  |                                  |                                       |                                       |                                       |                                       |
| Cough c                                         | 405 (12.8)                       | 4 (0.1)                          | 549 (13.4)                            | Very common                           | 5 (0.1)                               | Uncommon                              |
| Dyspnoea c                                      | 330 (10.5)                       | 26 (0.8)                         | 471 (11.5)                            | Very common                           | 43 (1.0)                              | Common                                |
| Skin and subcutaneous tissue disorders          |                                  |                                  |                                       |                                       |                                       |                                       |
| Rash c                                          | 235 (7.4)                        | 4 (0.1)                          | 342 (8.3)                             | Common                                | 5 (0.1)                               | Uncommon                              |
| Dermatitis c                                    | 14 (0.4)                         | 1 (0.0)                          | 18 (0.4)                              | Uncommon                              | 1 (0.0)                               | Rare                                  |
| Erythema nodosum                                | 2 (0.1)                          | 0                                | 2 (0.0)                               | Rare                                  | 0                                     | -                                     |

d Patients with multiple ADRs are counted once for each grouped term.

e Each patient has only been represented with the maximum reported CTCAE grade within each ADR group.

- f Anaemia includes PTs of anaemia, anaemia macrocytic, erythropenia, haematocrit decreased, haemoglobin decreased, normocytic anaemia, and red blood cell count decreased; Neutropenia includes PTs of febrile neutropenia, neutropenia, neutropenic infection, neutropenic sepsis, and neutrophil count decreased; Thrombocytopenia includes PTs of platelet count decreased and thrombocytopenia; Lymphopenia includes PTs of lymphocyte count decreased and lymphopenia; Leukopenia includes PTs of leukopenia and white blood cell count decreased; Cough includes PTs of cough and productive cough; Stomatitis includes PTs of aphthous ulcer, mouth ulceration, and stomatitis; Fatigue and Asthenia includes PTs of asthenia and fatigue; Hypersensitivity includes PTs of drug hypersensitivity and hypersensitivity; Rash includes PTs of erythema, exfoliative rash, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, and rash pruritic; Dermatitis includes PTs of dermatitis and dermatitis allergic; Dyspnoea includes PTs of dyspnoea and dyspnoea exertional; Dysgeusia includes PTs of dysgeusia and taste disorder; MDS/AML includes PTs of AML, MDS, and myeloid leukaemia.
- g As observed in the post-marketing setting. No cases were observed in the olaparib monotherapy combined therapeutic dose pool, therefore incidence has been determined based on the rule of 3 (3/3988).
- h The incidence of MDS/AML events reported in Table 45 are not the same as reported in Section Myelodysplastic Syndrome/Acute Myeloid Leukaemia and Table 46 . In Table 45 , MDS/AML events are only reported for AEs with an onset date between the date of first dose of continuous treatment and 30 days following the date of last dose of continuous treatment and do not include events based on long-term collection of data beyond treatment discontinuation and 30-day follow-up. In Section Myelodysplastic Syndrome/Acute Myeloid Leukaemia and Table 46 , MDS/AML events are reported based on the long-term collection of data beyond treatment discontinuation and 30-day follow-up.

Includes Adverse Events with an onset date between the date of first dose of continuous treatment and 30 days following the last dose of continuous treatment.

Frequencies of occurrence of adverse reactions are defined as: very common (≥1/10); common (≥1/100 to &lt;1/10); uncommon (≥1/1,000 to &lt;1/100); rare (≥1/10,000 to &lt;1/1000); and very rare (&lt;1/10,000) including isolated reports

ADR = adverse drug reaction; AE = adverse event; AML = acute myeloid leukaemia; CTCAE = Common Terminology Criteria for Adverse Events; DCO = data cut-off; MDS = myelodysplastic syndrome; n = number of patients with an event; N = total number of patients; PT = preferred term.

Source: Safety Update Tables 2.7.4.4.1.1 and 2.7.4.4.6 (DCO 12 July 2021).

<div style=\"page-break-after: always\"></div>

Table 46: Frequency of ADR of MDS/AML in the 300 mg bd Pool and Overall (Olaparib Monotherapy Combined Therapeutic Dose Pool) for All Reported Events

|                                                                     | 300 mg bd pool N=3155   | 300 mg bd pool N=3155   | Overall(olaparibmonotherapy combined therapeuticdose pool[tabletandcapsule]) N=4098   | Overall(olaparibmonotherapy combined therapeuticdose pool[tabletandcapsule]) N=4098   | Overall(olaparibmonotherapy combined therapeuticdose pool[tabletandcapsule]) N=4098   | Overall(olaparibmonotherapy combined therapeuticdose pool[tabletandcapsule]) N=4098   |
|---------------------------------------------------------------------|-------------------------|-------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Systemorganclass/Preferredterm                                      | AllCTCAE Gradesa n (%)  | CTCAE Grades ≥3 b n (%) | AllCTCAE Grades a n (%)                                                               | Frequency descriptor                                                                  | CTCAE Grades ≥3b n (%)                                                                | Frequency descriptor                                                                  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                         |                         |                                                                                       |                                                                                       |                                                                                       |                                                                                       |
| MDS/AMLc                                                            | 28 (0.9)                | 26 (0.8)                | 34 (0.8)                                                                              | Uncommon                                                                              | 32 (0.8)                                                                              | Uncommon                                                                              |

a PatientswithmultipleADRsarecountedonceforeachgroupedterm.

b EachpatienthasonlybeenrepresentedwiththemaximumreportedCTCAEgradewithineachADRgroup.

C MDS/AML includes PTs of AML, MDS, and myeloid leukaemia.

Frequencies of occurrence of adverse reactions are defined as: very common (&gt;1/10), common (&gt;1/100 to &lt;1/10),uncommon (&gt;1/1000 to &lt;1/100),rare (&gt;1/10000to&lt;1/1000),veryrare(&lt;1/10000)includingisolatedreports.

Includes all reported AEs(ie,long-term collection of data beyond treatment discontinuation and 30-dayfollow-up).

ADR= adverse drug reaction; AE= adverse event;AML= acute myeloid leukaemia;bd =twice daily;CTCAE=CommonTerminology Criteria for Adverse Events;DCO=data cut-off;MDS=myelodysplastic syndrome; n=number of patients with an event;N=total number of patients;PT=preferred term.

Source: Tables 2.7.4.4.1.4 and 2.7.4.4.6 (DCO 12 Jul 2021).

Table 47: Frequency of Adverse Laboratory Findings Associated with Olaparib Treatment in the Tablet Pool and Overall

|                                     | Tabletmonotherapypool          | Tabletmonotherapypool          | Overall(tabletandcapsule)      | Overall(tabletandcapsule)      |
|-------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                     | 27Mar2020 DCO                  | 12 Jul 2021 DCO                | 27Mar 2020 DCO                 | 12 Jul 2021 DCO                |
| Laboratoryparameter                 | >2 CTCAE Grade changes n/N (%) | >2 CTCAE Grade changes n/N (%) | >2 CTCAE Grade changes n/N (%) | >2 CTCAE Grade changes n/N (%) |
| Haemoglobin a                       | 632/3018 (20.9)                | 650/3126 (20.8)                | 825/3951 (20.9)                | 843/4059 (20.8)                |
| Neutrophils a                       | 496/2712 (18.3)                | 515/2820 (18.3)                | 615/3636 (16.9)                | 634/3744 (16.9)                |
| Platelets a                         | 130/3017 (4.3)                 | 134/3125 (4.3)                 | 183/3950 (4.6)                 | 187/4058 (4.6)                 |
| Lymphocytes a                       | 756/3007 (25.1)                | 784/3114 (25.2)                | 968/3759 (25.8)                | 996/3866 (25.8)                |
| Leukocytes a                        | 600/3004 (20.0)                | 616/3112 (19.8)                | 749/3937 (19.0)                | 765/4045 (18.9)                |
| Increaseinserum creatinine a        | 414/3018 (13.7)                | 426/3126 (13.6)                | 443/3950 (11.2)                | 455/4058 (11.2)                |
| Increase in mean corpuscularvolumeb | 1472/2723 (54.1)               | 1511/2830 (53.4)               | 1827/3583 (51.0)               | 1866/3690 (50.6)               |

Represents patients who had any 2 Grade change (ie, 0 to 2 or higher, 1 to 3 or higher, or 2 to 4).

b Represents patients who had a change in mean corpuscular volume from low or normal to: &gt;1 x ULN.

CTCAE = Common Terminology Criteria for Adverse Events; DCO = data cut-off; n = number of patients with an event; N = total number of patients; ULN = upper limit of normal.

and Safety Update Tables 2.7.4.4.2.1.1, 2.7.4.4.2.1.3, 2.7.4.4.2.2.1, 2.7.4.4.2.2.3.

<div style=\"page-break-after: always\"></div>

## Haematological Toxicity

## Anaemia

Anaemia is the most common haematological effect reported with olaparib treatment. The proposed product information includes anaemia as an adverse reaction of olaparib therapy. In OlympiA, the majority of events of anaemia were mild or moderate in intensity. Onset was early, generally in the first 3 months of starting olaparib although the risk of developing anaemia remained constant throughout exposure with no evidence of cumulative effect. AEs of anaemia were manageable by interrupting or reducing the olaparib dose or giving blood transfusions or other blood preparations in accordance with local practice. Adverse events of anaemia (grouped term) led to temporary dose interruptions in 11.4% of patients and to dose reduction in 8.5% of patients. In OlympiA, transfusions were reported as either concomitant medications or procedures during treatment and the 30-day follow-up period. Overall, 53 patients (5.8%) in the olaparib arm and 8 patients (0.9%) in the placebo arm received a transfusion, with 16 patients (1.8%) and 2 patients (0.2%) receiving &gt;1 transfusion in the olaparib and placebo arms, respectively.

Between 2 and 3 months, 21 patients (2.3%) in the olaparib arm compared to 0 patients in the placebo arm required a transfusion. Over time, fewer transfusions were observed and at ≥12 months, there were 2 patients (0.2%) in the olaparib arm and 2 patients (0.2%) in the placebo arm who required transfusions. AEs of anaemia requiring discontinuation occurred in 1.8% of olaparib-treated patients and were consistent with the tablet pool.

Table 48: OlympiA and the 300 mg bd Pool: Patients Who Had at least One AE of Anaemia (SAS)

|                                                  | Number (%) of patients     | Number (%) of patients     | Number (%) of patients   | Number (%) of patients   | Number (%) of patients           |
|--------------------------------------------------|----------------------------|----------------------------|--------------------------|--------------------------|----------------------------------|
|                                                  | OlympiA SAS                | OlympiA SAS                | OlympiA SAS              | OlympiA SAS              | Olaparib 300 mg bd pool (N=3155) |
|                                                  | Olaparib 300 mg bd (N=911) | Olaparib 300 mg bd (N=911) | Placebo (N=904)          | Placebo (N=904)          | Olaparib 300 mg bd pool (N=3155) |
| AE category a                                    | 27 Mar 2020 DCO            | 12 Jul 2021 DCO            | 27 Mar 2020 DCO          | 12 Jul 2021 DCO          | 12 Jul 2021 DCO                  |
| Any AE                                           | 216 (23.7)                 | 217 (23.8)                 | 35 (3.9)                 | 35 (3.9)                 | 1110 (35.2)                      |
| Any AE of CTCAE Grade ≥3                         | 79 (8.7)                   | 79 (8.7)                   | 3 (0.3)                  | 3 (0.3)                  | 466 (14.8)                       |
| Any AE with outcome=death                        | 0                          | 0                          | 0                        | 0                        | 0                                |
| Any SAE (including events with outcome=death)    | 15 (1.6)                   | 15 (1.6)                   | 1 (0.1)                  | 1 (0.1)                  | 142 (4.5)                        |
| Any AE leading to dose interruption of treatment | 103 (11.3)                 | 104 (11.4)                 | 2 (0.2)                  | 2 (0.2)                  | 517 (16.4)                       |
| Any AE leading to dose reduction of treatment    | 73 (8.0)                   | 77 (8.5)                   | 2 (0.2)                  | 2 (0.2)                  | 354 (11.2)                       |
| Any AE leading to discontinuation of treatment   | 16 (1.8)                   | 16 (1.8)                   | 0                        | 0                        | 67 (2.1)                         |

<div style=\"page-break-after: always\"></div>

## Neutropenia, Lymphopenia, Thrombocytopenia and Leukopenia

The  incidence  of  other  haematological  effects  associated  with  olaparib  such  as  the  grouped  terms neutropenia,  thrombocytopenia,  leukopenia,  and  lymphopenia  were  low  in  OlympiA.  These  events  are known  ADRs  for  olaparib  and  were  reported  for  a  higher  percentage  of  patients  in  the  olaparib  arm compared with the placebo arm. These events were predominantly Grade 1 or 2 in severity and rarely led to permanent discontinuation of treatment.

Table 49: OlympiA and the 300 mg bd Pool: Patients Who Had at least One AE of Neutropenia (Grouped Term) (SAS)

|                                                | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   |
|------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                                                | QlvmDiA SAS              | QlvmDiA SAS              | QlvmDiA SAS              | QlvmDiA SAS              | Qlaparib                 |
|                                                | Olaparib300mgbd (N=911)  | Olaparib300mgbd (N=911)  | Placebo (N=904)          | Placebo (N=904)          | 300 mg bd pool (N=3155)  |
| AE category a                                  | 27Mar 2020 DCO           | 12 Jul 2021 DCO          | 27Mar2020 DCO            | 12 Jul 2021 DCO          | 12 Jul 2021 DCO          |
| Any AE                                         | 149 (16.4)               | 150 (16.5)               | 60 (6.6)                 | 60 (6.6)                 | 536 (17.0)               |
| Any AE ofCTCAE Grade≥3                         | 47 (5.2)                 | 48 (5.3)                 | 7 (0.8)                  | 7 (0.8)                  | 183 (5.8)                |
| Any AE with outcome=death                      | 0                        | 0                        | 0                        | 0                        | 1 (0.0)                  |
| Any SAE (including events with outcome=death)  | 4 (0.4)                  | 4 (0.4)                  | 0                        | 0                        | 23 (0.7)                 |
| AnyAEleading todoseinterruption of treatment   | 55 (6.0)                 | 55 (6.0)                 | 6 (0.7)                  | 6 (0.7)                  | 211 (6.7)                |
| Any AEleading to dosereduction of treatment    | 40 (4.4)                 | 43 (4.7)                 | 6 (0.7)                  | 6 (0.7)                  | 95 (3.0)                 |
| Any AE leading to discontinuation of treatment | 10 (1.1)                 | 10 (1.1)                 | 1 (0.1)                  | 1 (0.1)                  | 22 (0.7)                 |

C Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

Grouped term consisting of the PTs of agranulocytosis, febrile neutropenia, granulocyte count decreased, granulocytopenia, idiopathic neutropenia, neutropenia, neutropenic infection, neutropenic sepsis, and neutrophil count decreased.

Includes AEswith an onset date between the date of first dose of continuous treatment and 30 days following the date of last dose of continuous treatment.

AE=Adverse event;bd=Twice daily;CSR=Clinical study report;CTCAE=CommonTerminology Criteria for Adverse Events;DCO=Data cut-off; N = Total number of patients; PT =Preferred term; SAE = Serious adverse event;SAS = Safety analysis set.

Source: Table 2.7.4.1.5.1 and Table 2.7.4.1.5.2.13b, Pooled Safety Outputs, Module 5.3.5.3. and Safety Update Table 2.7.4.1.5.2.13a, and Table 2.7.4.1.5.2.13b.

<div style=\"page-break-after: always\"></div>

Table  50:  OlympiA  and  the  300  mg  bd  Pool:  Patients  Who  Had  at  Least  One  AE  of Thrombocytopenia (Grouped Term) (SAS)

|                                                  | Number(%) of patients   | Number(%) of patients   | Number(%) of patients   | Number(%) of patients   | Number(%) of patients             |
|--------------------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|-----------------------------------|
|                                                  | QlymDiASAS (N=911)      | Olaparib 300 mg bd      | Placebo                 | (N=904)                 | Qlaparib. 300 mg bd pool (N=3155) |
| AE category a                                    | 27Mar 2020 DCO          | 12 July 2021 DCO        | 27Mar 2020 DCO          | 12 July 2021 DCO        | 12 July 2021 DCO                  |
| Any AE                                           | 38 (4.2)                | 38 (4.2)                | 11 (1.2)                | 12 (1.3)                | 299 (9.5)                         |
| Any AE of CTCAE Grade ≥3                         | 2 (0.2)                 | 2 (0.2)                 | 1 (0.1)                 | 1 (0.1)                 | 66 (2.1)                          |
| Any AE with outcome=death                        | 0                       | 0                       | 0                       | 0                       | 0                                 |
| Any SAE (including events with outcome=death)    | 0                       | 0                       | 1 (0.1)                 | 1 (0.1)                 | 16 (0.5)                          |
| Any AE leading to dose interruption of treatment | 6 (0.7)                 | 6 (0.7)                 | 1 (0.1)                 | 1 (0.1)                 | 85 (2.7)                          |
| Any AE leading to dose reduction of treatment    | 6 (0.7)                 | 6 (0.7)                 | 1 (0.1)                 | 1 (0.1)                 | 35 (1.1)                          |
| Any AE leading to discontinuation of treatment   | 2 (0.2)                 | 2 (0.2)                 | 0                       | 0                       | 23 (0.7)                          |

Patients with multiple events in the same category were counted only once in that category. Patients with

Grouped term consisting of PTs of platelet count decreased, platelet production decreased, plateletcrit decreased, and thrombocytopenia.

Includes AEs with an onset date between the date of first dose of continuous treatment and 30 days following the date oflast dose of continuous treatment.

AE =Adverse event; bd = Twice daily: CTCAE = Common Terminology Criteria for Adverse Events:

DCO = Data cut-off; N = Total number of patients; PT = Preferred term; SAE = Serious adverse event; SAS = Safety analysis set.

Source: Table 2.7.4.1.5.1, Table 2.7.4.1.5.2.15a, and Table 2.7.4.1.5.2.15b, Pooled Safety Outputs, Module 5.3.5.3 and Safety Update Table 2.7.4.1.5.2.15a, and Table 2.7.4.1.5.2.15b.

<div style=\"page-break-after: always\"></div>

Table 51: OlympiA and the 300 mg bd Pool: Patients Who Had at Least One AE of Lymphopenia (Grouped Term) (SAS)

|                                                  | Number (%)of patients      | Number (%)of patients      | Number (%)of patients   | Number (%)of patients   | Number (%)of patients           |
|--------------------------------------------------|----------------------------|----------------------------|-------------------------|-------------------------|---------------------------------|
|                                                  | QlvmpiA SAS                | QlvmpiA SAS                | QlvmpiA SAS             | QlvmpiA SAS             | Qlaparib 300 mgbd pool (N=3155) |
|                                                  | Olaparib 300 mg bd (N=911) | Olaparib 300 mg bd (N=911) | Placebo (N=904)         | Placebo (N=904)         | Qlaparib 300 mgbd pool (N=3155) |
| AE category a                                    | 27 Mar 2020DCO             | 12 Jul 2021 DCO            | 27 Mar 2020DCO          | 12 Jul 2021 DCO         | 12 Jul 2021 DCO                 |
| Any AE                                           | 63 (6.9)                   | 64 (7.0)                   | 15 (1.7)                | 15 (1.7)                | 180 (5.7)                       |
| Any AE of CTCAE Grade ≥3                         | 11 (1.2)                   | 12 (1.3)                   | 0                       | 0                       | 41 (1.3)                        |
| Any AE with outcome=death                        | 0                          | 0                          | 0                       | 0                       | 0                               |
| Any SAE (including events with outcome=death)    | 0                          | 0                          | 0                       | 0                       | 0                               |
| Any AE leading to dose interruption of treatment | 9 (1.0)                    | 9 (1.0)                    | 0                       | 0                       | 24 (0.8)                        |
| Any AE leading to dose reduction of treatment    | 2 (0.2)                    | 2 (0.2)                    | 0                       | 0                       | 6 (0.2)                         |
| Any AE leading to discontinuation of treatment   | 0                          | 0                          | 0                       | 0                       | 1 (0.0)                         |

Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

Grouped term consisting of the PTs of B-lymphocyte count decreased, lymphocyte count decreased, lymphopenia, and T-lymphocyte count decreased.

Includes AEs with an onset date between the date of first dose of continuous treatment and 30 days following the date of last dose of continuous treatment.

AE = Adverse event: bd = Twice daily; CTCAE = Common Terminology Criteria for Adverse Events;

DCO = Data cut-off; N = Total number of patients; PT = Preferred term; SAE = Serious adverse event; SAS = Safety analysis set.

Source: Table 2.7.4.1.5.1, Table 2.7.4.1.5.2.14a, and Table 2.7.4.1.5.2.14b, Pooled Safety Outputs,

Module 5.3.5.3. and Safety Update Table 2.7.4.1.5.2.14a, and Table 2.7.4.1.5.2.14b.

<div style=\"page-break-after: always\"></div>

Table 52: OlympiA and the 300 mg bd Pool: Patients Who Had at Least One AE of Leukopenia (Grouped Term) (SAS)

|                                                  | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients           |
|--------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|----------------------------------|
|                                                  | QlvmpiA SAS              | QlvmpiA SAS              | QlvmpiA SAS              | QlvmpiA SAS              | Qlaparib 300 mg bd pool (N=3155) |
|                                                  | Olaparib300 mgbd (N=911) | Olaparib300 mgbd (N=911) | Placebo (N=904)          | Placebo (N=904)          | Qlaparib 300 mg bd pool (N=3155) |
| AE category a                                    | 27 Mar 2020DCO           | 12 Jul 2021DCO           | 27 Mar 2020 DCO          | 12 Jul 2021DCO           | 12 Jul 2021 DCO                  |
| Any AE                                           | 153 (16.8)               | 154 (16.9)               | 54 (6.0)                 | 54 (6.0)                 | 432 (13.7)                       |
| Any AE of CTCAE Grade ≥3                         | 27 (3.0)                 | 27 (3.0)                 | 3 (0.3)                  | 3 (0.3)                  | 83 (2.6)                         |
| Any AE with outcome=death                        | 0                        | 0                        | 0                        | 0                        | 0                                |
| Any SAE (including events with outcome=death)    | 0                        | 0                        | 0                        | 0                        | 4 (0.1)                          |
| Any AE leading to dose interruption of treatment | 33 (3.6)                 | 34 (3.7)                 | 3 (0.3)                  | 3 (0.3)                  | 111 (3.5)                        |
| Any AE leading to dose reduction of treatment    | 16 (1.8)                 | 17 (1.9)                 | 3 (0.3)                  | 3 (0.3)                  | 44 (1.4)                         |
| Any AE leading to discontinuation of treatment   | 6 (0.7)                  | 7 (0.8)                  | 1 (0.1)                  | 1 (0.1)                  | 11 (0.3)                         |

Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

Grouped term consisting of the PTs of leukopenia and WBC count decreased.

Includes AEs with an onset date between the date of first dose of continuous treatment and 30 days following the date of last dose of continuous treatment.

AE = Adverse event; bd = Twice daily: CTCAE = Common Terminology Criteria for Adverse Events:

DCO = Data cut-off; N = Total number of patients; PT = Preferred term; SAE = Serious adverse event;

SAS = Safety analysis set; WBC =White blood cell.

Source: Table 2.7.4.1.5.1, Table 2.7.4.1.5.2.16a, and Table 2.7.4.1.5.2.16b, Pooled Safety Outputs,

Module 5.3.5.3 and Safety Update Table 2.7.4.1.5.2.16a, and Table 2.7.4.1.5.2.16b.

## Myelodysplastic Syndrome/Acute Myeloid Leukaemia

MDS/AML is considered an adverse event of special interest (AESI) and an important identified risk for olaparib and events are collected beyond the 30-day safety follow-up for the duration of the survival followup.

A summary of AEs of MDS/AML occurring in OlympiA together with cases in other pivotal studies, the larger olaparib monotherapy therapeutic dose pool, and across the clinical trial programme is shown in Table 53 .

Following the marketing authorisation in December 2014 for olaparib capsules, and as of 15 June 2021, there  have  also  been  reports  of  MDS/AML  from  post-marketing  surveillance,  consistent  with  the characterisation of the events reported from monotherapy clinical studies.

<div style=\"page-break-after: always\"></div>

Table 53 Summary of AEs of MDS/AML Occurring Across the Olaparib Programme

|                                                             |                                                             | Olaparib                      | Olaparib        | Olaparib                      | Olaparib        | Comparator a                  | Comparator a    | Comparator a                  | Comparator a    |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------|-----------------|-------------------------------|-----------------|-------------------------------|-----------------|-------------------------------|-----------------|
|                                                             |                                                             | Numbe r of patient s with AEs | Incide nce b    | Numbe r of patient s with AEs | Incide nce b    | Numbe r of patient s with AEs | Incide nce b    | Numbe r of patient s with AEs | Incide nce b    |
|                                                             |                                                             | 27 Mar 2020 DCO               | 27 Mar 2020 DCO | 12 Jul 2021 DCO               | 12 Jul 2021 DCO | 27 Mar 2020 DCO               | 27 Mar 2020 DCO | 12 Jul 2021 DCO               | 12 Jul 2021 DCO |
| OlympiA N=911 olaparib N=904 placebo                        | Breast cancer                                               | 2                             | 0.2%            | 2                             | 0.2%            | 3                             | 0.3%            | 3                             | 0.3%            |
| POLO N=90 olaparib N=61 placebo                             | Pancreati c cancer, prior platinum                          | 0                             | 0               | 0                             | 0               | 0                             | 0               | 0                             | 0               |
| SOLO2 N=195 olaparib N=99 placebo                           | Ovarian                                                     | 16                            | 8.2%            | 16                            | 8.2%            | 4 c                           | 4.0%            | 4 c                           | 4.0%            |
| PAOLA-1 N=535 olaparib/bevaci zumab N=267 placebo/bevaci    | Ovarian                                                     | 5                             | 0.9%            | 5                             | 0.9%            | 4                             | 1.5%            | 4                             | 1.5%            |
| SOLO3 N=178 olaparib N=76 chemotherapy                      | Ovarian                                                     | 4                             | 2.2%            | 5                             | 2.8%            | 3                             | 3.9%            | 3                             | 3.9%            |
| SOLO1 N=260 olaparib N=130 placebo                          | Ovarian                                                     | 3                             | 1.2%            | 3                             | 1.2%            | 0                             | 0               | 0                             | 0               |
| Study 19 N=136 olaparib N=128 placebo                       | Ovarian                                                     | 2                             | 1.5%            | 2                             | 1.5%            | 1                             | 0.8%            | 1                             | 0.8%            |
| PROfound N=256 olaparib N=130 investigators choice of NHA   | Prostate cancer                                             | 1                             | 0.4%            | 1                             | 0.4%            | 0                             | 0               | 0                             | 0               |
| OlympiAD N=205 olaparib N=91 physician's choice             | Breast cancer, prior platinum                               | 0                             | 0               | 0                             | 0               | 0                             | 0               | 0                             | 0               |
| VIOLETTE N=110 olaparib monotherapy (Patient Population E   | Breast cancer                                               | NA                            | NA              | 0                             | 0               | NA                            | NA              | NA                            | NA              |
| Olaparib monotherapy, 300 mg bd tablet pool N=3155 olaparib | Olaparib monotherapy, 300 mg bd tablet pool N=3155 olaparib | 28                            | 0.9%            | 28                            | 0.9%            | NA                            | NA              | NA                            | NA              |

<div style=\"page-break-after: always\"></div>

| Olaparib monotherapy combined therapeutic dose pool N=4098 olaparib   |   34 | 0.9%   |   34 | 0.8%   | NA   | NA   | NA   | NA   |
|-----------------------------------------------------------------------|------|--------|------|--------|------|------|------|------|
| Entire clinical programme pool d N=17923 olaparib                     |   96 | 0.5%   |   96 | 0.5%   | NA   | NA   | NA   | NA   |

- i The comparator was placebo in OlympiA, POLO, PAOLA-1, SOLO1, SOLO2, and Study 19. The comparator was physician's choice of chemotherapy in OlympiAD (which consisted of either capecitabine, eribulin, or vinorelbine) and SOLO3 (which consisted of either pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan). The comparator was NHA (enzalutamide or abiraterone acetate with prednisone) in PROfound. There was no comparator in VIOLETTE.
- j The percentage of patients experiencing any event of MDS/AML.
- k One of the 4 placebo patients had received olaparib treatment 3 months prior to developing AML.

l As of 15 June 2021.

AE = Adverse event; AML = Acute myeloid leukaemia; bd = Twice daily; CSR = Clinical study report; DCO = Data cut-off; MDS = Myelodysplastic syndrome; N = Total number of patients; NA = Not applicable; NHA = New hormonal agent.

Source: Table 14.3.2.32.1 and Table 14.3.2.33, OlympiA CSR, Module 5.3.5.1 and Table 2.7.4.4.1.4, Pooled Safety Outputs, Module 5.3.5.3 (DCO 27 March 2020); Safety Update Table 2.7.4.4.1.4, Table 14.3.2.32.1 and Table 14.3.2.33 (DCO 12 July 2021); Table 11.3.2.3 and Table 11.3.2.7, POLO CSR Addendum 1, (DCO 21 July 2020); Table 14.3.2.2.1, Appendix 16.2.7.1.1, and Appendix 16.2.7.1.4, SOLO2 CSR Addendum, (DCO 03 February 2020); Table 14.3.2.12 and Appendix 16.2.7.1.1, PAOLA-1 CSR Addendum (DCO 22 March 2020); Table 11.3.4.2.1 and Table 11.3.2.9.4, SOLO3 CSR Addendum (DCO 10 January 2020); SOLO3 CSR Addendum 2 (DCO 16 April 2021); Table 11.3.2.3, SOLO1 CSR (DCO 17 May 2018); Appendix 12.2.7.1.b Study 19 CSR Addendum 3 (DCO 09 May 2016); Table 14.3.2.3.1, PROfound CSR Addendum (DCO 20 March 2020); Table 11.3.2.2 and Table 11.3.2.4, OlympiAD CSR (DCO 09 December 2016), Table 14.3.2.15e, VIOLETTE CSR (DCO 08 November 2019 and 13 November 2020).

## Gastro-intestinal

## Nausea and Vomiting

AEs of nausea and vomiting were reported for a higher percentage of patients in the olaparib arm compared with the placebo arm in OlympiA. These events were predominantly Grades 1 or 2 in severity and rarely led to permanent discontinuation of treatment in the olaparib arm. Of the 18 olaparib-treated patients with DAEs of nausea, 2 were CTCAE Grade 3 events, both of which recovered; 13 events were CTCAE Grade 2 and 3 were Grade 1.

<div style=\"page-break-after: always\"></div>

Table 54 OlympiA and the 300 mg bd Pool: Patients Who Had at Least One AE of Nausea or Vomiting Reported in Any Category (SAS)

|                                                  | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients   | Number (%) of patients             | Number (%) of patients     | Number (%) of patients     | Number (%) of patients   | Number (%) of patients   | Number (%) of patients             |
|--------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------------------------------|----------------------------|----------------------------|--------------------------|--------------------------|------------------------------------|
|                                                  | Nausea                   | Nausea                   | Nausea                   | Nausea                   | Nausea                             | Vomiting                   | Vomiting                   | Vomiting                 | Vomiting                 | Vomiting                           |
|                                                  | OlympiA SAS              | OlympiA SAS              | OlympiA SAS              | OlympiA SAS              | Olapari b 300 mg bd pool (N=31 55) | OlympiA SAS                | OlympiA SAS                | OlympiA SAS              | OlympiA SAS              | Olapar ib 300 mg bd pool (N=31 55) |
|                                                  | Olaparib 300 mg bd       | Olaparib 300 mg bd       |                          |                          | Olapari b 300 mg bd pool (N=31 55) | Olaparib 300 mg bd (N=911) | Olaparib 300 mg bd (N=911) | Placebo                  | Placebo                  | Olapar ib 300 mg bd pool (N=31 55) |
| AE category a                                    | 27 Mar 2020 DCO          | 12 Jul 2021 DCO          | 27 Mar 2020 DCO          | 12 Jul 2021 DCO          | 12 Jul 2021 DCO                    | 27 Mar 2020 DCO            | 12 Jul 2021 DCO            | 27 Mar 2020 DCO          | 12 Jul 2021 DCO          | 12 Jul 2021 DCO                    |
| Any AE                                           | 519 (57.0)               | 519 (57.0)               | 211 (23.3)               | 212 (23.5)               | 1842 (58.4)                        | 206 (22.6)                 | 206 (22.6)                 | 74 (8.2)                 | 74 (8.2)                 | 904 (28.7)                         |
| Any AE of CTCAE Grade ≥3                         | 7 (0.8)                  | 7 (0.8)                  | 0                        | 0                        | 34 (1.1)                           | 6 (0.7)                    | 6 (0.7)                    | 0                        | 0                        | 35 (1.1)                           |
| Any AE with outcome=death                        | 0                        | 0                        | 0                        | 0                        | 0                                  | 0                          | 0                          | 0                        | 0                        | 0                                  |
| Any SAE (including events with outcome=death)    | 1 (0.1)                  | 1 (0.1)                  | 0                        | 0                        | 10 (0.3)                           | 2 (0.2)                    | 2 (0.2)                    | 0                        | 0                        | 17 (0.5)                           |
| Any AE leading to dose interruption of treatment | 50 (5.5)                 | 49 (5.4)                 | 6 (0.7)                  | 6 (0.7)                  | 154 (4.9)                          | 26 (2.9)                   | 26 (2.9)                   | 9 (1.0)                  | 9 (1.0)                  | 132 (4.2)                          |
| Any AE leading to dose reduction of treatment    | 43 (4.7)                 | 43 (4.7)                 | 2 (0.2)                  | 2 (0.2)                  | 93 (2.9)                           | 14 (1.5)                   | 15 (1.6)                   | 2 (0.2)                  | 2 (0.2)                  | 37 (1.2)                           |
| Any AE leading to discontinuation of treatment   | 18 (2.0)                 | 19 (2.1)                 | 3 (0.3)                  | 3 (0.3)                  | 34 (1.1)                           | 7 (0.8)                    | 7 (0.8)                    | 0                        | 0                        | 18 (0.6)                           |

a Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories

Includes AEs with an onset date between the date of first dose of continuous treatment and 30 days following the date of last dose of continuous treatment.

AE = Adverse event; bd = Twice daily; CTCAE = Common Terminology Criteria for Adverse Events; DCO = Data cutoff; N = Total number of patients; SAE = Serious adverse event; SAS = Safety analysis set.

Source: Table 2.7.4.1.5.2.1a, Table 2.7.4.1.5.2.1b, Table 2.7.4.1.5.2.2a, and Table 2.7.4.1.5.2.2b, Pooled Safety Outputs, Module 5.3.5.3 and Safety Update Table 2.7.4.1.5.2.1a, Table 2.7.4.1.5.2.1b, Table 2.7.4.1.5.2.2a, and Table 2.7.4.1.5.2.2b.

## Erythema Nodosum

The AE of erythema nodosum (single PT) has been added as an ADR for olaparib on the basis of data gathered in the post-marketing setting. There were no events of erythema nodosum in the olaparib arm of the OlympiA study.

## Angioedema

The AE of angioedema (single PT) has been added as an ADR for olaparib on the basis of data gathered in the post-marketing setting. There were no events of angioedema in OlympiA or the 300 mg bd pool.

<div style=\"page-break-after: always\"></div>

## Important potential risks

## New Primary Malignancies (NPM)

Excluding events of AML and leukaemia, non-melanoma skin cancers, and histologically-confirmed benign events there were 20 patients (2.2%) reporting 21 NPM events in the olaparib arm and 35 patients (3.9%) reporting 37 NPM events in the placebo arm occurring at any time on treatment or after the 30-day safety follow-up period.

Invasive and non-invasive contralateral breast cancers were reported as AESI when deemed to be new primary cancer by investigator's assessment.

Table 55: OlympiA: New Primary Malignancies (SAS)

|                                              | Number (%) of patients                       | Number (%) of patients                       | Number (%) of patients                       | Number (%) of patients                       |
|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|
|                                              | Olaparib 300 mg bd (N=911)                   | Olaparib 300 mg bd (N=911)                   | Placebo (N=904)                              | Placebo (N=904)                              |
|                                              | 27 Mar 2020 DCO                              | 12 Jul 2021 DCO                              | 27 Mar 2020 DCO                              | 12 Jul 2021 DCO                              |
| Patients with new primary malignancies       | 16 (1.8)                                     | 20 (2.2)                                     | 30 (3.3)                                     | 35 (3.9)                                     |
| AESI reported events (MedDRA preferred term) | AESI reported events (MedDRA preferred term) | AESI reported events (MedDRA preferred term) | AESI reported events (MedDRA preferred term) | AESI reported events (MedDRA preferred term) |
| Breast cancer                                | 4 (0.4)                                      | 7 (0.8)                                      | 6 (0.7)                                      | 7 (0.8)                                      |
| Breast cancer female                         | 0                                            | 0                                            | 3 (0.3)                                      | 4 (0.4)                                      |
| Invasive breast carcinoma                    | 0                                            | 0                                            | 1 (0.1)                                      | 2 (0.2)                                      |
| Invasive ductal breast carcinoma             | 1 (0.1)                                      | 1 (0.1)                                      | 0                                            | 0                                            |
| Intraductal proliferative breast lesion      | 0                                            | 2 (0.2)                                      | 0                                            | 1 (0.1)                                      |
| Invasive lobular breast carcinoma            | 1 (0.1)                                      | 1 (0.1)                                      | 0                                            | 0                                            |
| Lobular breast carcinoma in situ             | 0                                            | 1 (0.1)                                      | 0                                            | 0                                            |
| Second primary malignancy                    | 0                                            | 0                                            | 0                                            | 1 (0.1)                                      |
| Triple negative breast cancer                | 1 (0.1)                                      | 1 (0.1)                                      | 0                                            | 0                                            |
| Cervix carcinoma                             | 0                                            | 0                                            | 1 (0.1)                                      | 1 (0.1)                                      |
| Endometrial adenocarcinoma                   | 1 (0.1)                                      | 1 (0.1)                                      | 1 (0.1)                                      | 1 (0.1)                                      |
| Fallopian tube cancer                        | 0                                            | 1 (0.1)                                      | 2 (0.2)                                      | 3 (0.3)                                      |
| Fallopian tube cancer Stage I                | 0                                            | 0                                            | 0                                            | 1 (0.1)                                      |
| Female reproductive tract carcinoma in situ  | 0                                            | 0                                            | 0                                            | 1 (0.1)                                      |
| Ovarian cancer                               | 0                                            | 0                                            | 4 (0.4)                                      | 5 (0.6)                                      |
| Serous cystadenocarcinoma ovary              | 0                                            | 0                                            | 0                                            | 1 (0.1)                                      |

<div style=\"page-break-after: always\"></div>

|                                                     | Number (%) of patients                              | Number (%) of patients                              | Number (%) of patients                              | Number (%) of patients                              |
|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
|                                                     | Olaparib 300 mg bd (N=911)                          | Olaparib 300 mg bd (N=911)                          | Placebo (N=904)                                     | Placebo (N=904)                                     |
|                                                     | 27 Mar 2020 DCO                                     | 12 Jul 2021 DCO                                     | 27 Mar 2020 DCO                                     | 12 Jul 2021 DCO                                     |
| Ovarian cancer recurrent                            | 1 (0.1)                                             | 1 (0.1)                                             | 0                                                   | 0                                                   |
| Lung adenocarcinoma                                 | 1 (0.1)                                             | 1 (0.1)                                             | 0                                                   | 0                                                   |
| Lung neoplasm malignant                             | 0                                                   | 0                                                   | 1 (0.1)                                             | 3 (0.3)                                             |
| Colorectal cancer                                   | 1 (0.1)                                             | 1 (0.1)                                             | 0                                                   | 0                                                   |
| Gastric Cancer                                      | 0                                                   | 1 (0.1)                                             | 0                                                   | 0                                                   |
| Pancreatic carcinoma a                              | 0                                                   | 0                                                   | 1 (0.1)                                             | 1 (0.1)                                             |
| Rectal cancer                                       | 0                                                   | 0                                                   | 1 (0.1)                                             | 1 (0.1)                                             |
| Malignant melanoma                                  | 1 (0.1)                                             | 1 (0.1)                                             | 3 (0.4)                                             | 3 (0.3)                                             |
| Meningioma b                                        | 1 (0.1)                                             | 1 (0.1)                                             | 0                                                   | 0                                                   |
| Transitional cell carcinoma                         | 0                                                   | 0                                                   | 1 (0.1)                                             | 1 (0.1)                                             |
| Efficacy reported events (efficacy endpoint term) c | Efficacy reported events (efficacy endpoint term) c | Efficacy reported events (efficacy endpoint term) c | Efficacy reported events (efficacy endpoint term) c | Efficacy reported events (efficacy endpoint term) c |
| Contralateral DCIS                                  | 2 (0.2)                                             | 0                                                   | 1 (0.1)                                             | 0                                                   |
| Fallopian tube cancer                               | 1 (0.1)                                             | 0                                                   | 2 (0.2)                                             | 0                                                   |
| Ipsilateral DCIS                                    | 1 (0.1)                                             | 0                                                   | 1 (0.1)                                             | 0                                                   |
| Serous tubular intraepithelial carcinoma in situ    | 0                                                   | 0                                                   | 1 (0.1)                                             | 0                                                   |
| New primary - lung                                  | 0                                                   | 0                                                   | 1 (0.1)                                             | 0                                                   |

- b One patient experienced the serious AE of pancreatic cancer &gt;30 days after their last dose, which was incorrectly shown as non-serious in Listing 16.2.7.1, OlympiA CSR, Module 5.3.5.1 at DCO1 (27 March 2020). This was resolved at DCO2 (12 July 2021).
- c Pathology report of meningotheliomatous meningioma with bone invasion.
- d Events retrieved from the efficacy output, these were not coded to a MedDRA preferred term. Note: at DCO2 (12 July 2021), events previously reported as efficacy events are now reported as safety events.

Patients with multiple AEs were counted once for each preferred term.

Includes AEs with an onset date or that worsened from the first dose date to more than 30 days after date of last dose.

If the investigator considered the efficacy event to be a recurrence (eg, ipsilateral, contralateral breast cancer or DCIS) an AESI was not reported.

Adverse events sorted by frequency in the olaparib arm.

MedDRA Version 22.1 used for 27 March 2020 DCO and MedDRA Version 24.0 used for 12 July 2021 DCO.

AE = Adverse event; AESI = Adverse event of special interest; bd = Twice daily; DCIS = Ductal carcinoma in situ; DCO = Data cut-off; MedDRA = Medical Dictionary for Regulatory Activities; N = Total number of patients; SAS = Safety analysis set.

Source: Table 14.2.14, Table 14.3.2.32.1 and Table 14.3.2.33, OlympiA CSR, Module 5.3.5.1; Table 2832.3, Appendix 16.1.13, OlympiA CSR, Module 5.3.5.1; Safety Update Table 14.3.2.32.1, Table 14.3.2.33, and Listing 2970.3.1.

<div style=\"page-break-after: always\"></div>

New primary malignancies were identified from safety and efficacy outputs. Adverse events of special interest in the SOC Neoplasms benign, malignant and unspecified (including cysts and polyps) with onset date ≤30 days following date of last study treatmen t were identified in 6 patients (0.7%) in the olaparib arm and 18 patients (2%) in the placebo arm and with onset &gt;30 days after treatment end date in 19 patients (2.1%) in the olaparib arm and 27 patients (3%) in the placebo arm.

Table  56:  Summary  of  AEs  of  New  Primary  Malignancies  Occurring  Across  the  Olaparib Programme

|                                                                |                                  | Olaparib                    | Olaparib      | Olaparib                    | Olaparib       | Comparator a                | Comparator a   | Comparator a                | Comparator a   |
|----------------------------------------------------------------|----------------------------------|-----------------------------|---------------|-----------------------------|----------------|-----------------------------|----------------|-----------------------------|----------------|
|                                                                |                                  | Number of patients with AEs | Incidence b   | Number of patients with AEs | Incidenceb     | Number of patients with AEs | Incidence b    | Number of patients with AEs | Incidence b    |
|                                                                |                                  | 27Mar2020 DCO               | 27Mar2020 DCO | 12 Jul2021 DCO              | 12 Jul2021 DCO | 27Mar2020DCO                | 27Mar2020DCO   | 12 Jul2021 DCO              | 12 Jul2021 DCO |
| QlvmpiA N=911 olaparib N=904 placebo                           | Breast cancer                    | 16                          | 1.8%          | 20                          | 2.2%           | 30                          | 3.3%           | 35                          | 3.9%           |
| POLO N=90 olanarib N=61 placebo                                | Pancreatic cancer,prior platinum | 0                           | 0             | 0                           | 0              | 0c                          | 0              | 0c                          | 0              |
| SOLO2 N=195 olaparib N=99 placebo                              | Ovarian                          | 7                           | 3.6%          | 7                           | 3.6%           | 3                           | 3.0%           | 3                           | 3.0%           |
| Study 19 N=136 olararib N=128 placebo                          | Ovarian                          | 4                           | 2.9%          | 4                           | 2.9%           | 1                           | 0.8%           | 1                           | 0.8%           |
| SOLO3 N=178 olararib N=76 chemotherapy                         | Ovarian                          | 3                           | 1.7%          | 4                           | 2.2%           | 0                           | 0              | 1                           | 1.3%           |
| SOL01 N=260olararib N=130 placebo                              | Ovarian                          | 5                           | 1.9%          | 5                           | 1.9%           | 3                           | 2.3%           | 3                           | 2.3%           |
| PAOLA-1 N=535 olaparib/bevacizuma b N=267 placebo/bevacizuma b | Ovarian                          | 13                          | 2.4%          | 13                          | 2.4%           | 5                           | 1.9%           | 5                           | 1.9%           |

<div style=\"page-break-after: always\"></div>

|                                                                        |                                                                  | Olaparib                    | Olaparib     | Olaparib                    | Olaparib      | Comparator a               | Comparator a   | Comparator a                | Comparator a   |
|------------------------------------------------------------------------|------------------------------------------------------------------|-----------------------------|--------------|-----------------------------|---------------|----------------------------|----------------|-----------------------------|----------------|
|                                                                        |                                                                  | Number of patients with AEs | Incidenceb   | Number of patients with AEs | Incidence b   | Number of patients withAEs | Incidenceb     | Number of patients with AEs | Incidence b    |
|                                                                        |                                                                  | 27Mar2020DCO                | 27Mar2020DCO | 12 Jul2021DCO               | 12 Jul2021DCO | 27Mar2020DCO               | 27Mar2020DCO   | 12 Jul2021DCO               | 12 Jul2021DCO  |
| QlvmpiAD N=205 olaratib N=91 physician’s choice                        | Breast cancer, prior platinum                                    | 1                           | 0.5%         | 1                           | 0.5%          | 0                          | 0              | 0                           | 0              |
| PROfound N=256olararib N=130 investigators choice of NHA               | Prostate cancer                                                  | 1                           | 0.4%         | 1                           | 0.4%          | 2                          | 1.5%           | 2                           | 1.5%           |
| VIOLETTE N=110 olararib monotherapy (Patient Population E [Stratum A]) | Breast cancer                                                    | NA                          | NA           | 0                           | 0             | NA                         | NA             | NA                          | NA             |
| Olaparibmonotherapycombined therapeutic dose poo1 N=4098olaparib       | Olaparibmonotherapycombined therapeutic dose poo1 N=4098olaparib | 41                          | 1.0%         | 46                          | 1.1%          | NA                         | NA             | NA                          | NA             |
| Entire clinical programme poo1 d N=17923olanarib                       | Entire clinical programme poo1 d N=17923olanarib                 | 115                         | 0.6%         | 115                         | 0.6%          | NA                         | NA             | NA                          | NA             |

The comparator was placebo in QlvmpiA, POLO, PAOLA-1, SOLO1, SOLO2, and Study 19. The comparator was phvsicians choice of chemotherapy in QlvmpiAD （which consisted of either canecitabine.eribulin.or yinorelbine) and SOLO3(whichconsisted of either pegylated liposomal doxorubicin. Daclitaxel.gemcitabine.or topotecan).The comparator was NHA (enzalutamide or abiraterone acetate with prednisone) in PROfound

Areview of AEs that started &gt;30days following thelast doseof study treatment showed that 2placebo-treated patients hadAEs that were potential new primary malignancies(one patient had an AE ofrectal cancer that was CTCAE Grade 2 and one patient was reported to have metastatic ovarian cancer as primary cause of death; both events occurred more than 300 days after the last dose of placebo treatment).These AEs are not included in the table as they were not actively solicited.

## P As of 15 June 2021.

Note that events of tumour pain and benign malignancies were excluded from this analysis.

AE = Adverse event; CSR = Clinical study report; CTCAE = Common Terminology Criteria for Adverse Events; DCO = Data cut-off; N = Total number of patients; NA =Not applicable; NHA =New hormonal agent.

(DCO 21 July 2020); Table 14.3.2.2.1 and Table 14.3.2.3, SOLO2 CSR Addendum (DCO: 03 February 2020); Table 14.3.2.3, PAOLA-1 CSR Addendum (DCO (DCO 10 October 2018); SOLO3 CSR Addendum 2 (DCO 16 April 2021); Table 14.3.2.3.1 PRQfound CSR Addendum (DCO 20 March 2020); Table 14.3.2.15e, VIOLETTE CSR (DCO 08 November 2019 and 13 November 2020); Safety Update Listing 2970.3.1 (DCO 12 July 2021).

<div style=\"page-break-after: always\"></div>

Information was drawn from a larger pool of olaparib studies (olaparib monotherapy combined therapeutic dose  pool,  n=3988)  as  well  as  from  all  patients  exposed  to  olaparib  during  clinical  development  (ie, including data from ongoing studies, blinded studies, combination studies, ESRs, and the MAP) with data for 17923 patients (as of 15 June 2021). In this population, there have been 115 reports of NPMs out of a total  of  17923 patients estimated to have received olaparib in the clinical study programme, giving an estimated cumulative incidence of 0.6%.

## Pneumonitis

Adverse events of pneumonitis were routinely collected on-treatment and during the  30-day follow-up period only per protocol. Pneumonitis AEs were not actively solicited beyond the end of the 30-day followup period. At DCO2 (12 July 2021), 9 patients (1.0%) in the olaparib arm and 11 patients (1.2%) in the placebo arm had AEs of pneumonitis on treatment or during the safety follow-up period. One patient in the placebo arm had an AE of radiation pneumonitis after the 30-day follow up period.

Table 57: Summary of AEs of Pneumonitis Occurring Across the Olaparib Programme

|                                                              |                               | Olaparib                    | Olaparib       | Olaparib                    | Olaparib       | Comparatora                 | Comparatora    | Comparatora                 | Comparatora    |
|--------------------------------------------------------------|-------------------------------|-----------------------------|----------------|-----------------------------|----------------|-----------------------------|----------------|-----------------------------|----------------|
|                                                              |                               | Number of patients with AEs | Incidence b    | Number of patients with AEs | Incidence b    | Number of patients with AEs | Incidence b    | Number of patients with AEs | Incidence b    |
|                                                              |                               | 27Mar 2020 DCO              | 27Mar 2020 DCO | 12 Jul2021 DCO              | 12 Jul2021 DCO | 27Mar 2020 DCO              | 27Mar 2020 DCO | 12 Jul2021 DCO              | 12 Jul2021 DCO |
| QlvmpiA N=911 olararib N=904 placebo                         | Breast cancer                 | 9                           | 1.0%           | 9                           | 1.0%           | 11                          | 1.2%           | 11c                         | 1.2%           |
| QlvmpiAD N=205 olaparib N=91 physician’s choice              | Breast cancer, prior platinum | 0                           | 0              | 0                           | 0              |                             | 0              | 0                           | 0              |
| SOLO2 N=195 olaparib N=99 placebo                            | Ovarian                       |                             | 1.5%           | 3                           | 1.5%           | 0                           | 0              | 0                           | 0              |
| Study 19 N=136 olaparib N=128 placebo                        | Ovarian                       | 1                           | 0.7%           | 1                           | 0.7%           | 1                           | 0.8%           | 1                           | 0.8%           |
| SOL03 N=178olaparib N=76chemotherapy                         | Ovarian                       | 0                           | 0              | 0                           | 0              | 0                           | 0              | 0                           | 0              |
| SOL01 N=260 olaparib N=130 placebo                           | Ovarian                       | 5                           | 1.9%           | 5                           | 1.9%           | 0                           | 0              | 0                           | 0              |
| PAOLA-1 N=535 olaparib/bevacizumab N=267 placebo/bevacizumab | Ovarian                       | 6                           | 1.1%           | 6                           | 1.1%           | 0                           | 0              | 0                           | 0              |

<div style=\"page-break-after: always\"></div>

|                                                                      |                                                                      | Olaparib                    | Olaparib     | Olaparib                    | Olaparib       | Comparatora                 | Comparatora   | Comparatora                 | Comparatora    |
|----------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------|--------------|-----------------------------|----------------|-----------------------------|---------------|-----------------------------|----------------|
|                                                                      |                                                                      | Number of patients with AEs | Incidenceb   | Number of patients with AEs | Incidenceb     | Number of patients with AEs | Incidenceb    | Number of patients with AEs | Incidence b    |
|                                                                      |                                                                      | 27Mar2020DCO                | 27Mar2020DCO | 12 Jul2021 DCO              | 12 Jul2021 DCO | 27Mar2020DCO                | 27Mar2020DCO  | 12 Jul2021 DCO              | 12 Jul2021 DCO |
| POLO N=90 olanarib N=61 placebo                                      | Pancreatic cancer, prior platinum                                    | 2                           | 2.2%         | 2                           | 2.2%           | 0                           | 0             | 0                           | 0              |
| PROfound N=256 olararib N=130 investigators choice of NHA            | Prostate cancer                                                      | 5                           | 2.0%         | 5                           | 2.0%           | 2                           | 1.5%          | 2                           | 1.5%           |
| VIOLETTE N=110 olararib monotherapy (PatientPopulationE [Stratum A]  | Breast cancer                                                        | NA                          | NA           | 1                           | 0.9%           | NA                          | NA            | NA                          | NA             |
| Olaparib monotherapy combined therapeutic dose poo1 d N=4098olaparib | Olaparib monotherapy combined therapeutic dose poo1 d N=4098olaparib | 35                          | 0.9%         | 37                          | 0.9%           | NA                          | NA            | NA                          | NA             |

The compatator was placebo in QlvmpiA, POLO, PAOLA-1, SOLO1, SOLO2, and Study 19. The comparator was phvsician's choice of chemotherapy in QlvmpiAD (which consisted of either canecitabine. eribulin. or yinorelbine) and SOLO3 (which consisted of either peeylated liposomal doxorubicin. paclitaxel.gemcitabine.or topotecan).The comparator was NHA （enzalutamide or abiraterone acetate with prednisone) inPROfound

This table includes events that occurred up to the end of the 30-day follow up period. In QlvmpiAone additional patient in the placebo arm reported a pneumonitisevent after the30-dayfollowupperiod.

d As of 15 June 2021.

AE = Adverse event; CSR = Clinical study report; DCO = Data cut-off; N = Total number of patients; NA = Not applicable; NHA = New hormonal agent. Source: Table 14.3.2.32.1 and Table 14.3.2.33,QlvmpiA CSR, Module 5.3.5.1 (DCO 27 March 2020); Safety Update Table 14.3.2.32.1 and Table 14.3.2.33 (DCO 12 July 2021); Table 11.3.2.3,POLO CSR Addendum 1, (DCO 21 July 2020); Table 14.3.2.2.1,SOLO2 CSR Addendum (DCO 03 February 2020); Table 14.3.2.3, PAOLA-1 CSR Addendum (DCO 22 March 2020); Table 11.3.2.5, SOLO1 CSR (DCO 17 May 2018); Table 11.3.2.5.1 and Appendix 12.2.7.1.b, Study 19 CSR Addendum 3 (DCO 09 May 2016); Appendix 12.2.5.1.1, Appendix 12.2.7.1.1, and Appendix 12.2.7.1.2, OlvmpiAD CSR (DCO 09 December CSR Addendum (DCO 20 March 2020); Table 14.3.2.15e,VIOLETTE CSR (DCO 08 November 2019 and 13 November 2020).

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Haematology

Changes in the laboratory values for the haematology parameters of haemoglobin, neutrophils, platelets, and lymphocytes are considered ADRs for olaparib. The number and proportion of patients with maximum overall CTCAE Grade during treatment for selected haematology values are shown in the table below.

Table 58: OlympiA: Number (%) of Patients with Maximum Overall CTCAE Grade During Treatment for Key Haematology Parameters (SAS; DCO: 12 July 2021)

|                    | Maximum overall CTCAEgradeduring treatmentn/N(%)a   | Maximum overall CTCAEgradeduring treatmentn/N(%)a   | Maximum overall CTCAEgradeduring treatmentn/N(%)a   | Maximum overall CTCAEgradeduring treatmentn/N(%)a   | Maximum overall CTCAEgradeduring treatmentn/N(%)a   |
|--------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Parameter decease  | Grade 0                                             | Grade 1                                             | Grade 2                                             | Grade 3                                             | Grade 4                                             |
| Haemoglobin        |                                                     |                                                     |                                                     |                                                     |                                                     |
| Olaparib 300 mg bd | 315/899 (35.0)                                      | 410/899 (45.6)                                      | 102/899 (11.3)                                      | 72/899 (8.0)                                        |                                                     |
| Placebo            | 616/895 (68.8)                                      | 260/895 (29.1)                                      | 11/895 (1.2)                                        | 8/895 (0.9)                                         | 0                                                   |
| Lymphocytes        |                                                     |                                                     |                                                     |                                                     |                                                     |
| Olaparib 300 mg bd | 205/898 (22.8)                                      | 268/898 (29.8)                                      | 308/898 (34.3)                                      | 111/898 (12.4)                                      | 6/898 (0.7)                                         |
| Placebo            | 364/893 (40.8)                                      | 310/893 (34.7)                                      | 186/893 (20.8)                                      | 31/893 (3.5)                                        | 2/893 (0.2)                                         |
| Neutrophils        |                                                     |                                                     |                                                     |                                                     |                                                     |
| Olaparib 300 mg bd | 544/893 (60.9)                                      | 143/893 (16.0)                                      | 148/893 (16.6)                                      | 52/893 (5.8)                                        | 6/893 (0.7)                                         |
| Placebo            | 656/894 (73.4)                                      | 130/894 (14.5)                                      | 98/894 (11.0)                                       | 9/894 (1.0)                                         | 1/894 (0.1)                                         |
| Leukocytes         |                                                     |                                                     |                                                     |                                                     |                                                     |
| Olaparib 300 mg bd | 324/895 (36.2)                                      | 283/895 (31.6)                                      | 243/895 (27.2)                                      | 44/895 (4.9)                                        | 1/895 (0.1)                                         |
| Placebo            | 520/890 (58.4)                                      | 265/890 (29.8)                                      | 99/890 (11.1)                                       | 5/890 (0.6)                                         | 1/890 (0.1)                                         |
| Platelets          |                                                     |                                                     |                                                     |                                                     |                                                     |
| Olaparib 300 mg bd | 760/899 (84.5)                                      | 126/899 (14.0)                                      | 10/899 (1.1)                                        | 1/899 (0.1)                                         | 2/899 (0.2)                                         |
| Placebo            | 828/895 (92.5)                                      | 60/895 (6.7)                                        | 4/895 (0.4)                                         | 2/895 (0.2)                                         | 1/895 (0.1)                                         |

Derived from laboratory assessments between the start of treatment and up to and including 30 days following the date of last dose of study treatment. N=totalnumberofpatientsevaluable atbaseline.

CTCAE Version 4.03. CTCAE grade: 1 = Mild AE; 2 = Moderate AE; 3 = Severe AE; 4 = Life-threatening or disabling AE; 5 = Death related to AE.

bd =Twice daily; CSR = Clinical study report; CTCAE = Common Terminology Criteria for Adverse Events;DCO = Data cut-off; N=Total number of patients; n = Number of patients at each grade; SAS = Safety analysis set.

Source:SafetyUpdateTable14.3.4.4.

## Clinical Chemistry

A  summary  of  maximum  overall  CTCAE  grade  during  treatment  for  key  clinical  chemistry  parameters (creatinine, bilirubin, ALT, AST, and ALP) is presented in Table 59 . Changes in clinical chemistry parameters were generally mild or moderate and transient. In the majority of patients, the maximum CTCAE Grade was 0, 1, or 2 in both treatment arms. The proportion of patients with Grade 3 or 4 values was similar in the olaparib and placebo treatment arms.

<div style=\"page-break-after: always\"></div>

Table 59: OlympiA: Number (%) of Patients with Maximum Overall CTCAE Grade During Treatment for Key Clinical Chemistry Parameters (SAS; DCO: 27 March 2020)

|                    | MaximumoverallCTCAEgradeduringtreatmentn/N(%)a   | MaximumoverallCTCAEgradeduringtreatmentn/N(%)a   | MaximumoverallCTCAEgradeduringtreatmentn/N(%)a   | MaximumoverallCTCAEgradeduringtreatmentn/N(%)a   | MaximumoverallCTCAEgradeduringtreatmentn/N(%)a   |
|--------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
| Parameter          | Grade 0                                          | Grade 1                                          | Grade 2                                          | Grade 3                                          | Grade 4                                          |
| Creatinine         |                                                  |                                                  |                                                  |                                                  |                                                  |
| Olaparib 300 mg bd | 742/898 (82.6)                                   | 150/898 (16.7)                                   | 6/898 (0.7)                                      | 0                                                | 0                                                |
| Placebo            | 829/893 (92.8)                                   | 62/893 (6.9)                                     | 1/893 (0.1)                                      | 0                                                | 1/893 (0.1)                                      |
| Bilirubin          |                                                  |                                                  |                                                  |                                                  |                                                  |
| Olaparib300mgbd    | 845/896 (94.3)                                   | 39/896 (4.4)                                     | 10/896 (1.1)                                     | 2/896 (0.2)                                      | 0                                                |
| Placebo            | 821/893 (91.9)                                   | 59/893 (6.6)                                     | 11/893 (1.2)                                     | 2/893 (0.2)                                      | 0                                                |
| ALT                |                                                  |                                                  |                                                  |                                                  |                                                  |
| Olaparib 300 mg bd | 759/898 (84.5)                                   | 130/898 (14.5)                                   | 4/898 (0.4)                                      | 4/898 (0.4)                                      | 1/898 (0.1)                                      |
| Placebo            | 670/893 (75.0)                                   | 210/893 (23.5)                                   | 8/893 (0.9)                                      | 5/893 (0.6)                                      | 0                                                |
| AST                |                                                  |                                                  |                                                  |                                                  |                                                  |
| Olaparib300mgbd    | 769/895 (85.9)                                   | 118/895 (13.2)                                   | 1/895 (0.1)                                      | 7/895 (0.8)                                      | 0                                                |
| Placebo            | 704/891 (79.0)                                   | 172/891 (19.3)                                   | 8/891 (0.9)                                      | 6/891 (0.7)                                      | 1/891 (0.1)                                      |
| ALP                |                                                  |                                                  |                                                  |                                                  |                                                  |
| Olaparib300mgbd    | 718/898 (80.0)                                   | 177/898 (19.7)                                   | 3/898 (0.3)                                      | 0                                                | 0                                                |
| Placebo            | 642/892 (72.0)                                   | 244/892 (27.4)                                   | 6/892 (0.7)                                      | 0                                                | 0                                                |

Increases in creatinine

Mild  elevations  in  creatinine  have  been  observed  with  no  apparent  sequelae  and  with  resolution  on discontinuing olaparib, with no change in other renal function biochemistry tests (urea/blood urea nitrogen).

At the time of DCO1, No patients in the olaparib arm had CTCAE Grade 3 or 4 creatinine compared with 1 patient (0.1%) in the placebo arm who had CTCAE Grade 4 creatinine.

Three patients (0.3%) in the olaparib arm of the OlympiA study had a 2 grade increase from baseline in laboratory values for creatinine during the study, compared with 1 patient (0.1%) in the placebo arm; no patients in either arm had a 3 grade increase from baseline and no patients in the olaparib arm had a 4 grade increase from baseline compared with 1 patient (0.1%) in the placebo arm.

Laboratory values for creatinine showed an early increase: the median change in creatinine from baseline to Week 2 for patients in the olaparib arm was 8.8 μmol/L compared with no change for patients in the placebo arm.

## Potential for Drug-induced Liver Injury

There were no confirmed or suspected Hy's Law cases. No patients in the olaparib arm of OlympiA had concurrent elevations of bilirubin and ALT/AST. Although 2 patients in the placebo arm had concurrent elevations of ALT or AST and bilirubin, there were alternative explanations for the elevated liver function test results in these patients.

Data for OlympiA and the 300 mg bd tablet pool have been summarised according to the following categories for ALT and AST: ≤ 3 × ULN, &gt;3 × ULN to ≤ 5 × ULN, &gt;5 × ULN to ≤ 10 × ULN, &gt;10 × ULN to ≤ 20 × ULN, and &gt;20 × ULN.

Table 60: OlympiA: Maximum value during continuous treatment for Aspartate Aminotransferase and Alanine Aminotransferase Safety Analysis Set (DCO: 27 March 2020)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Safety in special populations

## Effect of Race

The safety profile in the 300 mg bd pool for olaparib in White, Asian, and other non-White patients was generally similar. Safety data are presented for the 713 non-White patients who received the proposed dose of 300 mg bd as a monotherapy in the 300 mg bd pool (Table 61).

The most common ( ≥ 20% patients) AEs in the Asian patient population were nausea, anaemia, vomiting, fatigue, WBC count decreased, decreased appetite, and neutrophil count decreased. The most common ( ≥ 20% patients) AEs in the other non-White patient population were nausea, fatigue, anaemia, diarrhoea, constipation, decreased appetite, and vomiting.

Adverse events that occurred at a higher incidence in Asian patients ( ≥ 5  percentage points difference) compared with White patients were: ALT increased, anaemia, AST increased, decreased appetite, malaise, neutrophil count decreased, platelet count decreased, upper respiratory tract infection, and WBC count decreased. Adverse events that occurred at a lower incidence in Asian patients ( ≥ 5 % difference) compared with  White  patients  were:  abdominal  pain,  arthralgia,  asthenia,  back  pain,  constipation,  diarrhoea, dyspnoea, fatigue, headache, and urinary tract infection.

Adverse events that occurred at a higher incidence in other non-White patients ( ≥ 5 percentage points difference) compared with White patients were anaemia, constipation, decreased appetite, hypertension, hypokalaemia, and oedema peripheral. Adverse events that occurred at a lower incidence in other nonWhite patients ( ≥ 5 percentage points difference) compared with White patients were asthenia, nausea, and vomiting.

<div style=\"page-break-after: always\"></div>

Table 61: 300 mg bd Pool: Number (%) of Patients Who Had at Least One AE in Any Category by Race (White Patients, Asian Patients, and Other Non-White Patients)

|                                                        | Number(%)of patients   | Number(%)of patients     | Number(%)of patients   | Number(%)of patients    | Number(%)of patients   | Number(%)of patients    |
|--------------------------------------------------------|------------------------|--------------------------|------------------------|-------------------------|------------------------|-------------------------|
|                                                        |                        |                          | Non-White patients b   | Non-White patients b    | Non-White patients b   | Non-White patients b    |
|                                                        | White patients         | White patients           | Asian patients         | Asian patients          | Otherpatients          | Otherpatients           |
| AE category a                                          | 27Mar2020 DCO (N=2307) | 12 Jul 2021 DCO (N=2385) | 27Mar2020 DCO (N=620)  | 12 Jul 2021 DCO (N=633) | 27Mar2020 DCO (N=93)   | 12 Jul 2021 DCO (N=100) |
| Any AE                                                 | 2209 (95.8)            | 2284 (95.8)              | 596 (96.1)             | 608 (96.1)              | 89 (95.7)              | 96 (96.0)               |
| Any AEofCTCAE Grade≥3                                  | 822 (35.6)             | 856 (35.9)               | 240 (38.7)             | 241 (38.1)              | 40 (43.0)              | 42 (42.0)               |
| Any AE with outcome=death                              | 23 (1.0)               | 25 (1.0)                 | 6 (1.0)                | 6 (0.9)                 | 0                      | 0                       |
| Any SAE (including events with outcome=death)          | 466 (20.2)             | 483 (20.3)               | 111 (17.9)             | 112 (17.7)              | 13 (14.0)              | 14 (14.0)               |
| Any AE 1eading to dose interruption of study treatment | 873 (37.8)             | 897 (37.6)               | 248 (40.0)             | 253 (40.0)              | 30 (32.3)              | 30 (30.0)               |
| Any AE 1eading to dose reduction of study treatment    | 514 (22.3)             | 534 (22.4)               | 147 (23.7)             | 148 (23.4)              | 22 (23.7)              | 23 (23.0)               |
| Any AE leading to discontinuation of study treatment   | 229 (9.9)              | 235 (9.9)                | 58 (9.4)               | 59 (9.3)                | 6 (6.5)                | 7 (7.0)                 |

Patients with multiple events reported in the same category were counted only oncein that category.Patients with events in more than one category were countedonceineachofthosecategories.

As ofDCO1(27March 2020),ofthe 713 non-White patients, 620 patients were Asian;56patients were Black or African American;13 patients were American Indian or Alaska Native; 2 patients were Native Hawaiian or Other Pacific Islander; and 22 patients were^other'. As of DCO2 (12 July 2021), of the 733 non-White patients, 633 patients were Asian; 58 patients were Black or African American; 13 patients were American Indian or A1aska Native; 2patientswereNativeHawaiian orOtherPacificIslander;and 27patientswere^other'.

Includes AEs with an onset date between the date of first dose of continuous treatment and 30 days following the last dose of continuous treatment. Twenty-five patients are not included in this table at DCQ1 and 37 patients are not included in this table at DCO2 because race was not collected.

AE =Adverse event;bd=Twice daily; CSR=Clinical study report;CTCAE=Common Terminology Criteria for Adverse Events;DCO =Data cut-off; N=Total number ofpatients;SAE=Seriousadverse event.

Source: Table 2.7.4.1.11.1 and Table 2.7.4.1.12.1, Pooled Safety Outputs, Module 5.3.5.3 and Safety Update Table 2.7.4.1.11.1 and Table 2.7.4.1.12.1.

## Discontinuation due to adverse events

The incidence of AEs leading to discontinuation of study treatment is presented in Table 62 . AE leading to treatment discontinuation were reported for 10.6% of patients in the olaparib arm and 4.6% of patients in the placebo arm. The most common AEs leading to discontinuation of olaparib (reported in ≥ 1.0% patients) were nausea, anaemia, fatigue, and neutrophil count decreased.

Table 62: Most Common AEs Leading to Discontinuation (Reported in ≥ 3 Patients in the Olaparib Arm of OlympiA and/or Reported in ≥ 2% of Patients in the 300 mg bd Pool; DCO: 12 July 2021)

|                                                  | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|--------------------------------------------------|----------------------------|----------------------------|----------------------------------|
|                                                  | OlympiA SAS                | OlympiA SAS                |                                  |
| System organ class / MedDRA preferred term       | Olaparib 300 mg bd (N=911) | Placebo (N=904)            | Olaparib 300 mg bd pool (N=3155) |
| Patients with an AE leading to discontinuation b | 97 (10.6)                  | 42 (4.6)                   | 306 (9.7)                        |
| Gastrointestinal disorders                       | 29 (3.2)                   | 8 (0.9)                    | 62 (2.0)                         |
| Nausea                                           | 19 (2.1)                   | 3 (0.3)                    | 34 (1.1)                         |
| Vomiting                                         | 7 (0.8)                    | 0                          | 18 (0.6)                         |
| Diarrhoea                                        | 4 (0.4)                    | 1 (0.)                     | 5 (0.2)                          |
| Blood and lymphatic system disorders             | 17 (1.9)                   | 0                          | 89 (2.8)                         |

<div style=\"page-break-after: always\"></div>

|                                                      | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a         |
|------------------------------------------------------|----------------------------|----------------------------|----------------------------------|
|                                                      | OlympiA SAS                | OlympiA SAS                |                                  |
| System organ class / MedDRA preferred term           | Olaparib 300 mg bd (N=911) | Placebo (N=904)            | Olaparib 300 mg bd pool (N=3155) |
| Anaemia                                              | 16 (1.8)                   | 0                          | 67 (2.1)                         |
| General disorders and administration site conditions | 17 (1.9)                   | 4 (0.4)                    | 42 (1.3)                         |
| Fatigue                                              | 14 (1.5)                   | 4 (0.4)                    | 27 (0.9)                         |
| Nervous system disorders                             | 12 (1.3)                   | 6 (0.7)                    | 21 (0.7)                         |
| Headache                                             | 7 (0.8)                    | 2 (0.2)                    | 7 (0.2)                          |
| Investigations                                       | 12 (1.3)                   | 4 (0.4)                    | 28 (0.9)                         |
| Neutrophil count decreased                           | 9 (0.1)                    | 1 (0.1)                    | 12 (0.4)                         |
| WBCcount decreased                                   | 7 (0.8)                    | 1 (0.1)                    | 9 (0.3)                          |
| Immune system disorders                              | 6 (0.7)                    | 0                          | 7 (0.2)                          |
| Drug hypersensitivity                                | 3 (0.3)                    | 0                          | 4 (0.1)                          |
| Metabolism and nutrition disorders                   | 3 (0.3)                    | 2 (0.2)                    | 10 (0.3)                         |
| Decreased appetite                                   | 3 (0.3)                    | 2 (0.2)                    | 7 (0.2)                          |

e Sorted by decreasing order of frequency for SOC and PT in the olaparib arm of OlympiA, and then by decreasing order of frequency in the placebo arm.

Adverse event action taken=olaparib/placebo permanently stopped.

Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

## MedDRA Version 24.0.

The majority (124 of 142 events) of the events that led to discontinuation of olaparib had resolved, or were resolving after study treatment was stopped. None of the events that led to discontinuation of olaparib were fatal; however, 16 AEs that led to permanent discontinuation of olaparib were considered by the investigator to be serious.

Seventy six of the 142 discontinuation events in the olaparib arm started within 30 days of the first dose of study treatment. For the majority (122 of 148 events) of events that led to discontinuation of olaparib, the investigator considered that the events were causally related to study treatment.

## Dose Reductions/Interruptions Due to Adverse Events

Adverse events leading to dose reduction in study treatment (olaparib or placebo) in ≥ 2 patients in either treatment arm of OlympiA occurred in 22.5% of patients in the olaparib arm and 3.5% of patients in the placebo arm.

The most common AEs leading to dose reduction ( ≥ 3% of patients) in the olaparib arm were anaemia, nausea, neutrophil count decreased, and fatigue. The AEs that led to dose reduction in the olaparib arm were generally events known to be associated with olaparib or were associated with the disease under investigation.

<div style=\"page-break-after: always\"></div>

The median time to first dose reduction of olaparib (for any reason) was 2.7 months (range 0 to 11 months). Once a patient was on a reduced dose, the dose could not be re-escalated.

Table 63 Adverse Events Leading to Dose Reduction Reported in ≥3 Patients in the Olaparib Arm of OlympiA or in ≥2% Patients in the 300 mg bd Pool (DCO: 12 July 2021)

|                                                                     | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|---------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|
|                                                                     | OlympiA SAS                | OlympiA SAS                | Olaparib 300 mg bd pool    |
| MedDRA Preferred term                                               | Olaparib 300 mg bd (N=911) | Placebo (N=904)            | (N=3155)                   |
| Patients with an AE leading to dose reduction of olaparib/placebo b | 213 (23.4)                 | 33 (3.7)                   | 711 (22.5)                 |
| Anaemia                                                             | 77 (8.5)                   | 2 (0.2)                    | 352 (11.2)                 |
| Nausea                                                              | 43 (4.7)                   | 2 (0.2)                    | 93 (2.9)                   |
| Neutrophil count decreased                                          | 41 (4.5)                   | 6 (0.7)                    | 56 (1.8)                   |
| Fatigue                                                             | 30 (3.3)                   | 6 (0.7)                    | 80 (2.5)                   |
| WBCcount decreased                                                  | 17 (1.9)                   | 3 (0.3)                    | 27 (0.9)                   |
| Vomiting                                                            | 15 (1.6)                   | 2 (0.2)                    | 37 (1.2)                   |
| Diarrhoea                                                           | 6 (0.7)                    | 2 (0.2)                    | 13 (0.4)                   |
| Platelet count decreased                                            | 6 (0.7)                    | 1 (0.1)                    | 16 (0.5)                   |
| Headache                                                            | 4 (0.4)                    | 3 (0.3)                    | 6 (0.2)                    |
| Abdominal pain                                                      | 5 (0.5)                    | 0                          | 7 (0.2)                    |
| Abdominal pain upper                                                | 3 (0.3)                    | 0                          | 4 (0.1)                    |
| Decreased appetite                                                  | 3 (0.3)                    | 0                          | 14 (0.4)                   |
| Malaise                                                             | 3 (0.3)                    | 0                          | 3 (0.1)                    |

f Sorted by decreasing order of frequency for PT in the olaparib arm of OlympiA, and then by decreasing order of frequency in the placebo arm.

g Adverse event action taken=dose reduced.

Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories. Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

Includes AEs that led to dose reduction and did not lead to permanent discontinuation of study treatment.

MedDRA Version 24.0.

AE = Adverse event; bd = Twice daily; CSR = Clinical study report; DCO = Data cut-off; MedDRA = Medical Dictionary for Regulatory Activities; N = Total number of patients; PT = Preferred term; SAS = Safety analysis set; WBC = White blood cell.

Source: Safety Update Table 14.3.2.29.1 and Table 2.7.4.1.1.6.

<div style=\"page-break-after: always\"></div>

Table 64: Adverse Events Leading to Treatment Interruption Reported in ≥5 Patients in the Olaparib Arm of OlympiA or in ≥2% Patients in the 300 mg bd Pool (DCO: 12 July 2021)

|                                                                        | Number (%) of patients a   | Number (%) of patients a   | Number (%) of patients a   |
|------------------------------------------------------------------------|----------------------------|----------------------------|----------------------------|
|                                                                        | OlympiA SAS                | OlympiA SAS                | Olaparib                   |
| MedDRA Preferred term                                                  | Olaparib 300 mg bd (N=911) | Placebo (N=904)            | 300 mg bd pool (N=3155)    |
| Patients with an AE leading to dose interruption of olaparib/placebo b | 284 (31.2)                 | 99 (11.0)                  | 1191 (37.7)                |
| Anaemia                                                                | 104 (11.4)                 | 2 (0.2)                    | 510 (16.2)                 |
| Neutrophil count decreased                                             | 54 (5.9)                   | 6 (0.7)                    | 101 (3.2)                  |
| Nausea                                                                 | 49 (5.4)                   | 6 (0.7)                    | 154 (4.9)                  |
| WBCcount decreased                                                     | 33 (3.6)                   | 3 (0.3)                    | 65 (2.1)                   |
| Fatigue                                                                | 26 (2.9)                   | 9 (1.0)                    | 90 (2.9)                   |
| Vomiting                                                               | 26 (2.9)                   | 9 (1.0)                    | 132 (4.2)                  |
| Diarrhoea                                                              | 9 (1.0)                    | 2 (0.2)                    | 60 (1.9)                   |
| Dyspnoea                                                               | 8 (0.9)                    | 4 (0.4)                    | 30 (1.0)                   |
| Abdominal pain                                                         | 8 (0.9)                    | 3 (0.3)                    | 41 (1.3)                   |
| Lymphocyte count decreased                                             | 8 (0.9)                    | 0                          | 13 (0.4)                   |
| Platelet count decreased                                               | 6 (0.7)                    | 1 (0.1)                    | 35 (1.1)                   |
| Pyrexia                                                                | 5 (0.5)                    | 4 (0.4)                    | 41 (1.3)                   |
| ALT increased                                                          | 5 (0.5)                    | 3 (0.3)                    | 22 (0.7)                   |
| Neutropenia                                                            | 0                          | 0                          | 110 (3.5)                  |

h Sorted by decreasing order of frequency for PT in the olaparib arm of OlympiA, and then by decreasing order of frequency in the placebo arm.

i Adverse event action taken=drug interrupted.

Patients with multiple events in the same category were counted only once in that category. Patients with events in more than one category were counted once in each of those categories.

Includes AEs with an onset date between the date of first dose and 30 days following the date of last dose of study treatment.

Includes AEs that led to a dose interruption and did not lead to permanent discontinuation of study treatment.

MedDRA Version 24.0.

AE = Adverse event; ALT = Alanine aminotransferase; bd = Twice daily; CSR = Clinical study report; DCO = Data cut-off; MedDRA = Medical Dictionary for Regulatory Activities; N = Total number of patients; PT = Preferred term; SAS = Safety analysis set; WBC = White blood cell.

Source: Safety Update Table 14.3.2.30.1 and Table 2.7.4.1.1.7.

<div style=\"page-break-after: always\"></div>

## 2.8.1. Discussion on clinical safety

The safety assessment is based on data collected from the phase III OlympiA study in which 911 patients received  olaparib.  The  OlympiA  data  have  been  pooled  with  the  data  from  patients  receiving  olaparib 300 mg bd tablet in additional monotherapy studies providing a pooled safety database of 3155 patients (1289 of whom had breast cancer).

Across  the  entire  clinical  programme,  17923  patients  are  estimated  to  have  received  treatment  with olaparib as of 15 June 2021.

The majority of patients exposed to olaparib reported adverse events (AEs), which were generally mild to moderate in severity and did not lead to discontinuation. The toxicity of olaparib was often manageable by dose interruptions, dose reductions and standard supportive treatment as required. Overall, the safety findings in olaparib arm of OlympiA were reported at lower frequency than the 300 mg bd pool, except for AE leading to discontinuation of study treatment or to dose reduction which were reported with similar frequencies.

## Exposure

The summary of clinical safety provided in support of the applied indication in early breast cancer (EBC) initially described the results of the interim analysis 2 of study OlympiA, with the data cut-off date of 12 July 2021 (DCO2). At the time of the DCO2, 1389 patients (75.7%) had completed study treatment per protocol and no patients remaned on study treatment. The planned duration of treatment was 12 months and most patients (76.1% in the olaparib arm and 81.7% in the placebo arm) received ≥ 11 months with most patients discontinuing treatment after 11.5 months.

## Adverse events

The most common AEs in the olaparib arm were nausea (56.9%), fatigue (40.1%), anaemia (23.6%), vomiting (22.6%), headache (19.6%), diarrhoea (17.6%), neutropenia (16.4%), WBC decreased (15.8%), decreased appetite (13.1%), dysgeusia (11.7%), dizziness (11.4%).

The AE preferred terms (PTs) that were reported at a ≥ 2% greater frequency in the olaparib 300 mg tablet bd  arm  compared  with  the  placebo  arm  were:  anaemia,  decreased  appetite,  diarrhoea,  dizziness, dysgeusia,  fatigue,  gastrooesophageal  reflux  disease,  headache,  lymphocyte  count  decreased,  nausea, neutrophil count decreased, platelet count decreased, stomatitis, vomiting, and WBC count decreased.

Safety and tolerability findings were consistent between OlympiA and the tablet pool.

Grade ≥ 3 AEs had a higher incidence in olaparib arm (24.5% of patients) than in the placebo arm (11.3%). Anaemia and neutropenia were the only AEs Grade ≥ 3 reported in ≥ 5% of patients in the olaparib arm (respectively 8.7% and 5.2% in the olaparib arm vs. 0.3% and 0.8% in the placebo arm). AEs of CTCAE Grade 3 or higher had overall lower frequencies in the olaparib arm of study OlympiA compared to the 300 mg bd olaparib pool (24.5% vs 36.6%).

SAEs were reported in a similar proportion of patients in the olaparib arm (8.7%) compared with the placebo arm (8.6%). The highest frequency of reported SAEs at the system organ class (SOC) level was blood and lymphatic system disorders (2% olaparib vs. 0.1% physician's choice of chemotherapy). The most common SAE in olaparib arm was anaemia (1.6% olaparib vs 0.1% placebo). A low proportion of patients had SAEs that were considered by the investigator to be causally related to study treatment (3.6% in the olaparib arm and 0.7% in the placebo arm). Anaemia (14 patients [1.5%] in the olaparib arm) was the only SAE reported in more than 2 patients. The majority of SAEs had resolved with either no action taken, or following a temporary dose interruption, delay/dose change or were recovering. SAEs were reported at a lower frequency in OlympiA than in the 300 mg bd pooled dataset (8.7% vs 19.5%).

<div style=\"page-break-after: always\"></div>

The lower proportion of AEs, AEs of CTCAE Grade ≥ 3 and SAEs compared with the pooled data is likely reflective of the younger age, better ECOG performance status, no evidence of disease at randomisation, and capped duration of treatment in the OlympiA study.

Overall, the safety and tolerability data of olaparib in OlympiA was considered consistent with the known safety profile of olaparib treatment across the various indications studied.

Most of the deaths occurring on study were related to the disease under investigation (171 of 181 deaths [94.5%]; 70 patients in the olaparib arm and 101 patients in the placebo arm). Only one patient in the olaparib arm experienced an AE leading to death (cardiac arrest) which was not considered related to study treatment  by  the  investigator.  The  frequency  of  deaths  for  any  reason  was  lower  for  olaparib-treated patients than for patients in the placebo arm (6.5% vs. 9.5% respectively), mainly driven by death related to disease under investigation only. The frequency of deaths for any reason was lower for olaparib-treated patients (6.5%) in OlympiA compared to the 300 mg bd pool (28.8%), reflecting a population with an overall more favourable disease setting.

Three deaths in the olaparib arm and one in the placebo arm were reported under 'other' (i.e. not reported as related to disease under investigation only, and not related to an AE).  For one of them, cause of death was a pulmonary embolism for which relation to treatment could be excluded. For the second event, death occurred 113 days after last dose of study treatment (duration of exposure was 141 days) but information available was insufficient to conclude on relationship with olaparib. The last event reported as other was a case  of  AML.  Although  previous  exposure  to  platinum  based  chemotherapy  and  taxanes  constituted important confounding factors this case should have been counted as an AE leading to death (see discussion on the risk of  new primary malignancies further below.

## Dose interruptions or delay and dose reductions

Dose interruptions or delay and dose reductions were reported respectively in 57% and 25% patients on olaparib and respectively in 44.8% and 5.2% patients on placebo.

A numerically higher proportion of patients in the olaparib arm (36.2%) had a dose interruption due to an AE compared with the proportion of patients in the placebo arm (14.2%). In the olaparib arm, the median total intended treatment duration was similar to the actual treatment duration, which shows treatment interruptions  did  not  have  a  significant  impact  on  treatment  duration.  Similarly,  a  larger  proportion  of patients in the olaparib arm (24.4%) compared to the placebo arm (3.9%) had a dose reduction due to an AE.

The proportion of patients who reported AEs leading to discontinuation of treatment was higher in the olaparib arm than in the placebo arm (10.6% vs 4.6%). Nausea (2.1%), Anaemia (1.8%), fatigue (1.5%) and neutrophils count decreased (1%) were the only AEs leading to discontinuation of olaparib in one percent or more of the patients in the olaparib arm. A majority of discontinuation events (76/142) in the olaparib arm started within 30 days of the first dose of study treatment.

The frequency of treatment discontinuation due to AE in OlympiA study (10.6%) was higher than the one observed in OlympiAD (metastatic breast cancer; 4.9%). However, treatment duration was longer in study OlympiA (11.5 months) compared to study OlympiAD (8.2 months). Furthermore, the rate of treatment discontinuation observed in study OlympiA was similar to the one observed in the 300 mg pool (9.7%) in which treatment duration was similar 11.2 months.

Higher discontinuation rate in the adjuvant setting compared to the metastatic setting have been observed with  several  treatments  against  breast  cancer.  This  might  be  related  to  different  acceptability  to  drug toxicity from patients in an early curative intent setting.

<div style=\"page-break-after: always\"></div>

## ADR and AESI

No new adverse drug reaction has been identified based on the data provided. The adverse drug reactions (ADRs) identified for olaparib tablets are adequately described in section 4.8 of the SmPC. The frequency of several ADRs has been updated based on pooled data from 4098 patients with solid tumours treated with Lynparza monotherapy in clinical trials at the recommended dose (see SmPC section 4.8).

The adverse events of special interest (AESIs) for olaparib are pneumonitis, Myelodysplastic Syndrome/Acute Myeloid Leukaemia (MDS/AML) and new primary malignancies. Investigators in OlympiA were required to record new primary malignancies and MDS/AML events beyond 30 days after the last dose of  olaparib  at  any  point  in  OS  follow-up.  A  causal  relationship  between  olaparib  treatment  and  the development or acceleration of new primary malignancies and pneumonitis has not been established.

In OlympiA, MDS/AML was reported in 0.2% (n=2) of olaparib-treated patients and 0.3% (n=3) of placebotreated patients at DCO2 (12 July 2021).  The incidence of MDS/AML in the olaparib arm of OlympiA (0.2%) was lower than the incidence reported for olaparib in PAOLA-1 (0.9%), SOLO 1 (1.2%), SOLO 2 (8.2%), SOLO 3 (2.2%), and Study 19 (1.5%), and the larger olaparib monotherapy combined therapeutic dose pool (0.9%). However, the follow-up period of OlympiA study was shorter than the monotherapy pool. Myelodysplastic syndrome/acute myeloid leukaemia are identified risk associated with Olaparib (see SmPC section 4.4 and 4.8) and will continue to be closely monitored (RMP).

In the OlympiA study, at DCO2 (12 July 2021) there were 20 patients (2.2%) reporting 21 new primary malignancies (NPM) events in the olaparib arm and 35 patients (3.9%) reporting 37 NPM events in the placebo arm occurring at any time on treatment or after the 30-day safety follow-up period. The incidence of new primary malignancies in the pool of patients who received olaparib in monotherapy studies (tablet and capsule formulations; all doses of olaparib) was 1% for olaparib (41 patients in a total of 3988 patients).

The risk of NPM is of particular concern in the adjuvant setting since patients have a longer life expectancy. The frequency of NPM was overall in line with previous experiences, even though slightly higher than the frequency reported in the general monotherapy pool and the total clinical trial population. Considering that the median follow-up time in OlympiA study was 3.5 years at DCO2, no final conclusion can be drawn on the potential increase in risk of NPM. This risk will continue to be monitored and follow up safety data will be provided in the PSUSA.

The causes for imbalance of NPM between olaparib and placebo arm remain difficult to assess. Considering the low absolute number of cases, a chance finding cannot be ruled out.

Considering the entire olaparib clinical programme 122 case reports have been received up to 15 June 2021 (crude incidence 122/17923; 0.7%). Overall, the majority of pneumonitis AEs reported in the olaparib monotherapy therapeutic dose pool were mild or moderate, non-serious, and resolved without treatment discontinuation.

The difference in exposure between study OlympiA and previous studies cannot fully explain the difference of pneumonitis incidence observed among studies. It is not possible to rule out a causal relation at this stage. However, considering that appropriate routine risk minimisation activities are implemented through the prescribing information, and that pharmacovigilance activities might not be able to provide further information on the issue, the MAH proposal to remove pneumonitis from the risk management plan is considered acceptable.

## Laboratory parameters

<div style=\"page-break-after: always\"></div>

Changes in the laboratory values for the haematology parameters of haemoglobin, platelets, leukocytes, neutrophils and lymphocytes are considered ADRs for olaparib. The changes in haematological parameters observed in study OlympiA were generally mild or moderate, manageable, and reversible.

Increases  in  creatinine  have  also  been  identified  as  an  ADR  with  olaparib  treatment.  AEs  of  increased creatinine were predominantly Grade 1 in severity and none led to permanent discontinuation of treatment. The laboratory observations of elevated serum creatinine were not associated with renal impairment and had apparently no clinical sequelae. No hepatobiliary or renal safety concerns were identified from a review of laboratory and AE data.

## Special populations

Assessment of the safety of olaparib in patient subgroups among the 300 mg bd pool showed an acceptable safety profile regardless of race, gender, or body weight. No dose adjustment is required on the basis of patient age, racial origin, gender or body weight. The study population from OlympiA study differed from the safety pool with an overall younger age.

It  was  considered  that  the  safety  in  Hormone  Receptor  (HR)  positive  population  should  be  evaluated separately as the patients received in a vast majority an endocrine therapy in parallel to the olaparib or placebo. A separated analysis of adverse events between HR positive patients with concomitant endocrine therapy and the safety analysis set (SAS) was provided (data not shown) and did not revealed differences in the safety profile of olaparib between the two populations.

The demographics and baseline characteristics of the Myriad gBRCAm subset (n=1539 patients) were broadly similar to the FAS (n=1836 patients) except for the different proportions of White (66.7% overall in the FAS versus 76.8% overall among Myriad gBRCAm subset) and Asian patients (28.9% overall in the FAS versus 18.3% overall among Myriad gBRCAm subset). This was expected given that the Myriad test was not performed in patients from China.

The MAH was requested to justify the proposed extrapolation of safety to patients with tumours harbouring somatic  mutations  in  light  of  the  claimed  indication.  In  this  respect,  extrapolation  was  not  considered justified  due  to  limited  clinical  data  available  (see  also  discussion  on  clinical  efficacy).  From  a  safety perspective, clinical data with a longer follow-up to further assess the risk of AML/MS and new primary malignancies in this disease setting are lacking.

## 2.8.2. Conclusions on clinical safety

The safety profile of olaparib for patients in OlympiA study is generally consistent with the known safety profile of olaparib. It includes gastrointestinal AEs (nausea and vomiting), haematologic toxicity (anaemia) and general disorders (fatigue). No new safety signals were identified from patients with gBRCAm, HER2negative, high risk early breast cancer. AEs associated with olaparib are generally mild or moderate, and manageable with dose modification or standard supportive treatment. Higher discontinuation rate due to AEs was observed in the EBC population compared the MBC Phase 3 study. Many discontinuations occurred relatively early during treatment. This might be due to a lower acceptance of AEs affecting daily life in a younger, often actively working patient population.

Regarding new primary malignancies, a causal relationship between olaparib treatment and these adverse events has not been established. Therefore, they are still considered as important potential risk for olaparib with ongoing surveillance activities detailed in the RMP.

<div style=\"page-break-after: always\"></div>

## 2.8.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Risk management plan

The MAH submitted to submit an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 23.3 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 23.3 with the following content:

## Safety concerns

## Table 65: Summary of Safety Concerns

| Important identified risks   | Myelodysplastic syndrome/acute myeloid leukaemia                                                                                                               |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | New primary malignancies Medication errors associated with dual availability of capsules and tablets Effects on embryofoetal survival and abnormal development |
| Missing information          | Long term exposure to/potential toxicity to olaparib                                                                                                           |

## Pharmacovigilance plan

There are no ongoing or planned additional pharmacovigilance activities for Olaparib.

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

Table 66: Summary Table of Pharmacovigilance Activities and Risk Minimisation Activities by Safety Concern

| Safety concern                                                              | Risk minimisation measures                                                                                                                                                                                        | Pharmacovigilance activities                                                                                                                                                                         |
|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MDS/AML                                                                     | Routine risk minimisation measures: SmPC Section 4.4 and 4.8 PL Section 2 and 4                                                                                                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Follow-up targeted safety questionnaire Cumulative review (provided concurrent with each annual PBRER) |
| New primary malignancy                                                      | None                                                                                                                                                                                                              | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Follow-up targeted safety questionnaire                                                                |
| Medication errors associated with dual availability of capsules and tablets | Routine risk minimisation measures: SmPC Section 4.2 PL Section 3 Additional risk minimisation measures: Distribution of a DHPC to prescribers and pharmacists providing clear information on the 2 formulations. | Routine                                                                                                                                                                                              |
| Effects on embryofoetal survival and abnormal development                   | Routine risk minimisation measures: SmPC Sections 4.4, 4.6 PL Section 2                                                                                                                                           | Routine                                                                                                                                                                                              |
| Long term exposure to/potential toxicity to olaparib                        | None                                                                                                                                                                                                              | Routine                                                                                                                                                                                              |

## 2.10. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1 of the SmPC have been updated. Particularly, the warning with regard to women of childbearing potential/contraception in females has been modified to the product information. The SmPC of Lynparza capsule has been revised accordingly to reflect updated safety information. The Package Leaflet has been updated accordingly.

<div style=\"page-break-after: always\"></div>

In addition, the list of local representatives in the PL has been revised.

## 2.10.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable because the changes are limited and do not require user consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The indication is for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.

High risk early breast cancer patients were defined as follows:

- patients who received prior neoadjuvant chemotherapy: patients with either triple negative breast cancer (TNBC) or hormone receptor positive breast cancer must have had residual invasive cancer in the breast and/or the resected lymph nodes (non-pathologic complete response) at the time of surgery.  Additionally,  patients  with  hormone  receptor  positive  breast  cancer  must  have  had  a CPS&amp;EG score of ≥3 based on pre -treatment clinical and post-treatment pathologic stage (CPS), estrogen receptor (ER) status and histologic grade as shown in Table 5.
- patients who have received prior adjuvant chemotherapy: triple negative breast cancer (TNBC) patients  must have had node positive disease or node negative disease with a ≥2 cm primary tumour; HR positive, HER2negative patients must have had ≥4 pathologica lly confirmed positive lymph nodes.

## 3.1.2. Available therapies and unmet medical need

The decision  to  treat  patients  with  early  breast  cancer  with  neoadjuvant  or  adjuvant  chemotherapy  in addition to surgery/radiotherapy is driven by the consideration of clinical characteristics, tumour stage and pathology. Standard neo/adjuvant chemotherapy for HER2 negative early breast cancer is an anthracycline and taxane-based regimen. The clinical practice guidelines (ESMO 2019) recommend that a sequential anthracycline/taxane-based regimen be standard of care for the majority of patients.

Whilst platinum compounds are not routinely recommended, the addition of a platinum compound may be considered in high risk TNBC patients with deleterious BRCA1/2 mutations (ESMO 2019). In high risk TNBC patients not achieving pCR after standard neoadjuvant chemotherapy, the addition of adjuvant capecitabine post-operatively may be considered (NCCN Guidelines, ESMO 2019).

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

This application is based on the results from the pivotal Phase III, randomised, double-blind, parallel group, placebo-controlled, multi-centre study OlympiA (D081CC00006) in which patients with gBRCA1/2 mutations and  triple  negative  or  HR+/HER2-  high-risk  early  breast  cancer  who  had  completed  definitive  local treatment and neoadjuvant or adjuvant chemotherapy were randomised 1:1 to receive either olaparib (300 mg  bd,  tablet  formulation)  (n=921)  or  matching  placebo  (n=915).  Randomisation  was  stratified  by hormone receptor status (HR positive/ HER2 negative versus TNBC), by prior neoadjuvant versus adjuvant chemotherapy,  and  by  prior  platinum  use  for  current  breast  cancer  (yes  versus  no).  Treatment  was continued for up to 1 year, or until disease recurrence, or unacceptable toxicity.

Patients with HR+ breast cancer were allowed to receive concurrent treatment with endocrine therapy as per local guidelines.

Central testing at Myriad or local g BRCA testing, if available, was used to establish study eligibility. Patients enrolled based on local g BRCA test results provided a sample for retrospective confirmatory testing. Out of 1836  patients  enrolled  into  OlympiA,  1623  were  confirmed  as  g BRCA m  by  central  testing,  either prospectively  or  retrospectively.  There  were  no  patients  included  in  OlympiA  tested  for  somatic  BRCAmutated tumours.

The primary endpoint was invasive disease free survival (IDFS) as determined by investigator assessment and defined as the time from randomisation to date of first recurrence, where recurrence was defined as invasive loco-regional, distant recurrence, contralateral invasive breast cancer, new cancer or death from any cause. Secondary objectives included OS and distant disease free survival (DDFS, defined as the time from randomisation until evidence of first distant recurrence of breast cancer). A hierarchical testing strategy was employed.

## 3.2. Favourable effects

A total of 1836 patients were randomised and 284 IDFS events were observed in the ITT population at the time of the efficacy interim analysis (DCO 27 March 2020). The median follow-up time was 2.3 years in olaparib  arm  and  2.5  years  in  placebo  arm.  OlympiA  met  its  primary  endpoint  showing  a  statistically significant  improvement  in  IDFS  for  olaparib-treated  patients  compared  to  placebo-treated  patients.  A reduction of the risk of recurrence of disease was observed at any given point in time by 42% in ITT population (HR 0.58; 99.5% CI: 0.41, 0.82; p=0.0000073). The difference in the percentage of patients invasive disease free at 3 years was 8.8% (95%CI, 4.5%-13.0%) between arms in favour of the olaparib arm. The observed IDFS improvement is considered clinically meaningful. Updated descriptive analyses of IDFS based on more mature data (with median follow-up of 3.5 years) conducted at the time of the preplanned second OS interim analysis (DCO2: 12 July 2021) were consistent.

Results from the analyses of DDFS were consistent with the ITT analyses of IDFS showing a statistically significant 42.6% reduction in the risk of distant disease recurrence or death at any given point in time for olaparib vs placebo (HR=0.57; 99.5% CI: 0.39, 0.83; p=0.0000257]. The difference in the percentage of patients distant disease free at 3 year DDFS was 7.1% (95%CI, 3.0%-11.1%) and is considered clinically meaningful.

At the second planned analysis (DCO 12 July 2021), the OS results (10% maturity) showed a statistically significant  reduction  in  the  risk  of  death  at  any  given  point  in  time  (HR  0.68,  98.5%  CI:  0.47,  0.97, p=0.0091). At all-time points, a higher proportion of patients remained alive in the olaparib arm compared with the placebo arm (1 year [98.0%], 2 years [95.0%], 3 years [92.8%] and 4 years [89.8%] compared

<div style=\"page-break-after: always\"></div>

with 96.9%, 92.8%, 89.1% and 86.4% respectively). The median duration of follow-up for OS was 3.5 years in the olaparib arm and 3.6 years in the placebo arm.

## 3.3. Uncertainties and limitations about favourable effects

There are no clinical data available on the responsiveness of breast tumours with sBRCA mutation to PARPi in the early setting (see section 3.7.3).

## 3.4. Unfavourable effects

The most common (reported by ≥ 20% of patients) adverse events reported in the olaparib arm were nausea (56.9%), fatigue (40.1%), anaemia (23.5%) and vomiting (22.6%). Grade ≥ 3 AEs had a higher incidence in the olaparib arm (24.3%) than in the placebo arm (11.3%).

At DCO2, adverse events of CTCAE Grade ≥3 occurred in 24.5% of patients in the olaparib arm and 11.3% of patients in the placebo arm. Anaemia was the only AEs Grade ≥ 3 reported in ≥ 5% of patients in the olaparib arm (reported in 8.7% of olaparib arm versus 0.3% of placebo arm).

SAEs were reported in 8.7% (79/911 patients) of the olaparib-arm compared with 8.4% (76/904) of the placebo arm. The most common reported SAE was anaemia (1.6% olaparib vs 0.1% placebo). The highest frequency  of  reported  SAEs  at  the  system  organ  class  (SOC)  level  were  blood  and  lymphatic  system disorders (2.0% olaparib vs 0.1% placebo). For management of anaemia, 53 (5.8%) patients in the olaparib arm received transfusion and 8 (0.9%) in the placebo arm, with 16 patients (1.8%) and 2 patients (0.2%) receiving &gt;1 transfusion in the olaparib and placebo arms.

The  median  total  treatment  duration  to  olaparib  was  similar  to  placebo  (350  vs  358  days).  Dose interruptions were reported respectively in 31.4% patients on olaparib and 11.4% placebo patients.

Five patients in the olaparib arm died from other cause than the disease under investigation, two of them qualify as AE leading to death. One was a cardiac arrest that happened 1 day after the last dose and was not found related to olaparib. The second was a case of AML with a date of onset 448 days after olaparib discontinuation, and death happening 295 after date of onset.

There were 2 (0.2%) cases of AML/MDS reported in the olaparib arm, including one with outcome of death and 3 (0.3%) with placebo.

The incidence of NPMs in the OlympiA trial was 2.2% and similar with the incidences seen in other trials (SOLO2 [3.6%], Study 19 [2.9%], SOLO1 [1.9%], PAOLA-1 [2.4%]).

It was reported that 9 (1%) patients in the olaparib arm and 11 (1.2%) patients in the placebo arm had an AE of pneumonitis on treatment and no patients had AEs of pneumonitis in the post-follow-up period.

## 3.5. Uncertainties and limitations about unfavourable effects

Uncertainties remain on potential risks of new primary malignancies (NPM) and pneumonitis.

Causal relationship between the exposure to olaparib and the occurrence of pneumonitis events could not be  established  based  on  available  data.  This  risk  will  continue  to  be  monitored  as  part  of  routine pharmacovigilance activities.

With regards to NPM, the causality of olaparib in occurrence of rare cases of new primary malignancies could not be firmly established in the context of previous courses of chemotherapy. NPM will continue to

<div style=\"page-break-after: always\"></div>

be closely monitored in the post-marketing setting. This is of particular relevance in the adjuvant setting where  patients  have  a  long  life-expectancy.  Hence,  continuous  reporting  of  NPM  occurring  within  the duration of OS follow up period in study OlympiA remains necessary.

## 3.6. Effects Table

Table 67: Effects Table for olaparib tablet formulation in BRCA1/2-mutated HER2-negative high risk early breast cancer (data cut-off: IDFS/DDFS: 27 March 2020; OS: 12 July 2021)

| Effect                        | Short description                                                     | Unit                 | Olaparib N=921                      | Placebo N=915                       | Uncertainties / Strength of evidence                        | References           |
|-------------------------------|-----------------------------------------------------------------------|----------------------|-------------------------------------|-------------------------------------|-------------------------------------------------------------|----------------------|
| Favourable Effects            | Favourable Effects                                                    | Favourable Effects   | Favourable Effects                  | Favourable Effects                  | Favourable Effects                                          | Favourable Effects   |
| IDFS                          | Invasive Disease Free                                                 | N (%) a              | 106/921 (12)                        | 178/915 (20)                        |                                                             | OlympiA              |
| IDFS                          | Survival                                                              | HR (99.5 % CI) b     | 0.58 (0.41, 0.82) c p = 0.0000073 e | 0.58 (0.41, 0.82) c p = 0.0000073 e | Efficacy data available only in patients with germline BRCA | OlympiA              |
| DDFS                          | Distant disease free survival                                         | N (%)                | 89/921 (10)                         | 152/915 (17)                        | mutation.                                                   | OlympiA              |
| DDFS                          |                                                                       | HR a (99.5 % CI) b,c | 0.57 (0.39, 0.83) p=0.0000257 e     | 0.57 (0.39, 0.83) p=0.0000257 e     | mutation.                                                   | OlympiA              |
| OS                            | Overall survival                                                      | N (%)                | 75/921 (8.1)                        | 109/915 (11.9)                      |                                                             | OlympiA              |
| OS                            |                                                                       | HR a (99% CI) b,c    | 0.678 (0.503 - 0.907) p=0.0091 e    | 0.678 (0.503 - 0.907) p=0.0091 e    |                                                             | OlympiA              |
| Unfavourable Effects          | Unfavourable Effects                                                  | Unfavourable Effects | Unfavourable Effects                | Unfavourable Effects                | Unfavourable Effects                                        | Unfavourable Effects |
| AE of CTCAE Grade ≥ 3         | Related to study treatment according to investigator                  | N (%)                | 160 (17.6)                          | 20 (2.2%)                           |                                                             | OlympiA              |
| AE with death outcome         |                                                                       | N (%)                | 2 (0.2)                             | 4 (0.4)                             |                                                             | OlympiA              |
| Blood and lymphatic disorders | Anaemia All grades Grade 3-4 AE leading to treatment discontinuati on |                      | 215 (23.6) 79 (8.7) 16 (1.8)        | 35 (3.9) 3 (0.3) 0                  |                                                             | OlympiA              |
| General disorders;            | Fatigue All grade Grade 3-4 AE leading to treatment discontinuati on  |                      | 365 (40.1) 16 (1.8) 14 (1.5)        | 246 (27.2) 6 (0.7) 4 (0.4)          |                                                             | OlympiA              |
| Gastrointes tinal disorders;  | Nausea All grade Grade ≥3 Vomiting                                    | N(%)                 | 519 (57%) 7 (0.8%) 19 (2.1) 206     | 212 (23.5%) 0 3 (0.3) 74 (8.2%)     |                                                             | OlympiA              |

<div style=\"page-break-after: always\"></div>

| Effect   | Short description   | Unit   | Olaparib N=921           | Placebo N=915   | Uncertainties / Strength of evidence References   |
|----------|---------------------|--------|--------------------------|-----------------|---------------------------------------------------|
|          | All grade Grade ≥3  |        | (22.6%) 6 (0.7%) 7 (0.8) | 0 0             |                                                   |

- a Estimate of the treatment HR was based on the stratified Cox's Proportional Hazards Model, &lt;1 indicates a lower risk with olaparib compared with placebo arm. Stratification factors were the same as those used in the stratified log-rank test.
- b The CI for the HR was estimated using the profile likelihood approach.
- c Inferential, according to the alpha spending rules for the interim analysis.

d Exploratory, not inferential

- e P-value from a stratified log-rank test. Stratification was by chemotherapy type (2 levels: adjuvant vs neoadjuvant), hormone receptor status (2 levels: ER and/or PgR positive, HER2 negative vs TNBC), and prior platinum therapy (2 levels: yes vs no). Stratification factors were based upon the categories used in the randomisation system and were chosen by the pooling strategy. Once the pooling strategy was applied, only the hormone receptor status stratification factor was selected.

F Percentages of patients were from the Kaplan-Meier estimates and the 95% CIs were calculated using Greenwood's formula.

CI = confidence interval; DDFS = distant disease free survival; FAS = full Analysis Set; HR = hazard ratio; IDFS = invasive disease free survival; N = total number of patients; OS = overall survival;

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

In study OlympiA, a statistically significant improvement was observed in IDFS, DDFS and OS for olaparibtreated patients compared to placebo-treated patients. Treatment with olaparib was administered for up to 1 year and the results showed that there was a 41.9% reduction in the risk of invasive disease recurrence or death at any given point in time with olaparib arm compared to the placebo arm with 8.8% improvement in IDFS at 3 years. This is considered clinically meaningful.

The subgroup analyses of IDFS showed consistent effects with the primary analysis of IDFS in the ITT, with the treatment benefit of olaparib over placebo evidenced across all of the pre-defined subgroups.

Results of the analyses of DDFS were consistent with the analyses of IDFS, with a statistically significant benefit of olaparib vs placebo with a 42.6% reduction in the risk of distant disease recurrence or death at any given point in time. Between-group difference in 3 year DDFS was 7.1 percentage points (95%CI, 3.011.1) and is considered clinically meaningful.

Updated OS results from the second planned interim analysis (DCO2 12 July 2021), with a median duration of follow-up of 3.5 years in the olaparib arm and 3.6 years in the placebo arm showed a statistically 32.2% numerical  reduction  in  the  risk  of  death  at  any  given  point  in  time  (HR  0.68,  98.5%  CI:  0.47,  0.97, p=0.0091).

The safety profile of olaparib including patients from OlympiA is generally consistent with the known safety profile of olaparib. No new safety signals were identified from patients with gBRCAm HER2-negative early breast cancer of high risk of recurrence and safety findings in olaparib arm of OlympiA were consistent with the 300 mg tablet pool.

<div style=\"page-break-after: always\"></div>

The toxicity of olaparib was most often manageable, including by dose interruptions, dose reductions and standard supportive treatment as required. A relatively higher frequency of treatment discontinuation was observed in the EBC compared with the MBC setting. The risk of new primary malignancy will continue to be closely monitored and is of particular importance in this earlier disease setting. The SmPC is considered to contain relevant safety information on the risks associated with olaparib and their management.

## 3.7.2. Balance of benefits and risks

Despite completion of standard surgery, radiation and neo/adjuvant chemotherapy disease recurrence will occur in a proportion of patients, generally with distant metastatic lesions, at which point their disease is incurable and will ultimately be fatal.

Study OlympiA evaluated the safety and efficacy of olaparib as adjuvant treatment in adult patients with germline BRCA1/2-mutations who have high risk early breast cancer and who have previously been treated with  neoadjuvant  or  adjuvant  chemotherapy.  In  this  study,  olaparib  showed  a  statistically  significant improvement in terms of IDFS, DDFS and OS compared to placebo. This benefit was shown for olaparib both in monotherapy and in association with endocrine therapy for the treatment of TNBC patients and HR+/HER2- patients respectively.

HR+/HER2- patients who have received prior neoadjuvant chemotherapy were partly selected based on the the CPS&amp;EG scoring system to define high risk status. The MAH provided adequate clarification on the use of  CPS&amp;EG  scoring  system  as  a  prognostic  score  following  neoadjuvant  chemotherapy  in  several retrospective studies including a large population of patients (Mittendorf et al 2011, Abdelsattar et al 2016, Marmé et al 2016). The CPS&amp;EG scoring is considered adequately described in section 5.1 of the SmPC to inform prescribers.

The risks associated with olaparib are manageable and acceptable in the context of the meaningful treatment benefit observed with olaparib in patients with high risk early breast cancer treated in the proposed adjuvant setting.

## 3.7.3. Additional considerations on the benefit-risk balance

Clinical data in patients with somatic BRCA-mutated tumours are lacking as this population was not studied in  OlympiA  trial.  The  MAH  submitted  supportive  efficacy  data  for  olaparib  and  other  PARP  inhibitor treatments in gBRCAm, tBRCAm, and sBRCAm metastatic breast cancer patients. Overall available data support strong biological rationale and suggest antitumour activity in patients with sBRCA in the adjuvant treatment of EBC. However, the extrapolation of results from patients with germline BRCA mutations who developed  early  breast  cancer  to  patients  with  sporadic  breast  cancers  that  harbour  somatic  BRCA mutations  in  their  tumours  is  not  considered  justified  for  the  time  being  considering  the  remaining uncertainties. Although the mechanistic rationale is acknowledged, the magnitude of the potential effect in the context of early breast cancer is uncertain and long-term safety data are lacking. The indication has therefore been restricted to gBRCAm patients only until clinical outcome data for sBRCAm patients become available.

## 3.8. Conclusions

The overall B/R of Lynparza is positive in the following indication: Lynparza is indicated as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with

<div style=\"page-break-after: always\"></div>

neoadjuvant or adjuvant chemotherapy (see SmPC sections 4.1, 4.2 and 5.1).

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following group of variations acceptable and therefore recommends the variations to the terms of the Marketing Authorisation, concerning the following changes:

| Variations accepted   | Variations accepted                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| B.I.z                 | B.I.z - Quality change - Active substance - Other variation                                                                    | Type IB | None               |
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

C.I.6.a - Extension of indication to include the use of Lynparza tablets as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1 of the SmPC are updated. The SmPC of Lynparza capsule has been revised accordingly to reflect updated safety information. The Package Leaflet is updated in accordance. In addition, the list of local representatives in the PL has been revised. Version 23.3 of the RMP is approved.

B.I.z - to reassess the control strategy for potentially mutagenic impurities in the active substance in view of the proposed extension of indication to an earlier line of cancer treatment.

## Amendments to the marketing authorisation

In view of the data submitted with the group of variations, amendments to Annexes I and IIIB and to the Risk Management Plan are recommended.